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Introduction
Chapter 1
Viral hepatitis
Chronic viral hepatitis, predominantly caused by the hepatitis B 
and C viruses (HBV and HCV, respectively) and recently described 
by genotype (gt) 3 Hepatitis E virus (HEV), is a global health 
burden affecting almost five percent of the world’s population. 
Not all patients develop a chronic infection after exposure to 
these viruses. Chronicity rates for HBV are 95% in neonates, 30% 
in children below age of 6 years, and 5% in adults, whereas the 
chronicity rates for HCV are approximately 80% (1, 2). Patients at 
risk for developing chronic HEV infection are immunocompromised 
patients comprising mainly solid organ transplant (SOT) patients 
(3-5), and to lesser extent patients infected with the human 
immunodeficiency virus (HIV) (6, 7), patients on chemotherapy (8) 
and bone marrow transplant recipients (9, 10). In HEV gt3 infected 
SOT patients a chronicity rate up to 57% has been reported (11). 
In 50-70% of chronic hepatitis patients, liver fibrosis and cirrhosis 
ensues, which eventually may lead to hepatic failure and the 
requirement of a liver transplant (12-15).
Hepatitis B virus
HBV is an enveloped partially double-stranded DNA virus, 
belonging to the family of the Hepadnaviridae within the genus 
Orthohepadnavirus. The genome of HBV is 3.2kb and contains 
four  major open reading frames (ORF) called C, P, S, and X. ORF C 
encodes the Hepatitis B core antigen (HBcAg) and hepatitis B early 
or pre-core antigen (HBeAg), P encodes the DNA polymerase, 
the hepatitis B surface antigen (HBsAg) is encoded by S, and the 
HBV X protein (HBX) by X (Figure 1A) (12, 16, 17). HBV infects 
specifically human hepatocytes via the sodium taurocholate 
cotransporting polypeptide receptor (18). Upon entry the 
nucleocapsid is released in the cytoplasm and is transported to 
the nucleus where it releases its viral DNA. In the nucleus the 
viral DNA forms a minichromosome, so called covalently closed 
circular DNA (cccDNA), encoding all viral proteins (19). Incomplete 
eradication of cccDNA leads to resurgence of newly produced viral 
particles. Besides infectious virions HBV infection also produces 
an excessive amount of virus-like particles (VLP) consisting of 
HBsAg aggregates. These HBsAg containing VLPs have shown to 
modulate host immune functions by impairment of frequency 
and function of dentritic cells and possible interference of Toll-
Like Receptor (TLR) signaling (20).
Hepatitis C virus
HCV is an enveloped, positive-sense single-stranded RNA virus 
of the family Flaviviridae within the genus Hepacivirus. One 
single ORF encodes a polyprotein and is flanked by 5’ and 3’ non-
coding regions (NCR), within the HCV 9.6kb genome. The NCRs 
are essential for translation and replication of the viral RNA. 
After translation the viral polyprotein is cleaved by host and viral 
proteases into 3 structural proteins (Core protein, C; envelop 
proteins, E1 and E2) and 7 non-structural proteins (NS1, NS2, 
NS3, NS4a, NS4b, NS5a, and NS5b) important for viral replication 
(Figure 1B) (21-23). HCV primarily infects human hepatocytes 
through clathrin-mediated endocytosis after interaction with 
CD81, scavenger receptor BI, Claudin-1 and Occludin (24). In the 
cell HCV virions are uncoated and the genomic RNA can undergo 
replication or translation of the polyprotein generating new viral 
particles (25).
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Hepatitis E virus
For a long time viral infections with hepatitis E virus (HEV) were 
considered to be restricted to developing countries. However, 
recently European countries, including France, the United 
Kingdom and the Netherlands, have documented increasing 
numbers of endemic infections with gt3 HEV (26-28). HEV is a non-
enveloped positive-sense single-stranded RNA virus, belonging to 
the family Hepeviridae within the genus Orthohepevirus. Seven 
different genotypes have been described so far, of which gt1 
and gt3 are most prevalent in humans (29). The genome of HEV 
is approximately 7.2kb and contains three ORFs. ORF1 encodes 
several non-structural proteins including a methyltransferase, 
a y-domain, a papain-like cysteine protease, a helicase, and the 
RNA-dependent RNA polymerase. ORF2 encodes for structural 
proteins forming the viral capsid. ORF3 overlaps with ORF2 and 
encodes a viroporin essential for the release of infectious particles 
(Figure 1C) (30). The viral replication cycle of HEV is not completely 
understood. Non-specific molecules called heparin sulfate 
proteoglycans on the host cell facilitate virus attachment (31). 
However, subsequent entry into host cells is suggested to occur 
through unknown receptors (32). The genomic RNA is released 
into the cytosol after entry followed by translation of ORF1, 
including the RNA-dependent RNA polymerase, which synthesizes 
an intermediate, replicative negative-sense RNA strand (33). The 
negative-sense RNA strand serves as template for the production 
of new positive-sense viral genomes from which the ORF2 and 
ORF3 are translated, which eventually result in the packaging and 
release of new viral particles (34).
Treatment of chronic viral hepatitis
Despite the existence of a good vaccine against HBV, no curative 
treatment options are available at this moment and treatment 
of chronic HBV patients is therefore aimed at suppressing viral 
replication (37). Treatments available are either nucleoside 
(Lamivudine, Telbivudine, Entecavir) or nucleotide (Adefovir, 
and Tenofovir) analogues, which act as chain terminators for 
the viral DNA polymerase or reverse transcriptase, or pegylated-
interferon-alpha	 (pegIFNɑ),	 which	 activates	 the	 host’s	 anti-viral	
immune response (38). These current treatments fail to cure HBV 
as they have limited impact on the existing cccDNA reservoir in 
the nucleus of the infected cells. Current research is aiming to 
identify mechanisms which either eliminate or inactivate the HBV 
cccDNA (39, 40).
For	years,	treatment	of	chronic	HCV	patients	consisted	of	pegIFNɑ	
plus ribavirin (RBV), which resulted in sustained virological 
response rates (SVR) 24 weeks after treatment stop in up to 42% of 
the HCV gt1, and 80% of the HCV gt2 and gt3 patients (41, 42). Low 
intrahepatic interferon-stimulated gene (ISG) expression levels 
were	found	to	be	predictive	for	SVR	upon	pegIFNɑ	treatment	in	
chronic HCV patients (43, 44). Currently, chronic HCV patients are 
treated with a new generation of direct acting antivirals targeting 
viral protease, polymerase and RNA binding assembly binding 
complex, which are able to suppress HCV replication and result in 
an SVR in over 90% of all the patients with minimal side effects in 
a shorter timeframe of 12 weeks (45, 46). 
Antiviral treatment options for chronic HEV-infected 
immunocompromised patients are limited. Therefore, a dose 
reduction of immunosuppressive drugs in SOT patients is often 
tried as first intervention and has shown to result in HEV clearance 
in one third of the patients (3). The second treatment option 
available is RBV monotherapy, which is based on safety and 
efficacy treatment studies for chronic HCV infections, and leads to 
viral clearance in roughly 75% of chronic HEV patients. However, 
the optimal RBV treatment dosage and duration remain to be 
determined.	The	last	option	available	is	pegIFNɑ,	which	has	been	
administered to a number of patients in doses comparable to HCV 
Figure 1. Genomic structure of hepatitis viruses.  (A) The HBV DNA genome is a partially double-stranded relaxed circular DNA and is 3.2 kb long. The 
genome consists of four genes: C, core protein; P, polymerase; S, surface protein; X, x-protein, which partially overlap (adapted from Ohno M. et al WJG 
2015 (17)). (B) The HCV RNA consists of a major open reading frame (ORF), encoding a single polyprotein, within the 9.6kb-long genome. Cleavage of the 
polyprotein gives rise to the structural (core, envelope proteins E1 and E2, and p7) and nonstructural (NS) viral proteins (NS2 through NS5B) (adapted 
from Boonstra A. et al. Hepatol 2009 (35)). (C) The 7.2kb-long positive-stranded RNA genome of HEV consist of three ORFs. ORF1 encodes a polyprotein 
consisting of methyltransferase (Met), Y, putative papain-like cysteine protease (PCP), variable (V), macro, RNA helicase (Hel, and RNA-dependent RNA 
polymerase (RdRp) domains. ORF2 encodes the capsid protein, and ORF3 overlaps with ORF2 and encodes a viroporin (adapted from Debing Y. et al. J 
Hepatol 2016 (36)).
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treatment regimens with similar treatment success compared to 
RBV	 (47,	48).	However,	 the	use	of	pegIFNɑ	 in	kidney	and	heart	
transplant recipients is not recommended, due to concerns for 
acute graft rejection.
Animal models for the study of viral hepatitis
Due to ethical constraints, studies of liver-residing leukocytes 
are limited in patients, although these cells are essential in 
determining the outcome of the infection. The restricted host 
range of the hepatitis viruses has hampered the development 
of suitable animal models. Available models for HBV and HCV 
comprise Chimpanzee, Treeshrews, transgenic mice, and infection 
of viral homologues in their natural host; such as woodchuck 
hepatitis virus in woodchucks, duck hepatitis B virus in ducks, and 
Tamarins infected with GB-virus A and B (49, 50). Possible models 
for HEV consist mainly of naturally occurring HEV or hepatitis E-like 
virus infection in pigs, rabbits, ferrets, rats, and birds. Despite their 
proven use in the study of viral hepatitis, immunopathogenesis 
studies in these models are limited. Furthermore, HEV infections 
in natural hosts rarely result in chronic infections. In order to 
study these viruses in a scalable small animal model, different 
immune-deficient and immune-competent mouse models 
have been suggested, namely the immun-deficient human-liver 
chimeric mouse model and immune-competent lymphocytic 
choriomeningitis virus (LCMV) infection model. 
Immune-deficient mouse model
The development of human-liver chimeric mouse models was 
a big leap forward in the study of human hepatitis viruses (51-
62). These mice have a hepatocyte-specific, albumin promotor- 
directed, overexpression of a urokinase plasminogen activator 
(uPA) transgene, which induces severe liver damage generating 
a nich for viable hepatocytes. The diseased liver could be 
replaced with viable non-transgenic donor mouse hepatocytes, 
showing increased survival of mice (51). Backcrossing the uPA-
transgene into an immune-deficient background permitted the 
reconstruction of the transgenic liver with human hepatocytes, 
thereby generating human-liver chimeric mice. Successful 
engraftment and functionality of human hepatocytes was 
reflected by the production of human serum proteins including 
human albumin (52). Several groups used this idea to develop 
other models using the same principles, e.g. Fah–/–Rag2–/–
Il2rg–/–, HSVtk-NOD/Shi-scid IL2Rgnull (NOG), and uPA-NOG mice 
(53-55).
Human-liver chimeric mouse models showed to be susceptible to 
HCV and HBV, with active replication reaching high titers in serum 
and liver (52, 56-58). Besides HBV mono-infection, these models 
Figure 2. Schematic overview of the human-liver chimeric mouse model for the study of viral hepatitis. 1) uPA-transgenic mice were crossbred with 
immune-deficient (NOG) mice to generate uPA-NOG mice. uPA overexpression damages the liver generating space and need for viable hepatocytes. 
2) Isolation and transplantation of human hepatocytes via intra-splenic injection. Transplanted hepatocytes migrate with the bloodflow towards the 
liver. 3) Expansion of engrafted human hepatocytes. 4) Inoculation of hepatitis viruses (infectivity studies). 5) Viral replication in chimeric mouse liver 
(infection kinetics and virus-host interaction studies). 6) Preclinical evaluation of antiviral drugs (Antiviral treatment and intervention studies).
|  9
Chapter 1  |  Introduction
also showed to support HBV coinfection with hepatitis D virus 
(HDV) (59). To date, infected humanized mice resemble closest a 
natural infection in human. Therefore, besides infection studies 
of human hepatotropic viruses, antiviral compounds, viral entry 
inhibitors and IFN-based therapies were tested to cure or prevent 
viral infection (60-62) (Figure 2). 
The immune-deficient background of these mice prevents studies 
of the cellular and humoral immune responses. Nonetheless, this 
model is very useful to study the direct interaction of the virus with 
human hepatocytes. In addition, it has been shown that adoptive 
transfer of human immune cells in these mice is possible, and that 
these cells were able to prevent HCV infection in humanized mice 
(63). However, limitations in studying the immune cells in this 
model remain and illustrate the need for an immune-competent 
model to study chronic viral hepatitis.
Immune-competent animal model
As an alternative to study HCV- and HBV-induced immune 
responses in humans or chimpanzees, mice infected with the 
persistent variant of LCMV have been established to model virus-
host interactions. Since the first descriptions of human chronic 
viral infections, LCMV-challenged mice have been used as model 
to study immunological events during persistent viral replication. 
Several significant research milestones have been achieved 
using the LCMV model. In 1974, the Major Histocompatibility 
Complex (MHC)-restricted action of cytotoxic T lymphocytes was 
discovered by Zinkernagel and Doherty, which resulted in the 
Nobel Prize in 1996 (64-66). Studying LCMV also contributed to 
our understanding of perforin-based T cell-mediated cell lysis 
and a key feature of the adaptive immune response, namely T 
cell memory (67-70). Furthermore, the concept and experimental 
evidence of immune dysfunction and immune exhaustion 
arise in part from LCMV studies (71-74). In addition, LCMV also 
contributed to the understanding of the innate immune system. 
Early cytotoxic cells (now known as NK cells) emerged 1 day after 
LCMV inoculation, killing infected and non-infected cells (75). 
All these achieved milestones illustrate the importance of this 
immune-competent model to study persistent viral infections.
Several strains of LCMV are known, of which Armstrong and 
Clone (Cl) 13 are generally used to study acute and chronic 
infections, respectively. The genomes of these strains only differ 
in five nucleotides, resulting in two amino acid changes in the 
viral polymerase and glycoprotein (76, 77). Interestingly, these 
changes result in completely distinct infection profiles. Infection 
of C57/BL6 mice with LCMV Armstrong is cleared within 8 days 
and is due to strong induction of LCMV-specific CD4+ and CD8+ T 
cells, thereby coined the “acute LCMV strain” (78, 79). In contrast, 
LCMV Cl13 infections persist in several organs with high viral 
titers weeks after inoculation, as a result of insufficient antigen 
presentation and thus preventing a strong T cell response (80, 
81). Although LCMV Cl13 is genetically distant from HCV or HBV, 
the immunological landscape observed during chronic LCMV 
infection in mice mimics in many ways the immune alterations 
of the immune system upon persistent human viral infections. 
The ability of LCMV to infect hepatocytes, among other cells, 
underlines the relevance of this model for the study of virus 
induced hepatitis (82-84).
Innate immune response
Intracellular innate immune response
The host organism depends on a fast defense response in order 
to protect itself from potentially harmful viruses. Therefore, 
most cells contain so called pattern recognition receptors (PRR), 
which recognize foreign pathogen-associated molecular patterns 
(PAMP) (85). To protect against viruses, the cytosolic PRRs are 
most important and consist of TLR3, TLR7, TLR8, TLR9, retinoic 
acid-inducible gene (RIG)-I, melanoma-differentiation-associated 
gene 5 (MDA5), and the cyclic GMP-AMP Synthase (cGAS) - 
stimulator of Interferon Genes (STING) pathway. These PRRs 
bind viral nucleic acids such as CpG-DNA, 5’ppp-ssRNA, ssRNA, 
dsDNA, and dsRNA, which can be presented intracellularly upon 
infection of the host cell. Binding of PAMPs to PRRs can initiate 
various intracellular signaling cascades leading to the activation 
of transcription factors, including interferon-regulatory factors 
(IRF)	and	NF-�B.	Subsequently,	these	transcription	factors	initiate	
the production of inflammatory cytokines and interferons (IFN) 
(86, 87). Hepatocytes infected with HBV revealed minimal or 
no intracellular immune response, whereas infection with HCV 
showed a strong induction of defense responses, indicated by 
increased transcription of ISGs (88, 89). Despite the activated 
innate immune response in HCV-infected cells, HCV is rarely 
cleared. Interestingly, viruses have developed various ways to 
counteract the innate immune signaling cascades or prevent 
sensing by the host cell’s response (90, 91). Therefore, in order to 
clear the viral infection a cellular innate immune response and the 
development of a good adaptive immune response are required.
Cellular innate immune response
Immune-mediated clearance of HBV, HCV, and HEV infection 
in patients is executed by multi epitope-specific adaptive CD4+ 
T, CD8+ T and B cell responses (92-94). The development of 
good T and B cell immune responses against hepatitis viruses 
are dependent and shaped by the early immunological events 
provided by innate immune cells in the liver (95, 96). In the 
LCMV model it has been demonstrated that NK cells direct a 
good adaptive immune response (97). In addition to NK cells, the 
liver innate immune cells comprise granulocytes, dendritic cells, 
monocytes and macrophages. The latter two have been suggested 
to play various roles in homeostasis and during inflammation, but 
are not well studied in the context of viral hepatitis.
Macrophages 
Macrophages are, together with monocytes and dendritic 
cells, part of the mononuclear phagocyte system. Liver tissue 
macrophages, also known as Kupffer cells (KC), are derived from 
embryonic progenitors that seed developing tissues before birth 
and are the largest immune cel population in the liver. During 
life, these tissue macrophages can proliferate at low levels in 
the steady state (98). KCs are abundantly present in the liver 
sinusoids, are crucial players in maintaining tissue homeostasis, 
and form, together with sinusoidal endothelial cells, the first 
barrier for pathogens to enter the liver (99). KCs can respond to 
danger signals using a variety of PRRs, such as TLR, scavenger and 
antibody-receptors and, depending on the local environment, 
initiate an inflammatory response, or induce tolerogenic T cell 
responses (100, 101). Only a few studies have looked into the 
role of KC during LCMV infection in mice. One study showed rapid 
LCMV dissemination and enhanced viral replication in mice with 
chlodronate-depleted	 KCs	 or	 IFNα-receptor	 deficient	 KCs	 (102).	
Suggesting, a crucial role for KCs in controlling LCMV spread and 
replication. 
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Monocytes
Also part of the mononuclear phagocyte system are the 
monocytes, which are continuously generated in the bone 
marrow from hematopoietic stem cells (98). Monocytes survey 
the body for inflammatory foci and are therefore among the first 
innate immune cells to respond to infection. They are equipped 
with chemokine and adhesion receptors to mediate migration 
to the site of infection or inflammation, upon which they can 
further differentiate into tissue-like macrophages and dendritic 
cells (103). Depending on the nature of the inflammatory agent 
and organ system involved, monocytes can exert both a pro-
inflammatory as well as an anti-inflammatory role. They have 
the ability to produce tumor necrosis factor (TNF) and inducible 
nitric oxide synthase (iNOS) (104-106), to carry microbial antigens 
to local lymph nodes (107), and to present antigens to T cells 
(108-110). Alternatively, monocytes may differentiate into anti-
inflammatory macrophage-like cells (106) or suppress proliferation 
and production of cytokines by T cells (111), suggesting their role 
in maintaining homeostasis. 
Scope of this thesis
Objectives of this thesis are: 1) to better understand the cellular 
innate immune responses in the liver during LCMV-induced 
chronic hepatitis, and 2) to establish the human-liver chimeric 
mouse as model for chronic HEV infections in order to study the 
intracellular innate immune mechanisms upon HEV infection.
Outline of this thesis
In chapters 2 and 3, we aim to unravel how the cellular innate 
immune system deals with chronic viral infection in the liver. This 
knowledge is crucial to develop new antiviral strategies aimed at 
eradicating chronic viral infection. We model the chronic virus-
host interaction by inoculating mice with a LCMV Cl13. In chapter 
2, we set out to characterize in depth the phenotype, function 
and gene expression profiles of liver monocytes and KCs during 
the early phases of chronic LCMV infection. In chapter 3, we fully 
characterize the immune-related gene transcriptome of sorted 
KCs and liver monocytes during chronic LCMV infection.
In chapters 4, 5, and 6, we investigat Europe’s new hepatitis 
threat. No adequate in vivo model system exists to mimic this 
disease course, which hampers studies on HEV infectivity, 
transmission, and antiviral drug development. In chapter 4, we 
explore the use human-liver chimeric mice as model for chronic 
HEV. Chapter 5 describes the genomic adaptation of HEV to in 
vitro culture, and inter-patient clinical isolates. In chapter 6, we 
examine the intracellular innate immune responses in human 
hepatocytes upon infection with HEV in human-liver chimeric 
mice. In addition, HEV-infected human-liver chimeric mice are 
treated with the intracellular innate-immune activating drugs, 
pegIFNɑ.	The	results	presented	in	this	thesis	are	summarized	and	
discussed in chapter 7.
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Abstract
Due to a scarcity of immunocompetent animal models for viral hepatitis, little is known about the early innate immune 
responses in the liver. In various hepatotoxic models both pro- and anti-inflammatory activities of recruited monocytes 
have been described. In this study, we compared the effect of liver inflammation induced by the TLR4 ligand LPS with that 
of a persistent virus, lymphocytic choriomeningitis virus (LCMV) Clone 13, on early innate intrahepatic immune responses 
in mice. LCMV infection induces a remarkable influx of inflammatory monocytes in the liver within 24 hours, accompanied 
by increased transcript levels of several pro-inflammatory cytokines and chemokines in whole liver. Importantly, while a 
single LPS injection results in similar recruitment of inflammatory monocytes to the liver, the functional properties of the 
infiltrating cells are dramatically different in response to LPS versus LCMV infection. In fact, intrahepatic inflammatory 
monocytes are skewed towards a secretory phenotype with impaired phagocytosis in LCMV-induced liver inflammation, 
but exhibit increased endocytic capacity after LPS challenge. In contrast, F4/80high-Kupffer cells retain their steady-state 
endocytic functions upon LCMV infection. Strikingly, the gene expression levels of inflammatory monocytes dramatically 
change upon LCMV exposure and resemble those of Kupffer cells. Since inflammatory monocytes outnumber Kupffer cells 
during the early phase of LCMV infection, inflammatory monocytes might be more important during the early phase of 
liver inflammation. Our findings are instrumental in understanding the early immunological events during virus-induced 
liver disease and point towards inflammatory monocytes as potential target cells for future treatment options in viral 
hepatitis.
Recruited inflammatory monocytes adopt a 
Kupffer cell-like phenotype, but not function 
within 24 hours after virus-induced liver 
inflammation
Dowty Movita1, Martijn D.B. van de Garde1, Paula Biesta1, Kim Kreefft1, Bart Haagmans2, Elina Zuni-
ga3, Florence Herschke4, Sandra De Jonghe4, Harry L.A. Janssen1,5, Lucio Gama6,  Andre Boonstra1,#, 
Thomas Vanwolleghem1,#
1Department of Gastroenterology and Hepatology, 2Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands, 3Division of Biological Sciences, 
University of California San Diego, La Jolla, San Diego, California, 4Janssen Infectious Disease and Drug Safety Sciences, Beerse, Belgium, 5Liver Clinic, Toronto 
Western and General Hospital University Health Network Toronto, Toronto, Canada, 6Department of Molecular and Comparative Pathobiology, The Johns Hopkins 
University School of Medicine, Baltimore, Maryland, USA, #these authors contributed equally to this work
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Introduction
Chronic viral hepatitis, predominantly caused by the hepatitis 
B and C viruses (HBV and HCV, respectively), is a global 
health burden affecting almost three percent of the world’s 
population. In 50-70% of patients, liver fibrosis ensues, of which a 
considerable proportion go on to develop cirrhosis, hepatic failure 
or hepatocellular carcinoma (12, 13). Although clearance of HBV 
and HCV infection is executed by multi epitope-specific adaptive 
CD4+ T, CD8+ T and B cell responses (92-95), these responses are 
dependent and shaped by the early immunological events provided 
by innate immune cells in the liver (95, 96). Immunological studies 
of HCV- or HBV-induced hepatitis have been impeded since these 
viruses only replicate in humans and non-human primates. 
Furthermore, immunocompetent small animal models for chronic 
viral hepatitis are not yet available (reviewed in (35, 112)). As an 
alternative to study HCV- and HBV-induced immune responses 
in humans or chimpanzees, mice infected with the persistent 
variant of lymphocytic choriomeningitis virus (LCMV) clone 13 
(Cl13) has been proposed to model virus-host interactions during 
a chronic viral infection. Although LCMV Cl13 is genetically distant 
from HCV or HBV, the immunological landscape observed during 
chronic LCMV infection in mice mimics in many ways the immune 
alterations resulting from sustained stimulation of the immune 
system upon human persistent viral infections. In fact, numerous 
key findings observed in LCMV-induced immune regulation of 
adaptive immunity have later been confirmed in human studies, 
demonstrating the validity of this model system  (reviewed in 
(113)). Although mice persistently infected with LCMV exhibit 
altered innate responses to subsequent toll like receptor (TLR) 
stimulations and secondary infections (114, 115), the overall and 
intrahepatic alterations of the innate immune system during early 
LCMV infections have been less studied. 
Monocytes survey the body for inflammatory foci and are therefore 
among the first innate immune cells to respond to infection. 
They are equipped with chemokine and adhesion receptors to 
mediate migration to the site of infection or inflammation, upon 
which they can further differentiate into tissue macrophages and 
dendritic cells (103). Depending on the nature of the inflammatory 
agent and organ system involved, monocytes can exert both a 
pro-inflammatory as well as an anti-inflammatory role. They have 
the ability to produce TNF and iNOS (104-106), to carry microbial 
antigens to local lymph nodes (107), and to present antigens to 
T cells (108-110). Alternatively, monocytes may differentiate into 
anti-inflammatory macrophages (106) or suppress proliferation 
and production of cytokines by T cells (111), suggesting their role 
in maintaining homeostasis. In L. monocytogenes, M. tuberculosis 
and T. gondii mouse models for example, monocyte migration 
from bone marrow results in resistance to infection (105, 116-
118). While in T. brucei and influenza virus models, monocyte 
recruitment impairs pathogen clearance and exacerbates 
immune-mediated pathology (104, 119, 120). 
Upon recruitment to the liver, monocytes are referred to as 
inflammatory monocytes and identified as F4/80lowLy6C+CD11b+ 
cells (121-123). Similar to their systemic function, opposing 
roles during sterile toxin-induced liver inflammation have been 
identified. For example, in acetaminophen-induced hepatitis, 
hepatic inflammatory monocytes are endocytic and display an 
immunoregulatory phenotype (121), while in concanavalin A and 
CCl4 hepatitis, they promote Th1 cell proliferation and produce 
pro-inflammatory cytokines such as TNF and IL-6 (122-124). Due 
to the shortage of specific animal models, the role of these innate 
immune cells during virus-induced liver disease is less explored. 
Furthermore, before the recruitment of monocytes, Kupffer 
cells, together with dendritic cells, liver sinusoidal endothelial 
cells and stellate cells, are the first to encounter pathogens upon 
their passage through the liver sinusoids. Both Kupffer cells and 
inflammatory monocytes likely play a role in shaping the immune 
response, and thereby affect the outcome of a viral infection 
in the liver. We and others have previously shown that murine 
Kupffer cells can be unequivocally identified by the expression of 
F4/80, CD11b and CD68 and are predominantly phagocytic in a 
steady state condition (125, 126). 
In the current study, we set out to characterize in depth the 
phenotype, function and gene expression profiles of liver 
monocytes and Kupffer cells during the early phases of chronic 
LCMV infection. We demonstrate a strong influx of inflammatory 
monocytes in the liver within 24 hours after LCMV inoculation. 
Using Nanostring gene expression analysis on highly purified 
Kupffer cells and inflammatory monocytes isolated from mouse 
liver, we demonstrated that under steady state conditions 
these cells are transcriptionally and functionally distinct. As a 
consequence of LCMV infection the expression profiles of both 
Kupffer cells and inflammatory monocytes are strongly altered. 
Strikingly, 24 hours after LCMV infection differences in gene 
expression levels of both cell types largely –but not completely- 
disappear, resulting in strong resemblance of Kupffer cells and 
inflammatory monocytes. These findings provide insight in the 
function of the cells involved in the early stages of virus-induced 
liver disease and present potential target cell types for the early 
control of viral hepatitis. 
Materials and Methods
Mice, virus and antibodies 
LCMV Cl13 was propagated in BHK21 cells and the titer was 
determined by plaque assay as previously described (76, 80). 
C57BL/6 mice aged 8-12 weeks old (Charles River, France) 
received	 LCMV	Cl13	 (2	 x	 106	PFU)	 i.v,	 5	μg	 LPS	 (TLR4	 ligand,	 S.	
Minnesota	ultra-pure,	 Invivogen)	 i.p,	or	200	μl	 PBS	 i.p.	Animals	
were maintained in a BSL-III isolator according to Dutch national 
biosafety guidelines. Infection was confirmed by plaque assay 
on liver homogenate. All animal work was conducted according 
to relevant Dutch national guidelines. The study protocol was 
approved by the animal ethics committee of the Erasmus 
University Rotterdam. Antibodies used in flow cytometry: CD45 
eFluor450 (30-F11), F4/80 APC or F4/80 FITC (BM8), CD11b PECy7 
(M1/70), and TNF PerCPCy5.5 (MP6-XT22) from eBioscience, 
Ly6C APCCy7 (HK1.4) from Biolegend, MARCO FITC (ED31) from 
AbdSerotec, and Aqua Dead Cell Stain from Invitrogen. The VL4 
cells, producing LCMV-nucleoprotein (LCMV-NP) monoclonal 
antibody, were a kind gift from Dr. M. Groettrup, University of 
Constance, Germany. 
Isolation of total liver non-parenchymal cells  
Liver was removed without perfusion, cut into small pieces, 
incubated	 in	 RPMI	 1640	 containing	 30	 μg/ml	 Liberase	 TM	
(Roche)	 and	 20	 μg/ml	 DNAse	 type	 I	 (Sigma)	 for	 20	 min,	 and	
passed	through	a	100	μm	cell	strainer.	After	centrifugation,	cells	
were resuspended in PBS containing 1% FCS and 2.5 mM EDTA. 
Parenchymal cells were removed by low speed centrifugation at 
50 g for 3 min and erythrocytes were lysed with 0.8% NH4Cl. The 
remaining non-parenchymal cells were resuspended in culture 
medium (RPMI 1640, 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 
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100	U/ml	/	100	μg/ml	Pen/Strep,	50	μM	β-mercaptoethanol)	and	
used for further analysis. 
Flow cytometry
Total liver non-parenchymal cells were stained with Aqua 
Dead Cell Stain, CD45 eFluor450, F4/80 APC, CD11b PECy7 and 
Ly6C APCCy7 (unless otherwise indicated), and fixed with 2% 
formaldehyde for 1 hour. F4/80high-Kupffer cells were identified 
as CD45+F4/80highCD11b+ and inflammatory monocytes 
as CD45+F4/80lowCD11bhighLy6Chigh using a FACSCanto-II 
flowcytometer and FACSDiva software (BD Biosciences).
RNA isolation of liver homogenates, generation of cDNA and 
real-time PCR
Liver was homogenized in RNAlater (Qiagen). RNA was extracted 
using Trizol (LifeTech) and a NucleoSpin RNAII kit (Bioké). 
cDNA was generated using the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories) according to the manufacturer’s protocol. 
Quantitative PCR were performed using SYBR-green and MyIQ5 
detection system (Bio-rad Laboratories). Sequences of primers are 
listed in Table 1. Expression of target genes was normalized to the 
expression	of	18S	or	GAPDH	using	the	formula	2-ΔCt,	ΔCt=CtTLR-
Ct18S	or	ΔCt=CtRNAX-CtGADPH.
RNA isolation of sorted cells and Nanostring
Kupffer cells and inflammatory cells were purified by cell sorting 
after initial enrichment using CD45 PE followed by anti-PE 
Microbeads (Milteny Biotec) selection. To obtain sufficient cells 
the organs of 6 mice were pooled. Following staining to identify 
Kupffer cells and inflammatory monocytes as described above, 
cells were fixed with 2% formaldehyde for 1 hour, and sorted on a 
FACS Aria SORP flow cytometer (BD Biosciences).  Total RNA was 
isolated from these formaldehyde-fixed cells using reagents from 
the RNeasy FFPE kit (Qiagen) following manufacturers’ protocols 
starting with adding 150 µl Buffer PKD. The nCounter® GX Mouse 
Immunology Kit (NanoString Technologies, Seattle, WA, USA) was 
used to measure the expression of 561 genes in our RNA samples. 
Following hybridization, transcripts were quantitated using 
the nCounter® Digital Analyzer. Samples were run by the Johns 
Hopkins Deep Sequencing & Microarray Core (127). To correct 
for background levels, the highest negative control value for each 
sample was subtracted from each count value of that sample. 
Following background subtraction, any negative count values 
were considered as 0. Values were normalized by the geometric 
mean of 13 housekeeping genes provided by the company panel.
Immunohistochemistry for F4/80
Liver was fixed in 4% formaldehyde, embedded in paraffin 
and cut into 5 µm sections. F4/80 antigen was retrieved using 
Proteinase K. Endogenous peroxidase was eliminated using 
3% hydrogen peroxide. Liver sections were incubated with rat 
anti-F4/80 antibody (eBioscience) and rabbit anti-rat HRP (Dako). 
Upon addition of DAB, liver sections were counterstained with 
hematoxyline. 
Intracellular detection of LCMV-nucleoprotein (LMCV-NP)
Intracellular LCMV-NP detection was performed as previously 
described (128). Total liver non-parenchymal cells were incubated 
with Aqua Dead Cell Stain, fixed with 2% formaldehyde for 1 hour, 
and permeabilized by 1% Triton X-100 (Sigma) for 20 minutes. Cells 
were further incubated with rat anti-LCMV NP antibody (VL4), 
goat anti-rat Alexa594 (Invitrogen) and blocking buffer (5% BSA 
and 10% rat serum). F4/80 FITC was used in the antibody cocktail. 
LCMV-NP positive F4/80high-Kupffer cells were identified. 
Cytokine production by total liver non-parenchymal cells
Total liver non-parenchymal cells were cultured at 1x 106 cells/
well in a 24-well plate (Costar) in 1 ml culture medium alone 
or in combination with PMA/ionomycin (50 and 500 ng/ml, 
respectively)	for	5	hours.	Brefeldin	A	(10	μg/ml,	Sigma)	was	added	
after 1 hour. Next, cells were incubated with Aqua Dead Cell Stain, 
fixed with 2% formaldehyde for 1 hour, permeabilized with 0.5% 
saponin (Rectapur) and further stained with TNF PerCPCy5.5. TNF-
positive F4/80high-Kupffer cells and the inflammatory monocytes 
were determined.
In vitro receptor-mediated endocytosis assay
One million total liver non-parenchymal cells were incubated 
for	45	min	with	dextran-FITC	(10	μg/ml,	40,000	MW,	Invitrogen)	
at 37°C or on ice. Dextran-positive F4/80high-Kupffer cells and 
inflammatory monocytes were determined.
ALT measurement
Serum ALT level was measured using an ELISA kit for Alanine 
Aminotransferase (Biotang USA) according to the manufacturer’s 
protocol. 
Data analysis and statistics
Differences between groups were calculated using one-way 
ANOVA (Kruskal-Wallis test, with Dunn’s Multiple Comparison 
post-test) or two way ANOVA with Bonferroni post-test (GraphPad 
Prism version 5.01; GraphPad Software). Differences were 
considered significant when P < 0.05. Results are presented as the 
mean ± SEM, unless otherwise indicated.
Gene ID NCBI ID Primer sequence
GAPDH NM_008084.2 Forward CGTCCCGTAGACAAAATGGT
Reverse TCTCCATGGTGGTGAAGACA
18S NR_003278.3 Forward GTAACCCGTTGAACCCCATT
Reverse CCATCCAATCGGTAGTAGCG
TNF NM_013693.2 Forward CAGGCGGTGCCTATGTCTC
Reverse CGATGACCCCGAAGTTCAGTAG
IL-10 NM_010548.2 Forward CACAGGGGAGAAATCGATGACA
Reverse ATTTGAATTCCCTGGGTGAGAAG
IL-6 NM_031168.1 Forward TGGTGACAACCACGGCCTTCC
Reverse AGCCTCCTGACTTGTGAAGTGGT
MCP-1 NM_011333.3 Forward CAGGTCCCTGTCATGCTTCT
Reverse TCTGGACCCATTCCTTCTTG
RANTES NM_013653.3 Forward GCGGGTACCATGAAGATCTCTG
Reverse CACTTCTTCTCTGGGTTGGCAC
IFNɑ NM_010504.2 Forward AGGATTTTGGATTCCCCTTG
Reverse TATGTCCTCACAGCCAGCAG
IFNɓ NM_010510.1 Forward ATGAACAACAGGTGGATCCTCC
Reverse AGGAGCTCCTGACATTTCCGAA
IP-10 NM_021274.2 Forward CCCCGGTGCTGCGATGGATG
Reverse AGCTGATGTGACCACGGCTGG
Table 1. Gene-specific primers used in qPCR analysis
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Figure 1. Infiltration of inflammatory monocytes characterizes the activation of the intrahepatic immune response upon challenge by LCMV as 
well as LPS. A) Representative dotplots showing flow cytometric identification of Kupffer cells and inflammatory monocytes in mouse liver. Total liver 
cells were determined using viability, CD45, and size and granularity gates. Inflammatory monocytes and F4/80high-Kupffer cells were identified as 
CD45+F4/80lowCD11bhighLy6Chigh and CD45+F4/80highCD11b+ cells, respectively. B) The frequencies of inflammatory monocytes and F4/80high-
Kupffer cells in liver were determined as a percentage of total CD45+ cells at 24 hours post LCMV infection or LPS challenge or PBS control. The 
data were obtained from 4 separate experiments. Statistical analysis: one-way ANOVA (Kruskal-Wallis test with Dunn’s Multiple Comparison post-test), 
***p<0.001. Data shows the average ± SEM. C) Liver tissues from 6 PBS challenged or 6 infected mice (24h post infection) were subjected to F4/80 
staining and evaluated by immunohistochemistry. In healthy liver, F4/80 positive cells appear as elongated cells with intense brown F4/80 staining, 
whereas upon LCMV infection, F4/80+ cells appear slightly larger in size with diffuse brown F4/80 staining in comparison to the F4/80+ cells in healthy 
liver.	D)	Representative	dotplots	(from	n=8)	of	the	frequency	of	LCMV-infected	F4/80high-Kupffer	cells	and	inflammatory	monocytes	as	evidenced	by	
intracellular LCMV-NP staining 24 hours post infection. Control staining without the addition of LCMV-NP antibody or anti-rat CD45 was used to set the 
threshold gate.
Results
LCMV infection induces a rapid recruitment of inflammatory 
monocytes to the liver
Previous studies showed an accumulation of LCMV particles in the 
liver within minutes after an i.v challenge (102). In line with this, 
we observed a reproducible LCMV replication in the liver of mice 
inoculated 24 hours earlier, reaching average titers of 2.27 x 105 
PFU/ gram liver. To examine the impact of viral replication versus 
sterile TLR ligand-induced challenge on the innate immune cell 
repertoire in the liver, we performed a flow cytometric analysis 
on total liver non-parenchymal cells obtained from LCMV-infected 
and LPS-treated mice. LPS was used as a model mimicking 
bacterial infection. F4/80high-Kupffer cells and inflammatory 
monocytes were identified as CD45+F4/80highCD11b+ and 
CD45+F4/80lowCD11bhighLy6Chigh cells, respectively (122, 125) 
(Figure 1A). After 24 hours, LCMV induced an almost 5-fold increase 
in the fraction of inflammatory monocytes similar to a single LPS 
injection (from 5.8% in healthy liver to 25.6% and 24.5% of total 
intrahepatic CD45+ cells in LPS- and LCMV- challenged livers, 
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respectively; Figure 1B). Interestingly, monocyte recruitment was 
accompanied by a decrease in the frequency of F4/80high-Kupffer 
cells in the LPS-treated and LCMV-infected livers (from 10.4% in 
healthy to 5.7% and 4.4% of total intrahepatic CD45+ cells in 
LCMV-infected and LPS-treated livers, respectively). 
To examine whether the reduction of intrahepatic 
CD45+F4/80highCD11b+ cells upon LCMV challenge corresponded 
to a genuine reduction in the frequency of Kupffer cells or a 
diminished surface expression of these markers, we performed 
an immunohistochemical analysis on 24-hour LCMV-infected and 
healthy livers (Figure 1C). Interestingly, in contrast to the flow 
cytometric quantification, there was no clear depletion of Kupffer 
cells upon LCMV infection. Instead, the morphology of F4/80+ 
cells, which predominantly consist of Kupffer cells, changed 
towards larger or swollen cells, with a less intense F4/80 staining 
(Figure 1C), suggesting a down-regulation of F4/80 expression in 
comparison to healthy liver. Importantly, no cleaved caspase-3+ 
cells could be identified in both healthy and 24-hour LCMV-infected 
livers, thereby excluding the presence of apoptotic parenchymal 
or non-parenchymal cells (data not shown). Kupffer cells, which 
retained their F4/80 expression and were still identifiable by flow 
cytometry, were further termed F4/80high-Kupffer cells.
Corroborating earlier data on infection of Kupffer cells (102), we 
observed that 29% of F4/80high-Kupffer cells were LCMV-NP+ 
within 24 hours after infection (Figure 1D).  In addition, at this 
stage F4/80high-Kupffer cells were the predominant LCMV-NP+ 
cells in the liver (90%), while the remainder LCMV-NP+ cells were 
inflammatory monocytes (8%) and granulocytes (2%) (data not 
shown).  
During early LCMV infection, F4/80high-Kupffer cells remain 
endocytic.
Previous data from our group and others have shown that 
Kupffer cells from healthy mice are specialized phagocytes with 
only marginal cytokine production ex-vivo under steady-state 
conditions (125), and that Kupffer cells are among the first to be 
infected with LCMV thereby limiting viral spread (77, 83, 102). We 
here studied in detail the endocytic ability of F4/80high-Kupffer 
cells and inflammatory monocytes during early LCMV infection. 
As shown in Figure 2A, the endocytic ability of F4/80high-Kupffer 
cells, as expressed by the fraction of dextran+F4/80high-Kupffer 
cells, was reduced in LCMV-infected compared to PBS-injected 
mice, but the majority of cells were able to perform endocytosis, 
which was similar to F4/80high-Kupffer cells from LPS-challenged 
mice. Inflammatory monocytes exhibited a weaker endocytic 
ability in control mice, which was completely lost upon LCMV 
infection, while LPS treatment increased it (14.8% vs 29.3% vs 
1.5% dextran+ inflammatory monocytes, in healthy, LPS-treated 
and LCMV-infected livers, respectively; Figure 2A). 
Next, we evaluated whether the endocytic function was reflected 
by the gene expression profile of the cells. F4/80high-Kupffer 
cells purified from unchallenged mice show higher expression 
levels of various complement genes (C1qa, C1qb, C2, C4a and 
C6) as compared to inflammatory monocytes, both isolated from 
unchallenged mice (Figure 1 and Supplementary Figure 1). Also, 
gene	 expression	 levels	 of	 F4/80,	 genes	 encoding	 various	 Fcγ	
receptors and Marco were more expressed by F4/80high-Kupffer 
cells than inflammatory monocytes, indicating a more pronounced 
activity of the “classical scavenger functions” of F4/80high-Kupffer 
cells under steady state conditions. As shown in Figure 2B, infection 
with LCMV or challenge with LPS upregulated the expression 
levels of Marco on F4/80high-Kupffer cells, while the expression 
of various genes encoding for complement remained high with 
Figure 2. F4/80high-Kupffer cells retain a gene expression profile 
characteristic of phagocytic ability upon LCMV and LPS challenge, 
while this is only partially induced in inflammatory monocytes. Mice 
were infected with LCMV or challenged with LPS or PBS for 24 hours. 
A) Endocytosis was determined by flow cytometry by incubating total 
liver non-parenchymal cells with FITC-conjugated dextran at 0°C or 
37°C for 45 minutes. Inflammatory monocytes and F4/80high-Kupffer 
cells were identified as CD45+F4/80lowCD11bhighLy6Chigh and 
CD45+F4/80highCD11b+ cells, respectively. Control staining without the 
addition of dextran was used to set the threshold gate. The assays were 
performed 2 times. Statistical analysis: two-way ANOVA with Bonferroni 
post-test, ***p<0.001. Data shows the average ± SEM. B) and C) Gene 
expression was determined by NanoString technology on total RNA 
isolated from formaldehyde-fixed, FACS sorted Inflammatory monocytes 
and F4/80high-Kupffer cells from LCMV infected or LPS challenged mice.
the exception of C2 and C3, which were further upregulated. In 
LPS- or LCMV-challenged inflammatory monocytes the expression 
levels of the complement genes remained lower than observed 
in F4/80high-Kupffer cells: minimal upregulation of Marco, and 
complement genes, with the exception of C1qa and C1qb.
We then examined whether the observed differences in the 
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endocytic response of F4/80high-Kupffer cells and inflammatory 
monocytes to LPS or LCMV were related to changes in the 
expression of genes associated with cell activation at 24 hours 
after challenge. As presented in Figure 2C, induction of mRNA 
expression of the activation markers CD80 and CD86 was observed 
for both F4/80high-Kupffer cells and inflammatory monocytes 
purified from the liver of LCMV-infected mice, whereas CD14 mRNA 
expression was down-regulated. The effects of in vivo exposure to 
LPS on the expression levels of these markers were minimal at 
24 hours after challenge. In line with published data in Listeria 
monocytogenes as well as in vitro exposure of macrophages to 
IFNα	(129,	130),	we	now	show	that	both	F4/80high-Kupffer	cells	
and inflammatory monocytes isolated from LCMV infected mice 
exhibited	down-regulation	of	 the	 expression	of	 IFNγR1,	 despite	
enhanced	expression	of	IFNγ	and	Tbx21	mRNA.	
Both sorted Kupffer cells and inflammatory monocytes exhibit 
an active cytokine and chemokine transcriptional profile early 
after LCMV infection
Next, we determined the ability of F4/80high-Kupffer cells and 
inflammatory monocytes to produce cytokines upon stimulation 
with PMA and ionomycin. As we published before, Kupffer cells 
produce low or undetectable cytokines (such as TNF and IL-12p40) 
following in vitro stimulation (125). We now show that F4/80high-
Kupffer cells are weak producers even when isolated from mice 
challenged with LPS or LCMV (in all conditions on average less than 
5% TNF+ cells). In contrast, here we demonstrate that inflammatory 
monocytes isolated from LCMV-infected mice produced higher 
levels of TNF compared to control mice after in vitro exposure 
to PMA and ionomycin. An increased ability to produce TNF by 
these cells was not seen after LPS treatment (Figure 3A, 13.4% 
vs 13.3% vs 27.5% TNF+ inflammatory monocytes in PBS-treated, 
LPS-treated and LCMV-infected livers, respectively, upon in vitro 
restimulation with PMA and ionomycin).
Next, we examined the hepatic gene expression levels in whole 
liver of pro- and anti-inflammatory cytokines, chemokines, 
interferons and interferon-inducible antiviral mediators in both 
experimental challenge conditions. Twenty-four hours after LCMV 
Figure 3. Both sorted Kupffer cells and inflammatory monocytes exhibit an active cytokine and chemokine transcriptional profile early after LCMV. 
Mice	were	infected	with	LCMV	Cl13	or	challenged	with	LPS	or	PBS	(n=6-12	per	group),	and	sacrificed	24	hours	later.	A)	Total	liver	non-parenchymal	cells	
were stimulated with medium or PMA/ionomycin for 5 hours. Flow cytometric analysis and graphic representation of the frequency of TNF-producing 
inflammatory monocytes (CD45+F4/80lowCD11bhighLy6Chigh cells) determined by intracellular cytokine staining. Control staining without the addition 
of TNF detecting antibody was used to set the threshold gate.  Statistical analysis: 2-tailed t-test, *p<0.05, **p<0.01. B) Gene expression was determined 
in	whole	liver	(n=4-6)	by	qPCR,	and	in	RNA	isolated	from	formaldehyde-fixed,	FACS	sorted	inflammatory	monocytes	and	F4/80high-Kupffer	cells	from	
infected or challenged mice by NanoString technology. The data shown are obtained from 2 independent experiments using 6 pooled livers. Data shows 
the average ± SEM.
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inoculation, significant increases of intrahepatic mRNA levels of 
TNF,	IL-6,	IL-10,	MCP-1,	IP-10,	IFNα,	IFNβ	and	RANTES	were	noted	
by evaluation of the whole liver (Figure 3B).  Distinct to the LCMV 
infection, LPS treatment primarily increased the mRNA levels of 
innate pro- and anti-inflammatory cytokines and chemokines at 
an earlier time point (i.e. 4 hours after injection, data not shown), 
which the exception of RANTES, which remained upregulated 24 
hours post treatment. It is important to mention that this early 
LCMV-induced liver inflammation was not accompanied by a 
rise in serum transaminases or histological signs of liver damage 
(Supplementary Figure 2A and 2B). To determine the possible 
contribution of F4/80high-Kupffer cells and inflammatory 
monocytes as the source of the observed gene expression 
levels, we again determined the gene expression profile of cells 
isolated from mice challenged with LPS or LCMV. As shown in 
Figure 3B, overall, both F4/80high-Kupffer cells and inflammatory 
monocytes express mRNA for TNF, IL-6, IL-10, MCP-1, IP-10 and 
RANTES 24 hours after LCMV infection. In line with the findings 
in whole liver, challenge with LPS did not exhibit enhanced gene 
expression levels at 24h after challenge, except for RANTES mRNA 
in	F4/80high-Kupffer	cells.	Interestingly,	IFNβ	mRNA	was	strongly	
induced in F4/80high-Kupffer cells from LCMV infected mice, but 
not	 in	 inflammatory	monocytes,	whereas	 IFNα	was	only	weakly	
induced in both cell types. 
Purified F4/80high-Kupffer cells as well as inflammatory 
monocytes induce an interferon response following early LCMV 
infection
The	 induction	 of	 IFNβ	 by	 F4/80high-Kupffer	 cells,	 but	 not	
inflammatory monocytes may indicate that these cell types 
possess distinct functions in the early events following LCMV 
infection. We therefore examined the expression of IFN-
inducible genes in both cell types to determine to what extent 
inflammatory monocytes are triggered by IFN production derived 
from F4/80high-Kupffer cell-derived and other liver cells. As 
shown in Figure 4, both F4/80high-Kupffer cells and inflammatory 
monocytes strongly increase the expression of MxA mRNA early 
following LCMV infection. Similar findings were observed for Ifi35, 
Ifih1, Ifit2, various chemokines, as well as Irf1 and Irf7. In line with 
the expected induction of an IFN-dominated response, also the 
expression of Stat1, Stat2 and Stat3 mRNA was induced in both 
F4/80high-Kupffer cells and inflammatory monocytes, but not of 
Stat4, Stat5 and Stat6. 
Discussion
Due to a lack of suitable animal models, our current understanding 
of early virus-host interactions in virus-induced liver disease is 
limited. In this study we make use of a short-term LCMV Cl13 
infection in mice to examine phenotypical and functional changes 
in inflammatory monocytes and F4/80high-Kupffer cells, which 
are the first innate immune cells to encounter a viral pathogen in 
the liver. Here we show that LCMV induces a marked recruitment 
of infiltrating monocytes within 24 hours after infection. However, 
we observed that the major LCMV-NP+ population comprises 
F4/80high-Kupffer cells, which maintain their endocytic activity 
and present increased expression of several pro- and anti-
inflammatory cytokines and chemokines after LCMV infection. 
On the other hand, inflammatory monocytes obtained from the 
liver of LCMV-infected mice exhibited weak endocytic activity, 
while the expression pattern of these inflammatory monocytes 
strongly resembled those of F4/80high-Kupffer cells early after 
Figure 4. Both purified Kupffer cells and inflammatory monocytes are 
activated and induce an interferon response following early LCMV 
infection. Gene expression was determined in RNA isolated from 
formaldehyde-fixed, FACS sorted inflammatory monocytes and F4/80high-
Kupffer cells from LCMV infected mice by NanoString technology. The data 
shown are obtained from 2 independent experiments using 6 pooled 
livers.
LCMV infection. The observation that during early LCMV infection 
inflammatory monocytes outnumber the F4/80high-Kupffer cells 
indicates their important contribution to the early phase of LCMV-
induced liver inflammation. 
During early LCMV infection, we show that F4/80high-Kupffer 
cells become activated, take up LCMV-NP, and remain endocytic. 
The endocytic ability is in line with Lang et al, who demonstrated 
that active uptake of LCMV by Kupffer cells limits viral spread 
and immunopathology (102). Similar to the LCMV model, 
Kupffer cells represent the predominant cell population to 
eliminate adenovirus-5 from the liver (131). Previously, activated 
macrophages have been shown to reduce their F4/80 expression 
(132, 133). The immunohistological finding corroborates this flow 
cytometric down-regulation of F4/80 surface expression. Similar 
phenotypical changes in Kupffer cells have been observed after 
an adenovirus-5 infection in which cytoplasmic LysM expression 
was diminished as early as 20 minutes after infection, while 
membrane-associated MHC II expression was unaffected (131). 
Despite the observation that ex vivo stimulations show minimal 
TNF production by F4/80high-Kupffer cells upon polyclonal 
stimulation, the gene expression profile of sorted F4/80high-
Kupffer cells from LCMV-infected mice clearly show induction of 
pro- and anti-inflammatory cytokines and chemokines, including 
TNF, IL-6, IL-10 and others. The discrepancy between the results 
obtained from the in vitro and in vivo data need to be studied 
in detail, but may be due to the nature of the trigger used for 
restimulation of the cells in vitro. Detailed comparison of the 
gene expression levels of the cytokines and chemokines in whole 
liver versus the purified population strongly suggest that both 
F4/80high-Kupffer cells and inflammatory monocytes contribute, 
to a large extent, to the production of cytokines early during 
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LCMV infection. Importantly the mRNA expression levels of TNF, 
IL-6, MCP, IP-10, and RANTES are highly similar between both cell 
types, whereas IL-10 mRNA remains expressed at higher levels by 
F4/80high-Kupffer cells as compared to inflammatory monocytes. 
Despite	 the	 relatively	 high	 expression	 of	 IFNα	 mRNA	 in	 whole	
liver 24 hours after LCMV infection, low or undetectable levels are 
observed in F4/80high-Kupffer cells and inflammatory monocytes, 
indicating that other intrahepatic cells, such as plasmacytoid DC 
and hepatocytes are the source of this interferon. Another option 
is	that	both	sorted	cell	types	produce	other	IFNα	subtypes	then	
the	IFNα1	and	2	detected	by	the	Nanostring	probes	(NCBI	ID	codes	
NM_010502.2 and NM_010503.2 respectively). Furthermore, due 
to the known RNA fragmentation after formalin fixation, all tested 
qPCR primer sets yielded  inconsistent results when tested on RNA 
from sorted F4/80high-Kupffer cells and inflammatory monocytes 
cells	 (data	 not	 shown)	 (127).	 IFNβ,	 on	 the	 other	 hand,	 was	
expressed by F4/80high-Kupffer cells, but not by inflammatory 
monocytes,	which	may	be	the	direct	result	of	triggering	of	IFNβ	
production upon LCMV infection and replication in F4/80high-
Kupffer cells. Importantly, despite distinct and selective expression 
of type I IFN, both cell types have transcript levels for numerous 
ISG, encoding for chemokines as well as proteins that function 
to suppress viral replication, such as MxA. This might imply that 
Kupffer	cell	IFNβ-release	is	instrumental	in	activating	the	recruited	
inflammatory monocytes, which could therefore be an important 
therapeutic target.
Previous studies have shown the complexity of the functions 
of inflammatory monocytes found in different organs, during a 
bacterial, fungal, protozoal or viral infection (104-110). Although 
both LCMV infection and LPS treatment induce the recruitment 
of inflammatory monocytes to a similar extent, we show that 
the activity of LCMV-induced and LPS-induced inflammatory 
monocytes are functionally distinct. Similar to their role in 
colonic inflammation, LCMV-induced inflammatory monocytes 
are skewed towards a secretory function, as demonstrated by 
the increase in TNF production ability in comparison to liver 
monocytic cells from healthy mice and their gene expression 
profile, and completely lose their steady state endocytic ability 
(106). On the other hand, LPS-induced inflammatory monocytes 
do not increase their ability to produce or express cytokines 
or chemokines, but enhance their endocytosis potential. In 
mouse studies, TNF production by intrahepatic inflammatory 
monocytes has been associated with liver damage (123, 124). 
Similarly in patients with chronic inflammatory and fibrotic liver 
diseases, inflammatory monocyte-derived TNF, amongst other 
pro-inflammatory cytokines and chemokines, has been shown 
to be pro-fibrogenic (134). However, we did not find evidence of 
liver damage at this early stage after infection. In line with this, 
Karlmark et al have shown that the newly recruited inflammatory 
monocytes are not responsible for the early onset of CCl4-induced 
hepatitis (122). Alternatively, inflammatory monocyte-derived 
TNF might act as a positive feedback for further recruitment of 
inflammatory monocytes to the liver. Recently, the formation of 
intrahepatic myeloid cell aggregates that can stimulate local T cell 
proliferation (iMATE) has been attributed to monocyte-derived 
TNF (135). Our findings support the pro-inflammatory role of 
recruited monocytes in the setting of early virus-induced liver 
disease.
Our study substantiates the robustness of the liver as a filtering 
organ for viral pathogens. Early after LCMV infection a functional 
dichotomy is observed for inflammatory monocytes and 
F4/80high-Kupffer cells with respect to endocytosis, but their 
activation and cytokine gene expression profiles exhibit a strong 
resemblance. Especially inflammatory monocytes show a huge 
capacity for recruitment to the liver and plasticity dependent 
on the nature of the inflammatory signal, either viral or sterile. 
Although the relative contribution of inflammatory monocytes 
or F4/80high-Kupffer cells to the outcome of the infection 
needs to be investigated, our study points towards a crucial 
role for inflammatory monocytes in shaping the inflammatory 
environment in the liver early after infection.
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Mouse liver with Kupffer cells in brown (F4/80 staining) and infiltrating lymphocytes 
(small blue cells) after 22 days of LCMV infection. 
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Abstract
Due to the scarcity of immunocompetent animal models for chronic viral hepatitis, little is known about the role of the 
innate intrahepatic immune system during viral replication in the liver. These insights are however fundamental for the 
understanding of the inappropriate adaptive immune responses during the chronic phase of the infection. We apply the 
Lymphocytic Choriomenigitis Virus (LCMV) clone 13 mouse model to examine chronic virus-host interactions of Kupffer 
cells (KC) and infiltrating monocytes (IM) in an infected liver. LCMV infection induced overt clinical hepatitis, with rise 
in ALT and serum cytokines, and increased intrahepatic F4/80 expression. Despite ongoing viral replication, whole liver 
transcriptome showed baseline expression levels of inflammatory cytokines, interferons, and interferon induced genes 
during the chronic infection phase. Transcriptome analyses of sorted KC and IMs using NanoString technology revealed two 
unique phenotypes with only minimal overlap. At the chronic viral infection phase, KC showed no increased transcription 
of activation markers Cd80 and Cd86, but an increased expression of genes related to antigen presentation, whereas 
monocytes were more activated and expressed higher levels of Tnf transcripts. Although both KCs and intrahepatic IM 
share the surface markers F4/80 and CD11b, their transcriptomes point towards distinctive roles during virus-induced 
chronic hepatitis. 
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Introduction
Detailed knowledge of intrahepatic immune responses is 
crucial for a better understanding of the processes underlying 
immunopathology. Chronic viral hepatitis induced by the 
Hepatitis B (HBV) and hepatitis C (HCV) virus affects almost 500 
million people worldwide and leads to progressive liver fibrosis, 
decompensated cirrhosis, and hepatocellular carcinoma (136). 
Due to ethical constraints, studies of liver residing leukocytes are 
seldom performed in patients, although these cells are essential 
in determining the outcome of the infection. As alternative, the 
Lymphocytic Choriomeningitis Virus (LCMV) mouse model can 
be used. LCMV clone (Cl) 13 infection in mice is an established 
small animal model for immunological studies on persistent viral 
infection such as HIV, but also HBV and HCV (113). The ability of 
LCMV to infect hepatocytes, among other cells, underlines the 
relevance of this model for the study of virus induced hepatitis 
(77, 82-84, 137). 
The largest innate immune cell population in the liver are the 
tissue-resident macrophages, also known as Kupffer cells (KC). KCs 
are abundantly present in the liver sinusoids, are crucial players in 
maintaining tissue homeostasis, and form together with sinusoidal 
endothelial cells the first barrier for pathogens to enter the liver 
(99). KCs can respond to danger signals using a variety of pathogen 
recognition receptors, such as Toll like, scavenger and antibody-
receptors  and, depending on the local environment, initiate an 
inflammatory response, or induce tolerogenic T-cell responses 
(100, 101). Previously, we described that liver inflammatory 
monocytes  resembled KC but were functionally distinct after 24 
hours of LCMV Cl13 infection in mice. Both cell types showed an 
activated phenotype with increased transcription of activation 
markers Cd80 and Cd86, and inflammatory cytokines Tnf and Il6 
(137). 
Monocytes patrol the body for inflammatory foci and are 
therefore among the first cells to respond to inflammation. 
They are quickly recruited in great numbers thereby shaping the 
immune environment (137, 138). These early monocytes are 
recruited in a CCL2/CCR2-dependent manner and are phenotyped 
in mice as F4/80+CD11b+CCR2hiLy6ChiCX3CR1low. They can 
exert pro-inflammatory and antimicrobial functions, such as 
secretion of inflammatory cytokines IL-6 and TNF (103, 137, 139). 
Previously, we showed that ex vivo HBsAg stimulation of blood 
monocytes revealed high cytokine induction (140). However, 
chronic HBV patient derived blood monocytes were not activated 
despite abundant viral proteins in their plasma (140). The role of 
liver monocytes and possible regulatory mechanisms controlling 
monocyte activation during chronic infection are still elusive. 
KCs and monocytes are cells with high plasticity and can exert 
diverse functions depending on their environment. In mice, KCs 
have been shown to induce tolerogenic T-cells after phagocytosis 
of particle-bound antigens under homeostatic conditions, 
whereas monocytes showed no or minimal particle uptake. 
However, during early inflammatory conditions, monocytes 
were fit to counteract the tolerogenic KCs by taking up particles 
and producing TNF and inducible nitric oxide synthase (101). 
Experiments on Listeria monocytogenes infection revealed 
that monocytes replenish dead KCs in the liver and exert an 
inflammatory response, followed by a tissue-repair response to 
restore homeostasis (141). On the other hand, monocytes have 
also been described as regulatory cells that can suppress CD8+ T 
cell proliferation during LCMV Cl13 infection in mice (142).
We previously showed that CD14+ cells derived from chronic HBV 
patient livers displayed an activated phenotype and are able to 
interact directly with hepatitis B surface antigen (HBsAg) (143). In 
vitro, these CD14+ cells produce high amounts of tumor necrosis 
factor (TNF), interleukin (IL)-6, and CXCL8 after stimulation with 
HBsAg and can activate NK cells (143). As both IM and KC are CD14 
positive, the precise roles of both cells during a chronic infection 
still need further elucidation. In the current paper we set out to 
fully characterize the immunology related gene transcription of 
sorted KCs and IM during chronic LCMV infection as a surrogate 
model for chronic viral hepatitis. We investigate whether these 
cells are distinct populations at the transcriptome level, and 
examine the role and activation status of both cells throughout 
chronic infection. 
Clinical Score Observation
CS 0 Normal behavior, active, no aberrant fur
CS 1 Pilo-erection AND/OR mild ruffled fur
CS 2 Mild hunched posture OR mild ruffled fur AND 
slightly less active
CS 3 Hunched posture AND ruffled fur AND less 
active
CS 4 Hunched posture AND ruffled fur AND inactive 
(very low or absent mobility)
CS 5 Death
Table 1. Clinical Scoring of LCMV infected mice
Materials and Methods
Study design, mice and virus
LCMV Cl13 was obtained as a kind gift from E. Zuniga, University 
of California in San Diego. LCMV Cl13 was propagated in BHK21 
cells and the titer was determined by plaque assay as previously 
described (76, 80). Female C57BL/6 mice aged 4-6 weeks (Charles 
River, France) received 2 x 106 plaque forming units (PFU) LCMV 
Cl13 intravenously (i.v.). Mice were co-housed with a maximum 
of 4 mice per cage and were fed ad libitum. Animals were 
maintained in a Biosafety level-III isolator according to Dutch 
national biosafety guidelines. Body weight and the assessment 
of clinical symptoms were determined 2-3 times a week (Table 
1). Blood was drawn from 6 mice at indicated time points to 
assess serum cytokines and liver enzymes. Mice were sacrificed 
in groups of 4-6 at indicated time point for whole liver qPCR, 
Immunohistochemistry, FACS analyses, and cell sorting (S1 Fig.). 
The study was approved by the animal ethics committee of the 
Erasmus University Rotterdam, and conducted according to 
relevant Dutch national guidelines. 
Isolation of total liver non-parenchymal cells 
Liver was removed without perfusion, cut into small pieces, and 
treated	with	30	μg/ml	Liberase	TM	(Roche)	and	20	μg/ml	DNAse	
type I (Sigma) for 30 min. Parenchymal cells were removed by low 
speed centrifugation at 50 g for 3 min and erythrocytes were lysed 
with 0.8% NH4Cl. The remaining non-parenchymal cells were 
resuspended in culture medium consisting of RPMI-1640 (Lonza) 
supplemented with 10% FCS (Sigma), 10 mM HEPES (Lonza), 2 
mM L-glutamine (Lonza), 1% penicillin/streptomycin (Lonza) and 
used for further analysis. 
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Plaque Assay
Parts of infected livers were weighed, homogenized using ceramic 
beads, and centrifuged for 10 min at 450 g at 4°C. Supernatant 
was serially diluted in Dulbecco’s modified Eagles Medium 
(DMEM, Lonza) supplemented with 10% FCS before inoculation 
onto overnight grown 90% confluent VeroE6 cells in 6 well plates 
(Corning). After 1 hour incubation, each 10^2 to 10^7 serial 
diluted inocula was removed and the cell layers were covered with 
a solution of 0.5% SeaKem®Agarose (Lonza) in Minimal essential 
Medium Eagle (EMEM, Lonza) supplemented with 10% FCS. The 
agarose layer was removed after 5 days incubation at 37°C, 5% 
CO2, and cells were stained with a crystal violet solution in 2% 
formaldehyde (Merck). The number of plaques at each dilution 
was counted and averaged to obtain the viral concentration of the 
sample in  PFU/ml. Each sample was corrected for liver weight 
input and is expressed as PFU per gram liver.
Flow cytometry
Total liver non-parenchymal cells were stained with Aqua Dead 
Cell Stain from Invitrogen, and antibodies directed against CD45 
eFluor450 (30-F11), F4/80 APC (BM8), CD11b PECy7 (M1/70) 
from eBioscience and Ly6C APCCy7 (HK1.4) from Biolegend 
(unless otherwise indicated), and fixed with 2% formaldehyde for 
1 hour, after which cells were analyzed using a FACSCanto-II flow 
cytometer and FACSDiva software (BD Biosciences). 
RNA isolation of liver homogenates, generation of cDNA and 
real-time PCR
Liver was homogenized in RNAlater (Qiagen). RNA was extracted 
using Trizol (LifeTech) and a NucleoSpin RNAII kit (Bioké). 
cDNA was generated using the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories) according to the manufacturer’s protocol. 
Quantitative PCR were performed using SYBR-green and MyIQ5 
detection system (Bio-rad Laboratories). Sequences of primers are 
listed in Table 2. Expression of target genes was normalized to the 
expression of GAPDH using the formula 2-ΔCt,	ΔCt=CtRNAX-CtGADPH.
RNA isolation of sorted cells and NanoString
KC and IM from 4-6 pooled livers were purified at day 0 (in 
duplicate), day 15, day 21, and day 41  post infection (p.i.), by cell 
sorting based on the expression of F4/80, CD11b and Ly6C, after 
initial enrichment using CD45 PE followed by anti-PE Microbeads 
(Milteny Biotec) selection. Following staining, cells were fixed with 
2% formaldehyde for 1 hour, and sorted on a FACS Aria SORP flow 
cytometer (BD Biosciences). Total RNA was isolated from sorted 
cells using the RNeasy FFPE kit (Qiagen) following manufacturers’ 
protocols starting with adding 150 µl Buffer PKD, to reverse any 
possible formaldehyde induced RNA modification. The nCounter 
GX Mouse Immunology Kit (NanoString Technologies, Seattle, WA, 
USA) was used to measure the expression of 561 genes in the RNA 
samples. Following hybridization, transcripts were quantitated 
using the nCounter Digital Analyzer. Samples were run by the 
Johns Hopkins Deep Sequencing & Microarray Core. To correct 
for background levels, the highest negative control value for each 
sample was subtracted from each count value of that sample. 
Following background subtraction, any negative count values 
were considered as 0. Values were normalized by the geometric 
mean of 13 housekeeping genes provided by the company panel.
Immunohistochemistry for F4/80
Liver was fixed in 4% formaldehyde, embedded in paraffin, and cut 
into 5 µm sections. F4/80 antigen was retrieved using Proteinase 
K (Sigma). Endogenous peroxidase was inactivated using 3% 
hydrogen peroxide (Dako). Liver sections were incubated with rat 
anti-F4/80 antibody (eBioscience) and rabbit anti-rat HRP (Dako). 
Upon addition of DAB, liver sections were counterstained with 
hematoxyline (Merck). 
Cytokine measurement
Serum	 TNF,	 IL-10,	 IFNɣ	 and	 CXCL1	 levels	 were	measured	 using	
the MSD® MULTI-SPOT Assay System, Mouse Pro-Inflammatory 
7-plex Ultra-Sensitive Kit (MesoScaleDiscovery, ref. K15012C-2), 
following the instruction manual. After an overnight incubation 
at 4°C, samples were measured in monoplicate undiluted and 
standard curve and blanks in duplicate. Electrochemiluminescence 
was read on a Sector Imager 6000 (MesoScaleDiscovery). 
ALT measurement
Serum ALT levels were measured using an ELISA kit for Alanine 
Aminotransferase (Biotang) according to the manufacturer’s 
protocol. 
Data analysis and statistics
Differences between groups were calculated using one-way ANOVA 
with Dunn’s Multiple Comparison post-test (GraphPad Prism 
version 5.01; GraphPad Software). Differences were considered 
significant when P < 0.05. Results are presented as the mean ± 
SEM, unless otherwise indicated. Principal component analyses 
was performed on whole log 2 transformed data set  using Multi-
experiment viewer (MeV) software version 4.9 and hierarchical 
clustering was executed using one minus pearson correlation 
in GENE-E software version 3.0.204 (Broad Institute, Inc). The 
statistical variance of all transcripts of 2 KC samples at day 0 were 
determined. The fold change of these values was calculated and 
used as cutoff to determine differentially expressed genes (1.27-
fold for KC). The cutoff for differentially expressed genes in IM 
was determined similarly (1.15-fold for IM). Non-expressed genes 
were defined as <100 relative RNA counts and below four times 
the standard deviation in all samples.
Taqman gene expression primers
Gene ID Primer ID*
Ifng Mm01168134_m1
Gapdh Mm99999915_g1
SYBR green primers
Gene ID NCBI ID Direction Primer sequence 5’ – 3’
Il6 NM_031168.1 F TGGTGACAACCACGGCCTTCC
R AGCCTCCTGACTTGTGAAGTGGT
Tnf NM_013693.2 F CAGGCGGTGCCTATGTCTC
R CGATGACCCCGAAGTTCAGTAG
Ifnb NM_010510.1 F GCCTGGATGGTGGTCCGAGC
R ACTACCAGTCCCAGAGTCCGCC
Isg15 NM_015783.3 F CAGGACGGTCTTACCCTTTCC
R AGGCTCGCTGCAGTTCTGTAC
Oas12 NM_011854.2 F GGATGCCTGGGAGAGAATCG
R TCGCCTGCTCTTCGAAACTG
Gapdh NM_008084,2 F CGTCCCGTAGACAAAATGGT
R TCTCCATGGTGGTGAAGACA
Table 2. Gene-specific primers used for whole liver RNA analyses
*Primer/probe mixes from Life-technologies
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Results
LCMV clone 13 infection induces evident hepatitis accompanied 
by changes in F4/80 expressing cells
Previously, we showed that LCMV Cl13 is able to infect the liver 
in addition to other organs (137). Infection with LCMV results in 
active intrahepatic replication, which can last up to 40 days (144). 
The progression of infection was accompanied by wasting (Fig. 1A, 
p<0.001 at peak of infection) and increased clinical scores based 
on set criteria (Table 1, and Fig. 1B, p<0.001 at peak of infection), 
which aggravated just after the peak of infection around day 14 
p.i. and recovered towards viral clearance from the liver at day 
39. At peak of infection, intrahepatic LCMV titers reached 8 log 
PFU/gr liver, which dropped to an average of 4 log PFU/gr liver 
from day 15 onwards (Fig. 1C). LCMV-specific T cell exhaustion is 
at highest level and sustained from day 15 p.i., which is therefore 
regarded as the onset of chronic infection in this model (145). Peak 
of intrahepatic LCMV replication was associated with evident rise 
of	serum	ALT,	preceded	by	peak	in	IFNγ	and	CXCL1,	and	coincided	
with TNF  and IL-10 levels (Fig. 1D).
To get insight in the kinetics, location, and morphology 
of F4/80+ myeloid cells during LCMV-induced hepatitis, 
immunohistochemistry was performed at several time points 
post infection. At the peak of intrahepatic LCMV replication 
F4/80+ cells changed their morphology into more elongated and 
swollen cells with decreased F4/80 intensity. During early chronic 
infection, cells were found in liver sinusoids with strong F4/80 
intensity. Later on, liver F4/80 staining was comparable to non-
infected livers (Fig. 1E). The changes in cell morphology and F4/80 
intensity staining suggests that viral infection alters the phenotype 
and possibly the function of F4/80 positive cells.
No increased expression of cytokine and interferon in whole 
liver during LCMV-induced chronic hepatitis 
We next examined the impact of LCMV-induced hepatitis on 
liver-specific innate immune responses. Increased levels of pro-
inflammatory cytokine transcripts occurred before (Tnf), during 
(Ifng), or after (Il6) the peak of intrahepatic viral replication (Fig. 
2A-C). Interestingly, these levels were not significantly different 
from baseline during the chronic phase of the infection. A similar 
intrahepatic expression pattern was seen in transcript levels of 
interferon (IFN)-beta and selected IFN stimulated genes (ISG, 
Figure 1. Evident LCMV-induced hepatitis with overt clinical symptoms, rise in serum cytokines and intensified F4/80+ cell staining. During the course 
of LCMV Cl13 infection mice were weighed (A) and clinically scored using predefined criteria (Table 1) (B). At regular intervals mice were sacrificed to 
determine	the	intrahepatic	LCMV	viral	load	(C).	Serum	was	collected	at	different	time	points	to	measure	ALT	(D)	and	cytokines	TNF,	IFNγ,	CXCL1,	and	IL10	
(D) using a multiplex assay. X-axis shows days post infection (A-D). Error bars indicate mean ± SEM (A-D). ND, not determined (C). F4/80 IHC staining was 
performed at indicated time points to characterize the presence, morphology and localization of F4/80+ cells within the liver (E). Insert at day 0 shows 
non-primary	control	staining	of	mouse	spleen	(E).		Scale	bar	indicates	100	μm	(E).
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Figure 2. Hepatic cytokine and interferon transcript levels increase during the peak of LCMV replication but normalize thereafter. Whole liver RNA 
was isolated from LCMV infected mice at regular intervals and analyzed for transcription of inflammatory cytokines Tnf, (A) Ifng (B), Il6 (C), Ifnb (D) and 
interferon induced genes Isg15 (E) and Oas12 (F) using qPCR. Given values on y-axes are relative expression to GAPDH. X-axes shows days post infection. 
Error bars indicate mean ±SEM. Significance of each time point was assessed using one-way Anova with Dunnett’s Multiple comparison test to day 0. 
*p<0.05, **p<0.01, ***p<0.001.
Figure 3. Kinetics of distinct F4/80+ cell populations from LCMV infected mouse livers. Mice were infected with LCMV Cl13 and were sacrificed 
at day 15, 22 or 39 p.i.. Distinct cell populations were determined using FACS analysis gating strategy of Live/CD45+F4/80highCD11bint and Live/
CD45+F4/80lowCD11bhighLy6chigh (A). Arrow indicates follow-up gate for the selection of Live/CD45+F4/80lowCD11bhighLy6chigh (A). Quantification 
of	F4/80highCD11bint	(black	bars)	and	F4/80lowCD11bhighLy6chigh	(gray	bars)	cells	as	log	cells	per	gram	liver	(B)		isolated	from	mouse	livers	(n=4-6).	
Statistical significance was assessed using one-way Anova with Dunnett’s Multiple comparison test to day 0. **p<0.01
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Figure 4. Transcriptomic changes during chronic LCMV-induced hepatitis in liver derived monocytes and Kupffer cells. Liver derived CD45+F4/80+CD11bint 
KC and CD45+F4/80intCD11bintLy6chigh IM were sorted and purity of sorted cells was assessed by FACS analyses and overlay graph (A). RNA was 
isolated from sorted cells at baseline (day 0) and after LCMV infection during the early chronic phase (day 15), chronic phase (day 22) and at time of 
viral clearance (day 41). Gene expression was measured using the nCounter GX Mouse Immunology Kit. Principal component 1 and 2 comprise 65% of 
the variance between samples (B). Transcription of myeloid cell defining markers for F4/80+CD11bint (Left) and F4/80intCD11bintLy6chigh (right) cells 
(C). Gene legend is indicated on the right side (C). Y-axis shows days post infection and X-axis indicates relative RNA counts (C). # 29297, 23963, 32090 
relative RNA counts for Csf1r day 0, 22, and 41, respectively (C). $ 22720 relative RNA counts for Marco at day 41 (C).
Isg15 and Oas12) (Fig. 2D-F). Despite ongoing LCMV replication 
from day 15 onwards, gene expression of ISGs, interferons, and 
pro-inflammatory cytokines were not significantly different from 
baseline levels.
Kinetics of two distinct liver F4/80+ cell populations during 
chronic LCMV-induced hepatitis
Because F4/80 expressing cells showed clear histological changes 
despite normalized whole liver transcription for selected 
inflammatory signals, we analyzed the longitudinal changes of two 
distinct F4/80+ myeloid cell populations (CD45+F4/80highCD11bint 
and CD45+F4/80lowCD11bhighLy6chigh cells) by flow cytometry 
(Fig. 3A). Both cell subsets were observed at baseline and during 
different chronic phases of LCMV infection . Compared to non-
infected mouse livers, CD45+F4/80highCD11bint cells increased 
significantly during the early chronic infection phase. In contrast, 
CD45+F4/80lowCD11bhighLy6chigh were not significantly 
altered during chronic LCMV infection (Fig. 3B). The increase in 
CD45+F4/80highCD11bint cells coincided with the more intense 
F4/80 staining in liver at day 15 p.i. (Fig. 1E). Irrespective of the 
phase of chronic LCMV infection both cell populations maintained 
their characteristic surface phenotype.
F4/80+ cell populations keep a distinct KC and IM phenotype 
throughout chronic infection
We previously described distinctive functions for KC (phagocytic) 
and IM (TNF production) (137). Plasticity is a well-known property 
of cells derived from the monocyte-macrophage lineage. Therefore 
we examined transcriptome profiles of F4/80highCD11bint and 
F4/80lowCD11bhighLy6chigh cells longitudinally. Cells were 
sorted from uninfected (day 0) and LCMV-infected mouse livers 
at the early chronic infection phase (day 15), during the chronic 
phase (day 22), and after clearance of LCMV from the liver (day 
41). FACS analysis demonstrated highly pure non-overlapping 
cell populations (Fig. 4A, and S1 Fig.). Using the nCounter 
NanoString platform, transcripts of 547 immunology-related 
genes and 14 housekeeping genes were measured in sorted cells. 
Principal component analyses showed that 65% of the variance 
in gene expression could be explained using components 1 and 
2, showing that both cells remained distinct on a transcriptome 
level throughout and after intrahepatic LCMV replication (Fig. 
4B). The surface expression of the discriminating markers used 
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Figure 5. Kupffer cells and infiltrating monocytes exhibit a distinctive viral antigen associated gene expression. Hierarchical cluster of complete 
transcriptome of sorted KC and IM (A). Gene upregulation (left) and down regulation (right) associated with presence of viral antigens in the liver of KC 
(B) and IM (C). Viral antigen plots show simplified figure 1C (B, C). Dark red indicates row max value, dark blue indicates row min value (B, C).
for FACS analyses of both populations, as shown in figure 3, 
were reflected in the cell’s transcriptome. F4/80highCD11bint 
transcribed high amounts of Emr1 (F4/80) and low Itgam (CD11b) 
and vice versa for the F4/80lowCD11bhighLy6chigh cells (Fig. 4C 
and S3 Table). Furthermore, the F4/80highCD11bint cells showed 
higher expression of macrophage markers such as Marco, Cd81, 
and Csf1r. The F4/80lowCD11bhighLy6chigh cells expressed more 
Itgam and Ccr2 at all time points (Fig. 4C and S3 Table). These data 
unequivocally demonstrate that both F4/80+ cell populations 
remain distinctive during ongoing intrahepatic LCMV replication 
and confirm the KC and IM phenotypes of sorted cell populations.
Kupffer cells and Infiltrating monocytes display a distinct viral 
antigen associated gene regulation
Hierarchial clustering of sorted KC and IM from different time points 
showed that the transcriptomes at  baseline and viral clearance 
cluster together for both cell types (Fig. 5A). This indicates that 
ongoing viral replication determines gene expression in both cells 
independently. We examined gene expression for up- and down-
regulated patterns identical to the viral load pattern. Only 2 genes, 
Ccrl2 and Tnf, showed a similar expression pattern in both cells 
(Fig. 5 and S2 Fig.). Among other genes, KC upregulated the ISGs 
Ifi35 and Ifit2, and antigen presentation related genes H2-Ab1 and 
H2-Eb1, which positively correlated with the presence of virus in 
the liver (Fig. 5B). Inflammatory cytokine Il6 and activation marker 
Cd86 expression in KC negatively correlated to the presence of 
viral antigens in the liver (Fig. 5B). IM showed among others 
increased Ccl4 expression and decreased expression of Tlr8 and 
Tlr9 together with decreased inflammatory pathway molecules 
such as Myd88, Nfkb1, Irak1, Irak4. Furthermore, IM showed less 
transcription of several surface receptors including Ifnar2, Ifngr2, 
Il10ra, and Il10rb in the presence of viral antigens (Fig. 5C). These 
data indicates that each cell type distinctively respond to the 
presence of viral antigens during chronic infection.
IM and KC exhibit a distinctive activated transcriptional profile
The activation status of myeloid cells is often assessed by the 
expression of costimulatory molecules CD80 and CD86, and the 
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Figure 6. Kupffer cells and infiltrating monocytes display a distinct activation and functional transcriptomic profile. Gene expression profile of KC (left) 
and IM (right) related to myeloid cell activation (A), antigen presentation (B), and interferon response (C). Gene legend is indicated on the right side of 
each panel. Y-axis shows days post infection and X-axis indicates relative RNA counts. # 75413, 106998, 171430, 113981 relative RNA counts for Cd74 at 
day 0, 15, 22 and 41, respectively (B).
production of cytokines and chemokines (99). Compared to IM, 
KC were less activated as indicated by a non-regulated expression 
of Cd80 and decreased expression of Cd86, while an increased 
expression of Cd80 at the early chronic phase and Cd86 during 
the whole chronic phases pointed towards more activated IM (Fig. 
6A). Nevertheless, both cells transcribed more Tnf during chronic 
infection, albeit almost 2-fold higher in IM compared to KC (Fig. 
6A). Overall, these data point to a differential activation status 
of KC and IM despite extraction from the same tissue and viral 
antigen rich environment.
KC, but not IM show a transcriptional specialization towards 
antigen presentation during chronic infection
Macrophages are able to present antigens (99). Here we observed 
that KC strongly upregulated several genes associated with 
antigen presentation with highest expression during the chronic 
phase at day 22 p.i.. In comparison, IM showed an overall much 
lower expression of most antigen presentation-related genes 
(Fig. 6B), indicating transcriptional differences between KC and 
IM and underlining the potential of KC to present antigens during 
chronic infection. IM showed exclusive expression (Camp, Trem1, 
IL1r2, Ltb4r1, and Mbp) and relative higher expression (Plaur, 
Spn, Tgfbi, S100a8, S100a9, and Sell) of a diverse set of immune-
related genes, which comprised cytokines, membrane proteins 
and receptors, signal transduction molecules, compared to KC 
at baseline and during infection (S3 Table). However,  this set 
of genes does not point to a specific pro- or anti-inflammatory 
signature for the sorted IM throughout infection.
KC and IM show an ambiguous antiviral response during chronic 
infection
During chronic infection KC showed an increased expression 
of Cxcl10, another marker for immune activation, whereas IM 
downregulated their Cxcl10 transcription (Fig. 6C). Cxcl10 is 
upregulated in response to interferons, however Ifna, Ifnb, and 
Ifng transcription was very low or absent in KC and IM at any 
time point during infection (S3 Table). Despite clear induction of 
Cxcl10 in KC and reduction in IM, other ISGs showed an irregular 
regulation (Fig. 6C), indicating an ambiguous antiviral response by 
KC and IM during chronic hepatitis.
Discussion
Our current understanding of liver specific immune cells during 
virus-induced liver disease has been hampered by the limited 
possibilities studying patient derived liver samples and the lack of 
suitable animal models. Here we use a surrogate model for human 
viral hepatitis, based on the infection of mice with LCMV Cl13. We 
show that LCMV Cl13 induced overt clinical hepatitis, with rise 
in serum cytokines during acute but not throughout the chronic 
phase.	Similarly,	acute	HBV	patients	present	high	TNF	and	IFNγ	in	
serum, whereas chronic HBV patients show normal levels of these 
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serum cytokines (146). The model was used to study liver resident 
and infiltrating myeloid cells during chronic viral hepatitis. 
In order to sort cells from LCMV infected mice in a BSL-1 
environment, cells required formaldehyde fixation, inherently 
leading to RNA strand breaks. Extracted RNA yield allowed only 
a limited number of qPCR reads, related to their fragmentation. 
For these materials, Nanostring hybridization has however been 
shown to yield reproducible gene expression data (147). To 
obtain sufficient RNA for gene expression analysis, livers were 
therefore pooled from 4-6 mice prior to cell isolation, staining, 
and flowcytometric sorting. Gene expression analysis of sample 
pools pick up large differences and flatten out biological variation 
of individual animals. Results are therefore more robust, have 
higher accuracy, but minor transcriptome changes might be 
missed (148).
We show by gene expression analyses of sorted KC and IM that 
these cells are distinct and maintain their respective phenotypes 
throughout the infection. Cell distinctive phenotypes were most 
evident by genes solely expressed (Marco and Trem1) by either 
cell type or genes regulated in opposite fashion (Cxcl10 and 
Cd86) throughout infection, suggesting either distinct regulatory 
mechanisms or that either cell type complements the other to 
maintain a balanced overall immune response.
During chronic infection, KC showed a less-activated phenotype. 
Conversely, IM were more activated, as shown by the upregulation 
of Cd80, Cd86, and Tnf, albeit lower when compared to acute 
LCMV clone13 infection as previously shown (137). Myeloid cells 
have been shown before to exert various functions ranging from 
maintaining homeostatic balance to initiating inflammation, 
regulating immune response, and tissue repair, depending on their 
milieu (149). Here, we found that KC have an increased expression 
of transcripts related to antigen presentation, suggesting that 
these cells are better equipped to present antigens and activate T 
cells during chronic infection.
Previously, we showed that after 24 hours of LCMV infection, KC 
were capable of expressing Ifng and Ifnb (137). Here we observed 
no transcription of IFNs in KC and IM during chronic infection, 
despite the local presence of viral antigens. However, KC showed 
increased transcription of Cxcl10. Increased CXCL10 levels in 
serum have been associated with immune activation and has been 
classically regarded as a marker of ISG responses in HCV infected 
hepatocytes (150-152). Moreover, evident ISG response in KC 
and not in hepatocytes have been shown to predict treatment 
outcome in chronic HCV patients, suggesting that KC are crucial 
players during chronic hepatitis (153).
We previously showed that intrahepatic CD14+ cells (comprising 
both KC and IM) from chronic HBV patients display an activated 
phenotype, based on higher expression of CD40 and CD80 (143). 
Moreover, these CD14+ cells had an increased HLA-ABC and HLA-
DR transcription, which was also observed in KC isolated during 
chronic LCMV infection. In addition, upon encounter with HBV 
particles human liver non-parenchymal cells  had an induced 
IL1b, IL6, CXCL8, and TNF transcription (154). Here, highly pure 
KC derived from LCMV infected livers also showed increased 
Tnf, but decreased Il1b and Il6 transcription. Furthermore, Tnf 
transcripts were much higher in sorted IM, indicating a balance 
of KC towards antigen presentation and less to pro-inflammatory 
cytokine production.
We showed that monocytes infiltrating the liver during LCMV-
induced chronic hepatitis were activated and transcribed various 
genes including Tnf correlating with the presence of viral antigens. 
However, peripheral blood monocytes from chronic HBV patients 
remained unaffected by viral proteins and HBV DNA, although 
they can produce high amounts of IL-6 and TNF upon stimulation 
with HBsAg in vitro (140). In HBV patients, anti-inflammatory IL-10 
in serum has been shown to be elevated and decreases cytokine 
production by monocytes (140, 155, 156), suggesting that 
regulatory mechanisms are in play during chronic viral hepatitis. 
We found elevated serum IL-10 levels during chronic LCMV 
infection and an exclusive transcription of Il10 in sorted KC and not 
IM suggesting a cell-specific regulation of immune responses (Fig. 
1D and S3 Table). Based on the gene expression data presented 
here no clear functional specialization can as yet be ascribed to 
intrahepatic IM during virus induced hepatitis. Their function 
might be tightly regulated between a pro- or non-inflammatory 
state.  Further insight will require a selective depletion of either 
KC or IM during or before LCMV, without disturbing the entire 
mononuclear phagocyte system (157).
In summary, we show that LCMV Cl13 induces evident chronic 
viral hepatitis with limited intrahepatic cytokine and interferon 
responses during the chronic infection. LCMV-induced hepatitis is 
characterized by morphological changes and increased intensity 
of the F4/80+ cell population, designated as IM and KC. KC 
and IM are distinct cell populations before, during, and after 
chronic infection, with important differences in activation status, 
antigen presentation, and gene expression profile correlating 
with the presence of viral antigens. Overall, these data suggest 
that intrahepatic monocytes and KC play distinctive roles during 
chronic virus-induced hepatitis.Acknowledgement
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Abstract
Genotype (gt) 3 hepatitis E virus (HEV) infections are emerging in Western countries. Immunosuppressed patients are at 
risk of chronic HEV infection and progressive liver damage, but no adequate model system currently mimics this disease 
course. Here we explore the possibilities of in vivo HEV studies in a human-liver chimeric mouse model (uPA+/+Nod-
SCID-IL2Rγ-/-)	next	to	the	A549	cell	culture	system,	using	HEV	RNA	positive	EDTA-plasma,	feces	or	liver-biopsy	specimens	
from 8 immunocompromised patients with chronic gt3 HEV. HEV from feces- or liver-derived inocula showed clear virus 
propagation within 2 weeks after inoculation onto A549 cells, compared to slow or no HEV propagation of HEV RNA 
positive, EDTA-plasma samples. These in vitro HEV infectivity differences were mirrored in human-liver chimeric mice 
after i.v. inoculation of selected samples. HEV RNA levels up to 8 log IU HEV RNA/gram, were consistently present in 
100% of chimeric mouse livers from week 2-14 after inoculation with human feces or liver-derived HEV. Feces and bile of 
infected mice contained moderate to high amounts of HEV RNA, while HEV viremia was low and inconsistently detected. 
Mouse passaged HEV could subsequently be propagated for up to 100 days in vitro. In contrast, cell culture-derived or 
seronegative EDTA-plasma derived HEV was not infectious in inoculated animals. In conclusion, infectivity of feces-derived 
human HEV is higher compared to EDTA-plasma derived HEV both in vitro and in vivo. Persistent HEV gt3 infections 
in chimeric mice, show preferential viral shedding towards mouse bile and feces, paralleling the course of infection in 
humans. 
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Introduction 
Hepatitis E virus (HEV) is a non-enveloped positive-sense single-
stranded RNA virus of the genus Orthohepevirus and family 
Hepeviridae (29). Four major HEV genotypes infecting humans 
have been described so far. Genotype (gt) 1 and 2 strains are 
only isolated from humans, whereas gt3 and gt4 strains are 
considered zoonotic viruses, present in both humans and several 
other species like pigs and wild game. HEV is spread through 
the oral-fecal route via contaminated water in developing 
countries or amongst others, via direct contact with animals 
or the consumption of undercooked meat in industrialized 
countries. In immunocompetent individuals, HEV infection is 
mainly self-limiting, often asymptomatic and thus remains largely 
underdiagnosed. HEV infections in immunosuppressed patients, 
such as solid-organ transplant recipients, often persist and can 
progress quickly to liver fibrosis and cirrhosis (158-160).
HEV gt3 infections are emerging in western countries, including 
France, the United Kingdom and the Netherlands (26-28).  Despite 
an overall decrease in anti-HEV seroprevalence from 1996 to 2011, 
young adult blood donors demonstrated higher seroprevalences 
from 2000 to 2011 (161, 162). In addition, HEV RNA positive blood 
donations were reported to increase in the Netherlands since 
2012 (163). Although the exact source of this HEV gt3 infection 
is unknown, it is likely that domestic swine and pig farming plays 
a critical role. HEV RNA gt3 was detected in approximately half of 
the pig farms in the Netherlands (164).
Human-liver chimeric mice have contributed significantly to our 
understanding of viral pathobiology, virus-host interactions and 
antiviral therapy for hepatitis B, C and D infections (40, 55, 61, 
89, 165-167). Since no animal model for chronic HEV infection 
is available, we examined the infectivity of HEV gt3 samples of 
different clinical origins in the humanized liver urokinase-type 
plasminogen activator (uPA) transgenic mouse model on a 
severely	 immunodeficient	 NOD/Shi-scid/IL-2Rγnull	 background	
(uPA-NOG) and compared this to the established Adenocarcinoma 
human alveolar basal epithelial cells (A549) cell culture system (4, 
168-170). We demonstrate that in vitro infectivity differences of 
feces, liver and plasma-derived HEV are paralleled in vivo. These 
differences are most apparent when inocula from a single patient 
are used with similar HEV RNA content. Once infected, persistent 
intrahepatic viral replication is seen in all chimeric mice, with 
preferential viral shedding to mouse bile and feces, reminiscent of 
human HEV infections. Human chimeric liver mice are therefore 
a suitable model for future studies on HEV transmission and 
pathobiology. 
thoroughly in 10 ml saline and centrifuged (450g, 3 min). After 2 
additional centrifugation steps (14000g, 5 min), the supernatant 
was passed through a 0.45 µm filter. A cryopreserved liver biopsy 
fragment from one heart and one allogeneic hematopoietic stem 
cell-transplant patient was homogenized in 500 µl saline using 
ceramic beads. The supernatant was used as inoculum after 
centrifugation (5000g, 10 min). All inocula were kept at -80°C until 
use.
 
Hepatitis E virus propagation
A549 were seeded on a coverslip in 24-well plate, in A549 
growth medium containing Dulbecco’s modified Eagles Medium 
(DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, 
Greiner Bio-one, Kremsmünster, Austria), 0.08% NaHCO3, 2 mM 
L-glutamine (Lonza), 1% penicillin/streptomycin (pen/strep, Lonza) 
and 0.5 µg/µl amphotericin B (Pharmacy, ErasmusMC, Rotterdam, 
The Netherlands). Three days after seeding, cells were washed 
once with phosphate buffered saline (PBS, Oxoid, Hampshire, UK) 
and inoculated with either HEV derived from different sample 
types or mock and incubated for 1 hour at 36.5°C in a humidified 
5% CO2 incubator. Liver-derived samples were diluted 1:10 prior 
to inoculation, to dilute toxic substances. The virus suspension was 
then removed and cells were washed three times with PBS before 
adding maintenance medium, containing 1:1 mixture of DMEM/
Ham’s F-12 (Life technologies), supplemented with 2% FBS, 
20 mM HEPES (Lonza), 0.4% NaHCO3, 2 mM L-glutamine, 0.3% 
Bovine Albumin Fraction V (BSA, Lonza), 1% pen/strep and 2.5 
µg/µl amphotericin B and incubated at 36.5°C in a humidified 5% 
CO2 incubator. Proper washing was documented by the absence 
of HEV RNA (Ct>38) in the last PBS supernatant. For monitoring 
virus propagation, every two to three days cells were inspected 
on cytophathogenic effect (CPE) and viability, culture medium was 
refreshed with maintenance medium (1:1) and supernatant was 
taken for HEV qPCR.
Mouse origin and genotyping
uPA-NOG mice were kindly provided by the Central Institute for 
Experimental Animals (Kawasaki, Japan) (168). Mice were bred 
at the Central Animal Facility of the Erasmus Medical Center. 
Offspring zygosity was identified using a copy-number duplex qPCR 
performed on phenol/chloroform/isoamyl-alcohol (Sigma Aldrich, 
St. Louis, MO, USA) extracted genomic mouse DNA from toe snip. 
TaqMan Genotyping Master Mix (Life technologies, Carlsbad, CA, 
USA) with TaqMan uPA genotyping assay (Mm00422051_cn, Life 
Technologies) and Tert gene references mix (Life technologies) 
were used according to the manufacturer’s protocol. All animal 
work was conducted according to relevant Dutch national 
guidelines. The study protocol was approved by the animal ethics 
committee of the Erasmus Medical Center (DEC nr 141-12-11).
 
Human hepatocyte transplantation
uPA homozygous mice, 6-12 weeks of age, were transplanted as 
previously described (165). In short, mice were anesthetized and 
transplanted via intra-splenic injection with 0.5-2 x 106 viable 
commercially available cryopreserved human hepatocytes (Lonza, 
Basel, Switzerland and Corning, Corning, NY, USA). Graft take was 
determined by human albumin in mouse serum using ELISA with 
human albumin cross-adsorbed antibody (Bethyl laboratories, 
Montgomery, Tx, USA) as previously described (165).
Material and Methods
Inoculum preparation 
Inocula	 were	 obtained	 from	 heart-	 (n=4),	 liver-	 (n=1),	 and	
allogeneic	hematopoietic	stem	cell	(n=2)	transplant	recipients	and	
one recipient who received both heart and kidney grafts (Table 1), 
treated either at the University Hospital Antwerp or the Erasmus 
Medical Center (4, 170). Clinical sequelae have been described 
elsewhere (4, 160, 170). All had detectable HEV RNA in their 
EDTA-plasma for more than 6 months (defined as chronic HEV 
infection). Table 1 shows the results of the anti-HEV IgM and IgG 
antibody determination in the EDTA-plasma inocula obtained with 
a commercially available enzyme-linked immunosorbent assay 
(ELISA, Wantai, Beijing, China). Open reading frame (ORF) 1 and 2 
sequences of the inocula are available at GenBank (Table 1). Fecal 
suspensions were prepared as follows: 3 gram feces was vortexed 
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Mouse infection
Mice were inoculated intravenously (i.v.) with 135-200 µl pooled 
patient EDTA-plasma (6.8 log international units (IU/ml), individual 
patient EDTA-plasma (6.7 log IU/ml), a homogenized liver biopsy 
fragment (6.3 log IU/ml), feces (8.8 log IU/ml or diluted to 6.8 log 
IU/ml) or 7th passage (P7) culture supernatant initially derived 
from feces (7.4 log IU/ml) containing HEV gt3 as denoted in Table 
1 and Supp. Fig. 1. The use of patient material was approved by 
the medical ethical committees of Erasmus MC and Antwerp 
University Hospital.
 
Histology, immunohistochemistry and HEV ORF2 
immunofluorescence
Mouse livers were fixed in 4% formaldehyde solution (Merck-
Millipore). Standard H&E staining was performed and human 
hepatocytes were identified using goat anti-human albumin 
cross-adsorbed antibody (Bethyl laboratories) or mouse anti-
human mitochondria antibody (Merck). To visualize the detected 
antigens, 3,3’-diaminobenzidine (DAB, DAKO, Copenhagen, 
Denmark) was added as a substrate and slides were counterstained 
with hematoxylin. To confirm in vitro HEV replication after 7 to 
14 days post infection, cells were fixed in 80% acetone (Sigma-
Aldrich) for 10 minutes, washed 3 times with PBS and air-dried. 
Cells were then blocked for 30 min at 36.5°C with 10% normal 
goat serum (MP Biomedicals, Santa Ana, CA, USA), followed by 
three times washing in PBS. Subsequently cells were stained for 1 
hour	at	36.5°C	with	a	1:200	0.5%	BSA/PBS	diluted	mouse-α-HEV	
ORF 2 aa434-547 antibody (MAB8002, Merck-Millipore, Billerica, 
Massachusetts, USA), followed by staining with 1:200 0.5% BSA/
PBS diluted goat anti mouse IgG conjugated with Alexa Fluor 488 
(Life Technologies) for 1 hour at 37°C. After washing with PBS, 
cells were counterstained with 4,6-diamidino-2-phenylindole 
(DAPI) and pictures were taken using a confocal microscopy (ZEISS 
LSM700).  
HEV RNA detection
All samples were screened for the presence of HEV RNA by an 
ISO15189:2012 validated, internally controlled quantitative real-
time RT-PCR, described previously (4).  Ct values above 38 were 
considered background. HEV RNA detection in samples with Ct 
values below 38 are indicated with their calculated values. Feces 
was pre-treated with transport and recovery buffer (STAR buffer, 
Roche, Almere, The Netherlands) and chloroform. Liver tissues 
were homogenized using ceramic beads in 500 µl RPMI (Lonza). 
Mouse serum, bile and liver homogenate supernatants, were 
diluted 10x before extraction due to limited sample volume or to 
dilute any impurities inhibiting the qPCR. 
Statistics
Graphpad Prism 5.01 was used for statistical analysis. Non-
normally distributed data were log-transformed. Continuous 
variables are presented as mean ± SD. Michaelis-Menten non-
linear test was used to determine goodness of fit, Kruskal-Wallis 
one-way Anova and Mann-Whitney test were used to calculate 
the p-value. Significance was set at P<0.05.
Case no. 1st year 
HEV+
age
@ HEV+
Sex Morbidity# GenBank 
accession 
ORF1
GenBank 
accession 
ORF2
Serostatus 
Plasma$
HEV RNA (log IU/ml) reference
IgM/IgG plasma feces¶ liver
HEV0008 2008 55 F AlloHSCT JQ015407 KT198654 +/+ 6.18 6.09 5.31 (170)
HEV0014* 2011 40 F AlloHSCT KC171436 KP895853 -/- 5.46/6.84* 5.61 - (170)
HEV0033 2010 51 M HTx JQ015427 KT198656 +/+ 5.73 6.20 - (4, 160)
HEV0047 2010 56 M HTx JQ015425 KT198657 -/+ 6.72 6.69 - (4, 160)
HEV0063 2010 19 M LTX JQ015426 KT198658 +/+ 4.96 5.18 - (4, 160)
HEV0069* 2010 62 M HTx JQ015423 KP895854 -/- 6,23 6.37/8.80* - (4, 160)
HEV0081 2009 50 M HTx + KTx JQ015418 KT198659 +/+ 4.91 5.15 - (4, 160)
HEV0122* 2014 63 M HTX KP895856 KP895855 -/- 5.83/6.74* 6.12/8.80* 4.87/6.26* this 
publication
Table 1. Inocula of chronic HEV gt3 patients for in vitro and in vivo infection
*Undiluted Inocula used for  in vivo infection; #AlloHSCT allogeneic hematopoietic stem cell transplantation; HTx heart transplantation; LTx liver transplantation; KTx 
kidney transplantation; $as determined by anti-HEV IgM and anti-HEV IgG ELISA (Wantai, Beijing, China); ¶Feces inocula were diluted to the plasma HEV RNA level 
in order to use an identical HEV RNA level for infection of the A549 cells. 
Results
Infectivity differences of HEV gt3 from patient plasma, feces or 
liver on A549 cells in vitro
Different clinical isolates from 8 chronic HEV gt3 patients were 
used to infect cultured A549 cells (Table 1). Feces samples were 
diluted, in order to load an identical HEV RNA amount of both 
plasma and feces derived inocula on the A549 cells. A549 cells 
were efficiently infected with HEV derived from feces and liver 
biopsies with increasing HEV RNA titers in supernatant up to 5.05 
log IU/ml within 7 days (Fig 1A-H ). HEV propagation was less 
efficient when using HEV RNA positive EDTA-plasma specimens, 
with 4 (HEV0008, HEV0014, HEV0033 and HEV0122) out of 8 
samples showing increasing HEV RNA titers after 10 or 15 days 
post exposure regardless of their serostatus (Fig 1A-H, Table 
1). The different in vitro replication kinetics of feces vs plasma-
derived HEV is evident from the calculated slopes during the first 
2 weeks after inoculation on A549 cells (Fig 1I; mean slope 0.151 
versus 0.028 log HEV RNA IU per day, respectively, P<0.01). HEV 
gt3 derived from patient HEV0069 feces was passaged seven 
times onto new cells, which resulted in increasing HEV RNA 
titers after each passage up to 8 log IU/ml (Fig. 1J). Anti-HEV 
ORF2 fluorescence staining confirmed HEV protein expression in 
feces-but not in plasma-inoculated A549 cells at day 7 and day 
14  (Fig. 1K). HEV is visualized in cytoplasm of clustered infected 
cells without obvious cytopathogenic effects. The percentage of 
infected cells was counted at 3-5% of total cells.
Successful infection of chimeric mice with feces-derived HEV gt3
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Figure 1. Differences in in vitro infectivity of HEV gt3  containing clinical samples on A549 cells. Gradual increase in HEV RNA levels in supernatant 
of A549 cells after inoculation of feces- (A-H) or liver-derived (A, H) HEV (Red and green line, respectively). No or slower increase in HEV RNA levels in 
supernatants of A549 cells after inoculation of EDTA plasma derived HEV (A-H, blue line).  I) Log HEV RNA increase per day within the first two weeks 
after inoculation with feces, plasma and liver derived HEV as depicted in A-H. J) Increasing HEV RNA titers after prolonged culture. Arrows indicated first 
measurement after passage. Dotted circle around the last P7 viral load, indicates the inoculum used for in vivo challenge described in Fig 3A.K) HEV ORF2 
immunofluorescence of HEV infected A549 cells, 7 and 14 days after inoculation of HEV0081 feces and plasma derived virus, and uninfected control 
A549 cells. HEV RNA was quantified with qRT-PCR and Ct-values above 38 are considered background (-) (A-H, J) . The HEV RNA concentrations of the 
initial inocula are indicated on time point 0 (A-H, J) . Error bars indicated mean±SD, ** P-value <0.01 (I).
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uPA-NOG mice, successfully transplanted with human hepatocytes 
had increasing human albumin levels in serum (Fig. 2A), which 
correlated with liver repopulation by human hepatocytes as 
demonstrated by H&E; specific human albumin and human 
mitochondria staining (Fig. 2B) (165). To corroborate the observed 
feces-derived HEV in vitro infectivity, filtered undiluted fecal 
suspensions (see Methods) from patients HEV0069 and HEV0122 
were i.v. inoculated into chimeric mice and the infection course 
was documented for 2, 6 or 14 weeks until sacrifice. During follow-
up, HEV RNA was detected in feces of these mice with titers up to 
7 log IU/gram (3.1±2.4 log IU HEV RNA/gram, Fig. 2C), while HEV 
viremia was low and inconsistently detectable, with maximum 
viral loads of 3.6 log IU/ml (1.1±1.5 log IU HEV RNA/ml, Fig. 2D). 
All 13 inoculated animals had high intrahepatic HEV RNA titers at 
sacrifice (6.0±1.1 log IU HEV RNA/gram, mean±SD, Fig. 2E). HEV 
is preferentially secreted via feces in infected individuals. In fact, 
HEV seroconverted patients continue to shed HEV in feces for 
several weeks, even when HEV serum titers drop to undetectable 
levels (159). We found that in infected animals serum titers were 
lower compared to feces, bile and liver titers. In 5 infected mice 
at 6 weeks post infection, the mean HEV RNA titers in serum, 
feces, bile and liver were 0.7±1.6 log IU/ml, 5.1±1.5 log IU/gram, 
5.4±1.2 log IU/ml, 6.5±0.8 log IU/gram, respectively (mean±SD; 
P-value 0.004 for difference, Kruskall-Wallis test, Fig. 2F). These 
Figure 2. Persistent infection of human liver-chimeric mice with feces-derived HEV gt3 from two chronic HEV patients. A) Human albumin levels were 
measured	in	mouse	serum	via	ELISA	to	quantify	the	hepatocyte	graft	take	at	5	and	8	weeks	post	transplantation	(n=13,	geometric	mean	±	SD).	B)	Liver	
histology of chimeric mouse livers at 8 weeks post transplantation (upper panels) and non-chimeric mouse liver (lower panels); H&E (left panel), anti-
human	albumin	(middle	panel),	and	anti-human	mitochondria	staining	(right	panel).	Chimeric	mice	(n=13)	were	challenged	i.v.	with	8	log	IU	HEV	RNA	
derived	from	human	feces	from	patient	HEV0069	(black	dots)	or	patient	HEV0122	(red	dots)	for	2,	6	or	14	weeks	(n=2;	7;	4	respectively)	(C-E).	HEV	RNA	
levels were measured by qPCR in mouse feces (C), mouse serum (D), and in mouse liver (E). F) Comparison of HEV viral load in serum, feces, bile, and 
liver	at	week	6	post	infection	(n=5,	mean	±	SD).	G)		In	vitro	HEV	propagation	in	A549	cells	of	mouse	liver-derived	HEV0122	(red	dots)	or	HEV0069	(black	
dots) after in vivo replication for 6 or 14 weeks, respectively. Arrow indicates first new data point after passage onto new A549 cells. ** P-value <0.01
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data suggests that virions are secreted preferentially through the 
biliary canaliculi, instead of basolaterally in the liver sinusoids. 
In addition, HEV0069 and HEV0122 viruses isolated from mouse 
livers after 6 or 14 weeks of in vivo replication respectively, could 
be propagated in vitro after exposure to A549 cells (Fig. 2G). The 
HEV0122 isolate was passaged further and could be maintained 
for over 3 months reaching high HEV RNA levels (>6 log IU/ml) 
in the culture supernatant (Fig. 2G). Taken together, these data 
confirm the in vivo infectivity of feces-derived HEV gt3 with 
establishment of 100% persistent and productive HEV infections 
in chimeric mice.   
Differences in in vitro HEV gt3 infectivity are reflected in vivo
In order to assess the infectivity differences of HEV RNA containing 
clinical samples a total of 19 chimeric mice were challenged with 
EDTA-plasma samples from patients HEV0014 and HEV0122, 
with liver homogenate from patient HEV0122, with feces of 
patient HEV0069 or with a high titre P7 culture supernatant of 
this patient’s feces (Fig. 1J, Fig. 3A, Table 1). Care was taken to 
inject animals with similar HEV RNA containing inocula, with some 
variation due to differences in injected volumes (135 to 200 µL). 
The respective inocula are indicated below the X-axis (Fig. 3A). 
Given the need for liver HEV RNA determination to demonstrate 
or rule out HEV infectivity, large liver fragments of sacrificed 
animals were collected at week 6 to week 17 after inoculation. 
Only liver- and feces-derived inocula proved to be infectious in 
chimeric mice. EDTA-plasma or A549 cell culture-derived inocula 
did not result in detectable HEV RNA levels at 6, 14 or 17 weeks 
after inoculation in any of the examined biological matrices (feces, 
sera, bile and liver; Fig. 3A and data not shown). In addition, 
untransplanted uPA+/-NOG mice inoculated with undiluted fecal 
suspensions from patient HEV0069 (8 log IU HEV RNA) remained 
HEV RNA negative in liver, serum and feces, indicating that human 
hepatocytes	are	HEV	target	cells	in	vivo	(n=3;	data	not	shown).	
The absence of detectable HEV RNA could not be ascribed to loss 
of chimerism, as the variation of human albumin levels during 
the course of the experiment was similar in HEV-positive and 
HEV-negative mice (Fig. 3B). Intrahepatic HEV RNA titers do vary 
and correlate with the degree of liver chimerism, as reflected by 
the human albumin levels in mouse serum (R2 0.6866) (Fig. 3C). 
However, the latter does not explain the infectivity differences 
observed between the different HEV containing samples, as the 
animal with lowest human albumin values at end of follow-up (50 
µg/ml) still had detectable intrahepatic HEV RNA levels. These 
data therefore corroborate a genuine biological difference in 
infectivity of HEV containing samples of different origins. 
Discussion
Figure 3. Differences in in vivo infectivity of HEV gt 3  containing clinical samples in human liver chimeric mice.	Chimeric	mice	(n=19)	were	challenged	
i.v.	with	HEV	RNA	containing	inocula	derived	from	EDTA	plasma	(patient	HEV0014	and	HEV0122;	n=4	respectively),	a	cryopreserved	liver	biopsy	(patient	
HEV0122;	n=2),	feces	(patient	HEV0069;	n=2),	or	P7	culture	supernatant	of	patient	HEV0069	feces	(n=7)	(see	Methods).	The	respective	infectious	doses	
are indicated below the X-axis, as well as the duration of the infection in weeks. HEV RNA levels were measured by qPCR in mouse liver at sacrifice (A). 
B)	Changes	in	serum	human	albumin	levels	from	HEV	inoculation	to	end	of	follow	up	of	HEV	RNA	negative	and	HEV	RNA	positive	mice	(n=23,	P=0.9339).	
C) Non-linear regression of chimerism, indicated by human albumin level in mouse serum (X-axis), versus the HEV titer in the liver (Y-axis) at week 6 post 
infection	(n=11).
Human HEV gt3 are emerging in Western countries and 
immunosuppressed patients are at risk of developing chronic 
HEV with progressive liver fibrosis. In this study we establish 
the  human-liver chimeric mouse as model for chronic HEV gt 
3 infections and demonstrate intrinsic in vitro A549 cell culture 
and in vivo infectivity differences of HEV gt3 containing clinical 
samples. Our data show that human liver-chimeric mice can 
develop a 100% chronic HEV infection, mimicking the infection 
course in solid organ and bone marrow transplant recipients. 
HEV in these mice is preferentially shed in bile and feces, which 
corresponds to the secretion pattern seen in humans. 
Feces- and liver-derived inocula led to rapid HEV RNA increases 
in the A549 cell culture system. The plateauing viral titers early 
after plasma inoculation, may be ascribed to HEV cell surface 
detachment and gradual release into the supernatant as HEV 
ORF2 staining remained negative after 7 days of culture (Fig. 
1K). We observed intrinsic HEV infectivity differences that were 
most apparent when plasma-, feces- and liver- HEV isolates 
from the same patient (HEV0008 and HEV0122) were examined: 
plasma-derived HEV demonstrated slower or no replication 
in vitro and in vivo respectively.  HEV virions from plasma and 
feces have been found to differ in virion density, ascribed to a 
divergent lipid membrane content. In addition, culture derived 
HEV has comparable characteristics to plasma derived HEV 
(171, 172). Differences between these viruses might be caused 
by the detergent activity of bile acids, which could strip the HEV 
virions from their lipid membrane upon their passage towards 
the intestinal system (173). This different buoyant density may 
influence in vivo infectivity, as has previously been shown for the 
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hepatitis C virus (167). Circulating inhibiting factors, including 
virus-specific antibodies, on the other hand may also negatively 
influence the infectivity of the virus preparations. Nevertheless, 
we used only pre-seroconversion plasma samples in our in vivo 
infectivity assays. 
Similar to 4 late resurgences of HEV RNA levels in vitro 
demonstrated here, others found productive in vitro infections 
with insertions in the ORF1 region after 5 to 6 weeks of culture of 
chronic HEV gt3 sera, but not acute phase sera (174-177). 
The observation that human plasma-derived virus is less infectious 
in vivo may be relevant for the infectivity and epidemiology of HEV 
in humans. Indeed, only a limited number of cases of transfusion 
transmitted HEV have been reported despite administration of 
contaminated blood products (28, 159, 178, 179). In addition, 
a recent retrospective survey of United Kingdom’s plasma pool, 
surprisingly showed that only half of HEV viremic British blood 
donors infected their recipients (28). The HEV transmission rate 
seemed to be dependent on the HEV RNA load and  anti-HEV 
antibodies status in donor plasma. Ultimate proof of intrinsic 
infectivity differences of membranous or antibody coated HEV 
particles will require delipidation and antibody depletion of 
plasma derived inocula. While recent reports have shown HEV gt3 
viremia among blood donors (163), Dutch national blood safety 
guidelines do not require NAT testing of the donor pool (180). This 
is of concern for solid organ transplant patients who are prone to 
develop chronic infections.
In conclusion, we have shown that feces- and liver-derived HEV 
gt3 induces a sustained infection in human liver-chimeric mice 
with preferential viral shedding towards mouse bile and feces, 
mimicking the course of infection in humans. This novel small 
animal model offers new avenues to study chronic HEV infections.
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Abstract 
The hepatitis E virus (HEV) genotype (gt) 3 genome is predominantly detected in blood, feces and liver of an infected 
host. These sample types have in vivo and in vitro infectivity differences, in part ascribed to biophysical differences of the 
virions. However, less is known about the selection of viral quasispecies/clones in these different body compartments. 
Since extrahepatic manifestations have been described and single nucleotide variants have been suggested to alter HEV 
virulence, we examined the genomic stability of HEV virions in different clinical samples and experimental conditions, 
including propagation in immunodeficient humanized mice and in A549 cells. Near full HEV genome Sanger sequences 
of serum- and feces samples from two immunocompromised chronic HEV gt3 patients were obtained. After prolonged 
in vitro culture, a clinical HEV gt3 strain acquired 19 nucleotide mutations, leading to 7 non-synonymous amino acids 
changes in the papain-like cystein protease, variable, viroporin and capsid regions. The same clinical HEV gt3 strain 
showed only 4 nucleotide mutations without alterations in the amino acid sequence after prolonged infection in a human 
liver-chimeric mouse model with impaired adaptive and innate immune responses. Similarly, intra-patient comparison of 
feces- and serum-derived HEV gt3 showed 7 and 2 nucleotide mutations with 2 and 0 amino acid changes, in two patients 
respectively. Overall, our data suggest that in vivo selection pressure in immunodeficient hosts is minimal, but adaptation 
to in vitro culture occurs.
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Introduction 
Hepatitis E virus (HEV) is a non-enveloped positive-sense 
single-stranded RNA virus, belonging to the family Hepeviridae 
within the genus Orthohepevirus (29). The genome of HEV is 
approximately 7.2 kb and contains three open reading frames 
(ORF). ORF1 encodes several non-structural proteins including a 
methyltransferase, a y-domain, a papain-like cysteine protease, a 
helicase, and the RNA-dependent RNA polymerase. ORF2 encodes 
for structural proteins forming the viral capsid and ORF3, which 
overlaps with ORF2, encodes a viroporin essential for the release 
of infectious particles (30, 158). 
In an infected host, a virus can compartmentalize in different 
locations and tissues, resulting in intra-host viral variants. 
Indeed, genomic viral variants of hepatitis C virus (HCV), human 
immunodeficiency virus (HIV) and Epstein-barr virus (EBV) have 
been observed in different compartments with altered viral entry, 
viral replication and treatment response (181-186). In addition 
to the liver, HEV is also found in blood, feces, and sporadically 
in cerebrospinal fluid of infected patients. Furthermore, in some 
cases HEV infection resulted in extra-hepatic manifestations 
(187). HEV’s mutational drift in vivo is not well studied, except 
for genomic alterations of blood-derived HEV, with respect to 
emergence of treatment resistant strains (188). It therefore 
remains unknown whether genomic viral variants of HEV are 
selected in  different physiological compartments in a patient.
Previous studies have identified single nucleotide substitutions in 
the viral genome of strains that resulted in more severe clinical 
phenotypes compared to strains lacking these substitutions, 
and suggested that these single nucleotide variants could be 
associated with increased virulence (189-191). Whether such 
mutations can affect HEV infectivity has never been investigated. 
We recently  showed that HEV gt3 derived from feces and liver 
was more infectious in humanized mice and A549 cells compared 
to HEV gt3 from serum (192). The contribution of viral variants to 
these observed infectivity differences in vitro and in vivo remains 
elusive.
Here we examine HEV gt3’s mutational drift in different 
compartments of two chronically infected hosts and compare 
mutagenesis of one clinical strain after experimental in vivo 
and in vitro propagation. We show up to two nonsynonymous 
of total seven nucleotide differences in intra-patient sample 
types, four synonymous mutations after in vivo passage, and 
seven nonsynonymous of total 19 nucleotide mutations after 
the 7th in vitro passage on A549 cells. Overall this demonstrates 
minimal in vivo selection pressure on HEV gt3 genomes in an 
immunocompromised host, but greater selection pressure during 
in vitro propagation. 
Figure 1. Schematic representation of size and location of the amplicons of PCR amplification. PCR fragment coverage 
was determined by primer alignment to the wbGER27 reference genome (purple bar). Blue bars represent first round PCR 
fragments; grey bars represent nested PCR fragments. Red scale bar indicates approximate size of 1000 nt. Fragment names 
correspond to primer pairs in Table 1 and Table 2.
Figure 2. Schematic representation of size and location of the amplicons of alternate PCR amplification. PCR fragment 
coverage was determined by primer alignment to the wbGER27 reference genome (purple bar). Blue bars represent first round 
PCR fragments; grey bars represent nested PCR fragments. Red scale bar indicates approximate size of 1000 nt. Fragment 
names correspond to primer pairs in Table 3 and Table 4.
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Amplicon/Primer name Sequence 5’- 3’ Size amplicon (nt) Tm (°C)
1.1: FW1 
        RV4*
GCAGACCACGTATGTGGTCGATGCC 2136 58GTCCGGGTGTACAARGTTCCCTC 56
1.2: FW5
        RV8*
TTGTGGCTGCAYCCTGAGGGG 1912 55CAGTGGACTATGTCCGTGAGTTC 52
1.3: FW9
        RV12*
TGCCCTGAACTTGAGCAAGGC 2118 51ACCAAACCRGAAGTAGCCTCCTC 54
1.4: FW13
        RV15*
TATCGTAACCAGGGYTGGCGCTCTGT 1302 58GTTTTCCTCATGACGACCTA 60
1A: FW3
       RV6
GTTCATATYTGGGACCGGCTYATGCT 2381 54CCACYACRTCAACATCCCCCTGCTGTA 58
1B: FW7
       RV10
GCCAACCTAGCACTGGAGATCGATGC 2263 58CCGGCCGGCAAAGCGCACCACATC 61
1C: FW11
       RV14
GGTTGTATGCTGGCGTGGTGGTGGC 2349 59CAATCAGAATCTGATCAC 50
Table 1. Sequences and details of primers used for first round of PCR amplification method 1.
*Primers used for cDNA synthesis
Amplicon/primer name Template Sequence 5’ - 3’ Size amplicon (nt) Tm (°C)
1: FW1*
1: RV1 1.1
GCAGACCACGTATGTGGTCGATGCC
564
58
CGGGCCATRGCCTCCGCAACATC 59
2: FW2
2: RV2 1.1
GCCCTGCGGCTAACTGCCGCCG
669
61
CTAATCCCGCGGAGGTAGGTCATAAG 56
3: FW3*
3: RV3 1.1
GTTCATATYTGGGACCGGCTYATGCT
664
54
GGGATGTTAAGYGCCCTATACAG 52
4: FW4
4: RV4* 1A
GAGGGCTCTGAGGTCGAYCAGGC
604
59
GTCCGGGTGTACAARGTTCCCTC 56
5: FW5*
5: RV5 1A
TTGTGGCTGCAYCCTGAGGGG
500
55
GCGYTGGTAGAAGGCATGGCAAAG 56
6: FW6
6: RV6* 1.2
TTGGCTGGTYAAYGCGTCGAATCC
613
54
CCACYACRTCAACATCCCCCTGCTGTA 58
7: FW7*
7: RV7 1.2
GCCAACCTAGCACTGGAGATCGATGC
598
58
TGGACYGTAATCGCACCGGGGTT 54
8: FW8
8: RV8* 1B
GCGGTCTTTATTCTGGAATGAGCC
554
52
CAGTGGACTATGTCCGTGAGTTC 52
9: FW9*
9: RV9 1B
TGCCCTGAACTTGAGCAAGGC
596
51
CCAAGGGAGAAGTTATTTTGRGTGCTATC 55
10: FW10
10: RV10* 1.3
GACGCATAYGAGGAGTCTGTGTT
515
52
CCGGCCGGCAAAGCGCACCACATC 61
11: FW11*
11: RV11 1.3
GGTTGTATGCTGGCGTGGTGGTGGC
640
59
CGCTGGGAYTGATCACGCCAAG 55
12: FW12
12: RV12* 1C
CTCCCCTATATTCATCCAACCAACC
622
53
ACCAAACCRGAAGTAGCCTCCTC 54
13: FW13*
13: RV13 1C
TATCGTAACCAGGGYTGGCGCTCTGT
574
58
TCATAGTCTTGGATGACCACACG 50
14: FW14
14: RV14* 1.4
GTCGTCTCAGCCAATGGCGAGC
513
55
CAATCAGAATCTGATCAC 50
15: FW15
15: RV15* 1.4
AAACATTCTATGTTCTCCCGC
458
43
TTTTTTTTCCAGGGAGCGCG 60
Table 2. Sequences and details of primers used for nested PCR amplification method 1 and Sanger sequencing of 
resulting fragments.
*Primers also used in first round PCR (Table 1)
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Material and Methods
Virus isolates
Clinical samples were obtained from two heart transplant 
recipients (HEV0069 and HEV0122) (192), before treatment at 
either the Erasmus Medical Center or the University Hospital 
Antwerp. Both patients had detectable HEV RNA in their EDTA-
plasma for more than 6 months (defined as chronic HEV infection). 
Feces and plasma were collected for HEV0069 at 45 and 64 days 
respectively, and for HEV0122 at 8 months after estimated time of 
infection. In vitro derived HEV was obtained from A549 cell culture 
supernatant after seven passages of HEV0069 feces-derived HEV, 
showing increased replication capacity over other passages. In 
vivo derived HEV was obtained from a human-chimeric mouse 
liver 6 weeks after inoculation with feces-derived HEV0069. More 
details about the in vitro and in vivo experiments have recently 
been described (192).
Viral RNA isolation
HEV RNA was isolated using the QIAamp Viral RNA Mini kit 
according to manufacturer’s instructions. Viral RNA was eluted in 
2 x 30 µl elution buffer. 
cDNA synthesis
cDNA of HEV0069 feces, serum and in vitro culture supernatant 
was synthesized using 1 µM HEV-specific primer Rv4, Rv8, Rv12 
and Rv15 (Table 1) , 0.5 mM dNTP nucleotide mix (Roche) and 
44 µl HEV RNA. Before cDNA synthesis potential secondary 
RNA structures were removed by heating to 65°C for 5 minutes 
followed by 1 minute incubation on ice. Subsequently, 2 U/µl 
RNasin (Promega), 5 mM Dithiothreitol (DTT) (Invitrogen), 0.25x 
First Strand buffer (Invitrogen), and 10 U/µl Superscript III RT 
(Invitrogen) were added to a total volume of 80 µl and incubated 
for 60 minutes at 50°C. HEV0122 feces and serum, and HEV0069 
derived from mouse liver HEV RNA was made to cDNA with a 
Transcriptor First Strand cDNA Synthesis kit (Roche) following 
manufacturer’s instructions, with 10 µl HEV RNA input for each 
20 µl reaction, using a combination of random hexamers and an 
oligo-dT primer. 
PCR amplification
HEV primer design of method 1 was done on basis 113 GenBank 
gt3 genomes, taking into mind that HEV gt3 genome FJ705359.1| 
Hepatitis E virus isolate wbGER27 is the closest related genome to 
most prevalent HEV genomes within our chronic HEV gt3 patient 
population according to HEV genotyping method described 
before (193).
cDNA of HEV0069 feces, serum and in vitro culture supernatant 
was used to generate seven overlapping amplicons in first round 
PCR (Figure 1) of each ~2000bp. Subsequently, two or three 
amplicons per primary product were generated using nested 
primers to cover the full HEV genome, with each ~100bp overlap 
and ~500bp length (Figure 1). Table 1 and Table 2 depict primer 
sequences for primary PCR and nested PCR, respectively. Primary 
PCR mixture contained 10 µl HEV cDNA with 0.4 µM primers, 1x 
PCR buffer (Qiagen), 1mM MgCl2 (Qiagen), 0.2 mM dNTP mix 
(Roche), and 2.5 U Hotstar polymerase (Qiagen), filled up to 50 
µl with RNase/DNase free water. PCR program started with a 15 
Amplicon/Primer name Sequence 5’ - 3’ Size amplicon (nt) Tm (°C)
M1*: 1-F
          1-R
GCAGACCACGTATGTGGTCGATGCC
975 60
GTCCGGGTGTACAARGTTCCCTC 
M2*: 2-F
          2-R
TTGTGGCTGCAYCCTGAGGGG
1530 60
CAGTGGACTATGTCCGTGAGTTC
M3*: 3-F
          3-R
TGCCCTGAACTTGAGCAAGGC
1562 60
ACCAAACCRGAAGTAGCCTCCTC 
M4*: 4-F
          4-R
TATCGTAACCAGGGYTGGCGCTCTGT
1498 57
GTTTTCCTCATGACGACCTA
M5*: 5-F
          5-R
GTTCATATYTGGGACCGGCTYATGCT
1749 57
CCACYACRTCAACATCCCCCTGCTGTA
M6*: 6-F
          6-R
GCCAACCTAGCACTGGAGATCGATGC
1761 50
CCGGCCGGCAAAGCGCACCACATC
M7*: 7-F
          7-R
GGTTGTATGCTGGCGTGGTGGTGGC
838 57
CAATCAGAATCTGATCAC
M8*: 8-F
          8-R
TGCCTATGYTGCCCGCGC
1412 57
ACWGYYGGCTCACCATTGGC
M8x*: 6.2n-R
            8-R
CARACCTGCGCIACRTTCGT
1439 50
ACWGYYGGCTCACCATTGGC
M9*: 9-F
M*9: 9-R
GCIGCYACRCGITTYATGAA
897 57
TTYTAAGRCGCTGAAGYTCAG
1.4#: FW13
          RV15
TATCGTAACCAGGGYTGGCGCTCTGT
1302 50
GTTTTCCTCATGACGACCTA
1C#: FW11
         RV14
GGTTGTATGCTGGCGTGGTGGTGGC
2349 50
CAATCAGAATCTGATCAC
Table 3. Sequences and details of primers used for first round PCR amplification method 2.
*Amplicons are based on the primer set described by Muñoz-Chimeno, et al. (194); #Amplicons derived 
from method 1 (Table 2)
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minute hot start at 95°C, followed by 40 cycles of 1 minute at 
95°C, 1 minute at 50°C, and 3 minutes at 72°C, and finalized by 
10 minutes at 72°C. Nested PCR conditions were identical to first 
round PCR, except the template was 2 µl of corresponding first 
PCR product, and the 40 cycles of the PCR program consisted of 
30 seconds at 95°C, 30 seconds at 50°C, and 1 minute at 72°C. 
Amplicon 15  was amplified using altered annealing temperature 
of 45°C instead of 50°C. RNase/DNase free water served as a 
negative control.
In order to amplify cDNA from serum and feces-derived HEV0122, 
and HEV0069 mouse liver, an alternative method using 12 
amplicons in primary PCR, which served as template for a total of 
18 nested PCR products was adapted from Munoz-chimeno et al. 
(Figure 2) (194). Table 3 and Table 4 depict primer sequences for 
primary PCR and nested PCR, respectively. PCR conditions were 
identical	as	described	above,	except	5	μl	cDNA	was	used	as	input	
for	first	round	PCR,	and	2.5	μl	first	PCR	product	served	as	template	
for nested PCR. The annealing temperature in the PCR program 
was adjusted to match each primer set (Tables 3 and 4). RNase/
DNase free water served as a negative control.
Fragment detection and purification 
Presence and purity of the nested amplicons was assessed by 
gel electrophoresis on a 2% agarose gel. UV exposure was kept 
to minimum. Amplified nested amplicon was extracted using 
the GeneJET MinElute kit (QIAGEN) according to manufacturer’s 
instructions. DNA concentrations were determined using 
Nanodrop, and samples were diluted to 0.5 ng/µl – 20 ng/µl. 
Amplicon/Primer name Template Sequence 5’ - 3’ Size amplicon (nt) Tm (°C)
1n*: 1n-F
         1n-R M1
TCGAWGCCATGGAGGCCCA
539 60
GTCATCCCRTGICGRGCCAT
2n*: 2n-F
         2n-R M2
ATYTGGGAYCGGCTYATGCT
600 60
CCRTGRACIGCRTARGTCCC
3n*: 3n-F
         3n-R M3
GCTGTGGTGGTYCGGCCGTT
1194 57
CGRCAYTGIGCRTARAACTG
4.1n*: 4.1-F
            4.1-R M4
GGCYTAYGARGGITCIGARGT
564 54
AAIGGRTTIGCIGAYTCCCA
4.2n*: 4.2-F
            4.2-R M4
TRTGGYTRCAYCCYGAGGG
891 54
GTYTCICGRTAYGCYGCCTC
5.1n*: 5.1n-F
            5.1n-R M5
AGGRTYGARCAGAAYCCIAAGAG
667 54
CGRTGIGTIACRTGCCACCA
5.2n*: 5.2n-F
            5.2n-R M5
GAGCTYCGIAAYAGYTGGCG
465 54
CTRGCRTCRGCYGTRGCTAT
6.1n*: 6.1n-F
        *  6.1n-R M6
GAYGTITGYGARCTYATACG
792 50
TCCTGRCCCTTYTCIACCAT
6.2n*: 6.2n-F
            6.2n-R M6
ATAGTYCAYTGYCGIATGGC
1035 50
CARACCTGCGCIACRTTCGT
6.3n*: 7n-R
        *  6.2n-R M6
TTGGTTGGATGAATATAGGGGAGGG
351 50
CARACCTGCGCIACRTTCGT
7n*: 7n-F
         7n-R M7
GGAAYACYGTYTGGAAYATGGC
697 57
TTGGTTGGATGAATATAGGGGAGGG
8n*: 8n-F
         8n-R M8x
TGCCTATGYTGCCCGCGC
1178 57
CCCGCGCGGCYGARACRACIGGGCGGG
8.1n: 8n-F*
          FW13# M8x
TGCCTATGYTGCCCGCGC
736 50
TATCGTAACCAGGGYTGGCGCTCTGT
8.2n: FW13*
          8n-R# M8x
TATCGTAACCAGGGYTGGCGCTCTGT
462 50
CCCGCGCGGCYGARACRACIGGGCGGG
9n*: 9n-F
         9n-R M9
CCGACAGAATTRATTTCGTCGGC
715 57
TCMGGRCARAAATCATCRAAAGT
B2#: FW2
         RV2 M3
GCCCTGCGGCTAACTGCCGCCG
669 50
CTAATCCCGCGGAGGTAGGTCATAAG
B13#: FW13
           RV13 1C
TATCGTAACCAGGGYTGGCGCTCTGT
574 50
TCATAGTCTTGGATGACCACACG
B15#: FW15
           RV15 1.4
AAACATTCTATGTTCTCCCGC
458 45
TTTTTTTTCCAGGGAGCGCG
Table 4. Sequences and details of primers used for nested PCR amplification method 2 and Sanger sequencing 
of resulting fragments.
*Primer set described by Muñoz-Chimeno, et al.(194); #Amplicons derived from method 1 (Table 2)
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Figure 3. Neighbour-joining phylogenetic tree of ORF1 HEV gt3 
sequences. Phylogenetic relationships of a (224bp) part of ORF1 were 
calculated using Kimura2parameter and Neighbour-Joining Method, with 
500 bootstrapping steps. Total of 111 sequences, including HEV0069 and 
HEV0122 (in red) are depicted. Different subtypes and genotypes are 
indicated within the tree.
Sanger sequencing
Sequence PCR was performed on 1 - 40 ng purified HEV DNA 
amplicon using 0.4 µM nested PCR primers (Table 2 and 4), 2 µl 
Big Dye Terminator V3.1 reaction mix (Applied Biosystems), and 3 
µl Big Dye 5x sequence buffer (Applied Biosystems), filled up to 22 
µl with RNase free water. The PCR program started with 1 minute 
at 96°C, followed by 25 cycles of 30 seconds at 96°C, 30 seconds 
at 45°C, and 1 minute at 60°C. Enzymes and superfluous reactants 
were removed using a Performa DTR V3 96-well short plate kit 
(EdgeBio) following manufacturer’s instructions. Sequence data 
and base calling were acquired through an ABI PRISM 3130XL 
genetic analyzer with POP7 polymer and 50 cm capillaries. 
Data analysis
Sequences were assembled using SeqMan Pro v10.1.2 (Lasergene, 
DNA star) by aligning fragment sequences against the wbGER27 
full HEV genome as reference (GenBank accession number: 
FJ05359) for HEV0069 and HEV RKI strain (GenBank accession 
number FJ956757) for HEV0122. Assembled sequences were 
aligned using the ClustalW Multiple alignment algorithm in BioEdit 
v7.2.0. Comparison of samples were performed using pairwise 
nucleotide distance and amino acid distances. Phylogenetic 
relationships of a (224bp) part of ORF1 were calculated using 
Kimura2parameter and Neighbour-Joining Method, with 500 
bootstrapping steps using MEGA6 software. A total of 111 
nucleotide sequences, including HEV0069 and HEV0122 were 
used	to	generate	a	neighbor-joining	phylogenetic	tree. 
Results
Feces- and serum-derived HEV sequences are not completely 
identical
Serum and feces HEV RNA was extracted from two chronic HEV 
patients (HEV0069 and HEV0122), from in vitro A549 passaged 
(P7) fecal-HEV0069 supernatant, and in vivo passaged (P1) fecal-
HEV0069, in human-liver chimeric mice. Using primers from 
Table 1 and Table 2, 15/15 and 8/15 amplicons were amplified 
for HEV0069 and HEV0122 isolates, respectively. Increasing 
genome coverage could be obtained with 16/18 amplicons 
for HEV0122 using extra and alternated primers (Table 3 and 
4). Similarly, fragments (8n and 8.1n, Table 4) did not amplify 
HEV0069 derived from chimeric mouse livers. Full genome 
coverage could be obtained for HEV0069, but not HEV0122, using 
amplicon primers 11 and 12 (Table 2) from the initial set up. All 
amplified fragments were purified and sequenced. All HEV0069 
and HEV0122 sequences were assembled by aligning fragment 
sequences against the wbGER27 or HEV RKI full HEV genomes, 
respectively. Sequenced HEV0069 samples resulted in a genomic 
coverage of 98.3-100%, whereas for HEV0122 only 85.4-88.9% 
genomic coverage could be obtained. The sequenced regions of 
HEV0122 completely covered ORF1, but lacked the first part of 
ORF2 and ORF3. The pairwise nucleotide identity of feces-derived 
HEV ORF1 sequences from HEV0069 and HEV0122 was calculated 
at 80.1%, whereas the pairwise amino acid identity was 93.7%. A 
neighbour-joining phylogenetic tree analyses of a (224bp) part of 
ORF1 revealed that HEV0069 and HEV0122 are divergent strains 
belonging to different genotype subtypes, namely genotype 
3i and 3f respectively (Figure 3). The sequences obtained were 
used to compare serum and feces derived HEV. Intra-patient 
comparison of HEV0069 isolates revealed 5 synonymous and 2 
nonsynonymous nucleotide mutations (one in the variable and 
one in the capsid region), whereas HEV0122 isolates revealed only 
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HEV0069
Nucleotide changes Corresponding (non)synonymous amino acid changes.
nucleotide 
position* feces$ serum
A549 
Culture mouse liver mutation# ORF1 ORF3 ORF2
1409 Y Y C Y Y1409C FL462L  
1474 C C Y C C1474Y C483C  
1591 C C T C C1591T A522A  
1900 C C Y C C1900Y G625G  
2070 T Y T T T2070Y F682S  
2122 Y C Y C Y2122C T699T  
2246 T T C T T2246C W741R  
2710 C C Y C C2710Y L895L  
2962 C C Y C C2962Y H979H  
3577 S C C C S3577C L1184L  
3610 C C Y C C3610Y D1195D  
3931 Y T Y T Y3931T V1302V  
4951 T T Y T T4951Y L1642L   
5373 C C Y C C5373Y Y71Y P68S
5378 A A G A A5378G N73S Q69Q
5456 C C Y C C5456Y  P99L S95S
5980 A W A A A5980W E270V
5990 T C T T T5990C S273S
6071 T T Y T T6071Y L300L
6323 S G G G S6323G P384P
6503 C C Y C C6503Y D444D
6596 C C Y C C6596Y L475L
6765 T T Y T T6765Y Y532D
7045 A A T A A7045T   D625V
nt changes 
to feces n/a 7 19 4 24 13 3 11
aa changes 
to feces n/a 2 7 0 9 3 2 4
Table 5. Genomic differences of HEV0069 isolates and after in vitro and in vivo passage.
*Relative to HEV wbGER27 (GenBank accession number: FJ05359), $Feces strain is used as reference sequence, #feces nt_nt 
position_changed nt; nt, nucleotide; aa, amino acid; n/a, not applicable; ORF, open reading frame; Yellow marks nucleotide 
mutations, green marks synonymous aa changes, red marks nonsynonymous aa changes.
2 synonymous nucleotide changes (Table 5 and Table 6). 
HEV adapts to cell culture, but shows only synonymous 
nucleotide changes during in vivo passage
RNA viruses are known to have relative high mutation rates, 
resulting in fast adaptation and evolutionary more distant strains 
(195). To assess the mutational drift of HEV, A549 cells were 
infected in vitro, and a human-liver chimeric mouse in vivo with 
HEV derived from feces of patient HEV0069. Infection in A549 
cells was maintained for 7 passages and culture supernatant was 
harvested 10 days after last passage, covering a total of 111 days 
of in vitro propagation, as shown before (192). HEV from culture 
supernatant was sequenced and showed 19 single nucleotide 
mutations compared to the initial feces-derived HEV inoculum 
(Table 5). Seven of these mutations resulted in amino acid selection 
or substitutions; FL462L, W741R in ORF1, N73S, P99L in ORF3, 
and P68S, E270V, Y532D, D625V in ORF2. We next investigated 
viral mutagenesis in differentiated human hepatocytes without 
interference of  immune pressure. Therefore, humanized NOG 
mice harbouring differentiated human hepatocytes were infected 
with the same patient derived HEV0069 strain and humanized 
mouse liver was isolated 6 weeks later. HEV derived from chimeric-
mouse liver showed 4 synonymous nucleotide mutations Y2122C, 
S3577C, Y3931T in ORF1, and S6323G in ORF2 (Table 5).
Discussion
In an HEV-infected host, virus concentrations are higher in 
bile, liver and feces than in blood. It is not known whether this 
compartmentalization results in different viral variants. HEV single 
nucleotide variants in blood have been shown to alter clinical 
virulence (189-191). Furthermore, we have previously shown 
that the in vivo and in vitro infectivity of HEV from blood and 
feces differs substantially. Finally, the presence of extrahepatic 
manifestations in selected patients suggests viral selection or 
adaptation to different tissues. Therefore, we performed intra-
patient comparison of full genome sequences of HEV gt3 isolates 
from serum and feces of two chronic HEV patients. In addition, 
to assess mutation rate we examined the HEV sequences after in 
vitro and in vivo passage of HEV0069 feces-derived virus.
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HEV0122
Nucleotide changes Corresponding (non)synonymous amino acid changes.
nucleotide 
position* feces$ serum Mutation# ORF1 ORF3 ORF2
4984 Y T Y4984T V1652V
6416 T C T6416C V409V
Table 6. Genomic differences of HEV0122 isolates
HEV RNA was isolated and sequenced from serum and feces of 
two chronic HEV patients. Intra-patient HEV nucleotide sequences 
showed five synonymous and two nonsynonymous differences 
between feces and serum isolates from HEV0069, whereas only 
two synonymous mutations were found in HEV0122 isolates. 
The two amino acid changes occurred in the ORF1 in a region of 
unknown function, and ORF2 encoding the capsid, thereby possibly 
impacting viral entry. This illustrates that compartmentalized viral 
variants may exhibit distinct intrinsic viral properties. Whether the 
identified nonsynonymous mutations are the cause for altered 
infectivity remains to be determined. 
In addition to inter- and intra-patient comparison of serum- and 
feces-derived HEV gt3 strains, the genomic alterations after in vitro 
and in vivo passage were assessed. HEV0069 feces-derived virus 
was used to infected A549 cells in vitro and human hepatocytes 
in immunocompromised human-liver chimeric mouse. The latter 
host precludes immune selection pressure, due to the absent T, B 
and NK cells, and therefore allows to compare the mutagenesis 
between HEV replication in a lung adenocarcinoma cell-line 
and differentiated hepatocytes. A four nucleotide-different viral 
variant, without amino acid alterations, was identified in HEV 
derived from humanized mouse liver 6 weeks after inoculation. 
The absence of immune cells may explain the limited mutational 
drift of HEV in these mice. In addition, we recently showed no 
induction of intra-cellular innate immune response in HEV 
infected human hepatocytes, minimizing the intra-cellular 
immune pressure (255). The fact that only few viral variants are 
seen in patients between serum and feces supports this relatively 
low compartment-specific mutation rate.
However, when we culture HEV for 111 days (seven serial 
passages), 7 out of 19 mutations, which were identified, resulted 
in amino acid changes (2 occurred in ORF1, and 5 in ORF2/3) 
(Table 5). Previous studies have identified single nucleotide 
variants that displayed altered viral fitness (189-191). In addition, 
one study showed significant increased infectivity in HepG2/C3A 
cells upon insertion of a 171-nucleotide sequence of human S17 
ribosomal protein into a HEV gt3 cDNA clone (176). We did not 
detect any nucleotide insertions after 111 days of propagation 
in A549 cells with patient derived HEV. Whether the mutations 
found after culture in A549 cells influence viral fitness is subject 
for further study. 
The observed genomic alterations after in vitro culture and in 
vivo infection in humanized mice illustrate important model 
differences. Occurrence of several nucleotide substitutions can 
alter viral fitness and responsiveness to treatment. Therefore, 
it is important to identify viral mutations and selection with 
the models used to study HEV. Based on our results the in vivo 
model is most representative for genuine infection with no 
nonsynonymous mutations after 6 weeks of infection. Whether 
the in vitro acquired nucleotide substitutions are due to the in 
vitro setting or the adaptation of the virus to non-hepatic cell line 
remains to be determined.
Our observations showed clear differences between the major 
populations identified using Sanger sequencing, which is able 
to detect viral variants that comprise at least 20% of the total 
viral population (196). Therefore, we are not able to conclude 
on possible minority populations present. Future research could 
use Next generation sequencing (NGS) for detection of minority 
populations, which has a detection limit of as low as 1% (196)
In conclusion, our data suggest that HEV gt3 genomically adapts 
to in vitro culture, but that in vivo selection pressure in immune 
deficient hosts is minimal. However, possible genomic adaptation 
to compartmentalization in chronically infected patient can ensue. 
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Hepatitis B virus in brown (anti-HBsAg staining) in clusters of human hepatocytes in the 
mouse liver.
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Abstract 
Antiviral treatment options for chronic Hepatitis E Virus (HEV) infections are limited and immunological determinants of 
viral persistence remain largely unexplored. We studied the antiviral potency of pegylated interferon-ɑ (pegIFNɑ) against 
HEV infections in humanized mice and modelled intrahepatic interferon stimulated gene (ISG) responses. Human gene 
expression levels in humanized mouse livers were analyzed by qPCR and Nanostring. Human CXCL10 was measured in 
mouse serum. HEV genotype 3 (gt3) infections were cleared from liver and feces within 8 pegIFNɑ doses in all mice and 
relapsed after a single pegIFNɑ injection in only half of treated animals. Rapid viral clearance by pegIFNɑ was confirmed 
in HEV gt1, but not in Hepatitis B Virus infected animals. No ISG induction was observed in untreated HEV gt3 and gt1 
infected humanized livers compared to control chimeric mice, irrespective of the human hepatocyte donor, viral isolate or 
HEV infection duration. Human specific ISG transcript levels in mouse liver increased significantly after pegIFNɑ treatment 
and induced high circulating human CXCL10 in mouse serum. In conclusion, HEV gt1 and gt3 infections do not elicit innate 
intrahepatic immune responses and remain highly sensitive to pegIFNɑ in immunocompromised humanized mice.
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Introduction 
Hepatitis E Virus (HEV) infections are emerging in western 
countries (197). HEV is a non-enveloped positive-sense single-
stranded RNA virus, belonging to the family Hepeviridae within 
the genus Orthohepevirus (29). Transmission mainly occurs 
through the fecal-oral route via contaminated water in developing 
countries or through the consumption of undercooked meat in 
industrialized countries (158). Seven different genotypes have 
been described so far, of which genotype (gt) 1 and 3 are most 
prevalent in humans (29). In healthy individuals, HEV mostly 
resolves spontaneously without severe symptoms, but pregnant 
women seem to be at risk of developing fulminant liver failure 
by HEV gt1 with mortality rates up to 25% (198, 199). On the 
other hand, increasing rates of chronic gt3 infections have been 
described in immunocompromised patients in Europe, resulting 
in progressive liver fibrosis and cirrhosis (3-5). These data indicate 
that host pathogen interactions differ between both genotypes. 
Antiviral treatment options for chronic HEV infected 
immunocompromised patients are limited. Ribavirin (RBV) leads 
to sustained viral responses in roughly 75% of patients, but is 
hampered by RBV-induced anemia and the need for recombinant 
erythropoietin injections or transfusions in more than half of 
patients (47, 200). As an alternative, pegylated interferon-alpha 
(pegIFNɑ)	 has	 been	 administered	 to	 a	 few	 patients	 in	 doses	
comparable to Hepatitis C virus (HCV) treatment regimens (47, 48). 
However, factors associated with interferon (IFN)-susceptibility, 
the	optimal	pegIFNɑ	dose	or	treatment	duration	have	not	been	
investigated in vivo.
The	 anti-HEV	 effects	 of	 IFNɑ	 in	 vitro	 differ	 according	 to	 the	
target cell and viral strain used. In vitro HEV models consist 
of human hepatoma and lung adenocarcinoma cell-lines, in 
which replication of subgenomic or full length replicons and 
seldom intact patient-derived viruses are studied (169, 175, 
192, 201, 202). Patient-derived HEV gt3 cultures show slow viral 
propagation, whereas HEV gt1 can only be cultured in vitro after 
induction of endoplasmic reticulum stress in the host cell line 
(169, 192, 203). While HEV gt1 replication has been shown to be 
adequately	 suppressed	 by	 exogenous	 IFNɑ,	 HEV	 gt3	 replication	
has not (204-206). In addition, viral inhibition of the interferon 
stimulated gene (ISG) responses have been described as a 
determining	 factor	 for	 IFNɑ	 susceptibility	 in	 vitro	 (207).	 As	 the	
studied host cells are either no target cells in vivo (A549 cells) 
or are hampered by defects in their innate immune signaling 
(Huh7 and Huh7.5), the host response towards genuine patient-
derived HEV in differentiated human hepatocytes remains to be 
established (204, 208). In addition, several clinical observations 
are not matched by in vitro viral replication data. HEV containing 
an in vivo RBV acquired mutation (K1383N), showed conflicting 
results in vitro with decreased viral replication and increased RBV-
sensitivity (191). Furthermore, the antiviral efficacy of sofosbuvir 
against HEV showed discrepancies in different in vitro and in vivo 
studies (209-212).
Recently, we and others have shown that human-liver chimeric 
mice can be used to study HEV infection in differentiated human 
hepatocytes in vivo (192, 213, 214). Here, we examined baseline 
ISG	 expression	 levels	 and	 susceptibility	 to	 pegIFNɑ	 in	 HEV	 gt1	
and gt3 infected humanized mice. We demonstrate that HEV 
gt1 infections lead to higher virus loads in mouse feces, bile 
and liver compared to HEV gt3 infections, without the induction 
of intrahepatic human innate immune responses. Both HEV 
genotypes, but not Hepatitis B virus (HBV), are cleared after a 
few	doses	of	pegIFNɑ	 in	vivo,	an	effect	accompanied	by	a	clear	
increase of human ISG transcript levels in liver and of circulating 
human CXCL10 levels in mouse serum. 
Table 1. Hepatocyte donors
Donor ID Gender Age Race
HD1 Male 2 years Caucasian
HD2 Female 2 years Caucasian
HD3 Female 7 months Caucasian
Viral strains, mouse infection and treatment
HEV gt3 was derived from feces of one of two chronic HEV 
patients (HEV0069 and HEV0122) as described previously (192). 
HEV gt1 Sar-55 was derived from feces of a Rhesus macaque that 
had been originally inoculated with the human Sar-55 strain (216). 
Eight weeks after transplantation human-liver chimeric mice 
were inoculated intravenously (i.v.) with 200 µl feces suspension 
containing HEV gt3 (8.8 log IU/ml or diluted to 6.8 log IU/ml), HEV 
gt1 (7.9 log IU/ml or diluted to 6.2 log IU/ml) or 200 µl patient 
serum containing HBV gtA (7.7 log IU/ml). After viral inoculation, 
mice were housed individually. Mice were treated with a single 
subcutaneous	 pegIFNɑ-2a	 (30	 µg/kg	 unless	 stated	 otherwise,	
Pegasys, Roche, Basal, Switzerland) injection or every 3-4 days for 
2 or 4 weeks. Overview of viral isolates are shown in Table 2. An 
overview of experimental groups is shown in  Table 3 and Suppl. 
Fig. 4. 
  
HEV RNA and HBV DNA detection
The presence of HEV RNA in mouse serum, feces, bile and liver 
was determined by an ISO15189:2012-validated, internally 
controlled quantitative real-time RT-PCR, described previously 
(4, 192). Cycle threshold (Ct) values above 38 were considered 
Material and Methods
Ethics, consent and permissions
The use of patient material was approved by the medical ethical 
committees of Erasmus Medical Center and Antwerp University 
Hospital. Informed consent was obtained from all subjects. All 
animal work was conducted according to relevant Dutch national 
guidelines. The study protocol was approved by the animal ethics 
committee of the Erasmus Medical Center (DEC nr. 141-12-11).
Mouse origin and genotyping
Urokinase-type plasminogen activator (uPA)/NOD/Shi-scid/IL-
2Rγnull(NOG)	mice	were	kindly	provided	by	the	Central	Institute	
for Experimental Animals (Kawasaki, Japan) (53). Mice were bred 
at the Central Animal Facility of the Erasmus Medical Center. 
Zygosity of mice was determined as described previously (192). 
Mice were co-housed with a maximum of 4 mice per individually 
ventilated cage and were fed normal chow ad libitum. 
Human hepatocyte transplantation
Six to twelve week old male uPA-homozygous mice were 
transplanted as described previously (215). In short, mice were 
anesthetized and transplanted via intrasplenic injection with 0.5 
x 106 to 2 x 106 viable commercially available cryopreserved 
human hepatocytes from 1 of 3 donors (Corning, NY, USA; Lonza, 
Basel, Switzerland; Table 1). Graft take was determined by human 
albumin in mouse serum using an ELISA with human albumin 
cross-adsorbed antibody (Bethyl laboratories, Montgomery, TX, 
USA) as previously described (192). 
52  |
Chapter 6  |  Immunodeficient human-liver chimeric mouse model
background, which corresponds to a lower limit of detection of 
2.16 log10 HEV RNA units/ml in undiluted human serum. HEV 
RNAs detected in samples with Ct values below 38 are indicated 
with their calculated values. HBV viral load was measured in 
mouse serum and liver using a dual target approach, using primers 
and probes targeting preS-gen, as described before (217, 218), 
and the X gene (HBV XJfwd12 5’-ggtctgtgccaagtgtttgst-3’, HBV 
XJprobe 5’-FAM-acgcaacccccactggctggg-BHQ1-3’, HBV XJrev12, 
5’-tycgcagtatggatcgsc-3’).
RNA isolation of whole liver, generation of cDNA and real-time 
qPCR
Whole liver RNA was isolated using RNeasy mini kit (Qiagen, 
Hilden, Germany) including DNAse treatment according to 
manufacturer’s protocol starting with homogenization of liver 
tissue in RLT buffer. cDNA was generated by using an iScript cDNA 
synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) according 
to the manufacturer’s protocol. Human specific gene expression 
was measured using Taqman primer/probe quantitative PCR, in 
TaqMan® Gene Expression Master Mix (Thermo Fisher Scientific, 
Waltham, MA, USA). Primer/probe combinations were purchased 
from Thermo Fisher Scientific; CXCL10 (Hs01124251_g1), 
CXCL9 (Hs00171065_m1), DDX58 (Hs01061436_m1), GAPDH 
(Hs00266705_g1), IFIT1 (Hs01911452_s1), ISG15 (Hs01921425_
s1), IFNA1 (Hs00855471_g1), IFNA4 (Hs01681284_sh), IFNB1 
(Hs01077958_s1), MX1 (Hs00895608_m1), OAS1 (Hs00973637_
m1), RSAD2 (Hs00369813_m1), STAT1 (Hs01013996_m1), TLR3 
(Hs01551078_m1). Expression of target genes was normalized to 
the	expression	of	GAPDH	using	the	formula	2-ΔCt,	ΔCt	=	Cttarget-
CtGADPH. cDNA from non-chimeric mouse livers was used as 
control to test cross-reactivity of housekeeping and target genes. 
Due to the difference in hepatocyte donor baseline expression 
levels of examined genes (Suppl. Fig. 1), fold changes of transcripts 
were calculated to those of non-infected humanized livers from 
mice transplanted with the identical hepatocyte donor. 
Cytokine measurement
Human CXCL10 was measured in 1:5 diluted mouse serum 
samples using the Human CXCL10/IP10 Quantikine ELISA Kit (R&D 
Systems, Minneapolis, MN, USA) according to manufacturer’s 
protocol.
Nanostring analyses
RNA was isolated from chimeric mouse livers as described 
above. The nCounter  GX human Immunology V2 Kit (NanoString 
Technologies, Seattle,WA, USA) was used to measure the 
expression of 594 human genes in the RNA of these samples. 
Following hybridization, transcripts were quantitated using 
the nCounter Digital Analyzer. Samples were run at the Johns 
Hopkins Deep Sequencing & Microarray Core facility. To correct 
for background levels, the highest negative control value for 
each sample was subtracted from each count value of that 
sample, as described previously (137, 219). Following background 
subtraction, any negative count values were considered as 0. 
The geometric mean of 5 housekeeping genes provided by the 
company panel was calculated and used to normalize expression 
values.  RNA from non-chimeric mouse livers was used as control 
to test cross-reactivity of genes. Fifty cross-reactive genes were 
removed prior to analyses of the data set. Non-expressed genes 
were defined as <100 relative RNA counts and below four times 
the standard deviation in all samples. 
Statistics
Differences between groups were calculated using two tailed 
Mann-Whitney test or Kruskal-Wallis one-way ANOVA with Dunn’s 
all column comparison post-test (GraphPad Prism version 5.01; 
GraphPad Software). Differences were considered significant 
when P<0.05. Results are presented as the mean ± SEM. Principal 
component analyses was performed on log 2 transformed data 
set and heatmap of IFN signaling/response genes was generated 
using Multi-experiment viewer (MeV) software version 4.9.
Virus Genotype Strain/
Isolate*
Source Inoculum
HEV 1 Sar-55 Rhesus 
macaque feces
feces 
suspension
HEV 3 HEV0069* Chronic HEV 
patient feces
feces 
suspension
HEV 3 HEV0122* Chronic HEV 
patient feces
feces 
suspension
HBV A Chronic HBV 
patient serum
serum
Table 2. Viral isolates
Treatment Chimeric liver Virus n= Hepatocyte 
donor
None
no None 3 n/a*
yes None 8 HD1, HD2
yes HEV gt1 10 HD1
yes HEV gt3 
(HEV0069)
16 HD1, HD2, 
HD3
yes HEV gt3 
(HEV0122)
4 HD1
yes HBV gtA 5 HD3
pegIFNɑ-2a 
no None 2 n/a*
yes None 2 HD2
yes HEV gt1 3 HD2
yes HEV gt3 
(HEV0069)
11 HD2
yes HBV gtA 6 HD2
Table 3. Overview of experimental groups
*n/a, not applicable
Results
Higher viral burden in HEV gt1 compared to gt3 infected human-
liver chimeric mice
Humanized UPA+/+NOG mice were i.v. inoculated with a filtered 
feces suspension containing either HEV gt3 or HEV gt1 and were 
observed for 2, 6 or 14 weeks until euthanization. Infected mice 
were housed individually to prevent inter-mice contamination. 
During the infection course a higher percentage of HEV gt1 
infected mice presented viremia, but the peak viral load in 
serum was similar to HEV gt3 infected mice (2.6 ± 0.4 and 1.4 
± 0.4 log HEV RNA IU/ml, respectively, Fig. 1a). The peak HEV 
RNA load in feces was significantly higher in HEV gt1, compared 
to HEV gt3 infected mice (5.9 ± 0.2 and 4.2 ± 0.5 log HEV RNA 
IU/gram,	respectively,	P	=	0.029;	Fig.	1b).	HEV	gt1	infected	mice	
also had higher viral loads in bile (6.1 ± 0.2 vs. 5.2 ± 0.4 log HEV 
RNA	 IU/ml,	 respectively,	 P	 =	 0.038;	 Fig.	 1c)	 and	 liver	 (6.8	 ±	 0.2	
vs	5.8	±	0.3	 log	HEV	RNA	 IU/gram,	 respectively,	P	=	0.015;	 	Fig.	
1d) at euthanasia, despite similar levels of serum human albumin 
compared to HEV gt3 infected mice, indicative for similar degrees 
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of human chimerism (1.6 ± 0.4 and 1.9 ± 0.5 mg/ml, respectively, 
Fig. 1e). Despite lower absolute HEV gt1 inocula compared to 
HEV gt3, animals challenged with undiluted feces suspensions 
demonstrated similar results reaching higher HEV gt1 RNA levels 
in	 bile	 (P=0.038),	 liver	 (P=0.006),	 and	 feces	 (P=0.06)	 compared	
to HEV gt3 RNA levels.  These results point to a higher in vivo 
virulence of HEV genotype 1 compared genotype 3.
No induction of intrahepatic innate immune responses in HEV 
gt1 or gt3 infected human-liver chimeric mice
Because of the HEV gt1 and gt3 clinical differences (3-5, 198) 
and different viral burdens in humanized mice, we examined the 
human host response in chimeric livers 2, 6, or 14 weeks after 
infection with either HEV gt1 or gt3. Using qRT-PCR we could 
not detect a significant increase in transcript levels of alpha or 
beta IFNs (data not shown), pathogen recognition receptors 
TLR3 and DDX58 (Fig. 2a), transcription factor STAT1 (Fig. 2b), or 
ISGs CXCL9, CXCL10, ISG15, RSAD2, OAS1, MX1, and IFIT1 (Fig. 
2c). Furthermore, longer duration of HEV gt3, but not HEV gt1 
infection led to significantly decreased STAT1, RSAD2 and MX1 
expression levels in the liver (Fig. 2b+c). None of these human 
transcripts were detected in non-chimeric mouse livers.
In order to evaluate a broader number of genes, Nanostring 
analysis of 594 human specific immunology-related genes was 
performed on chimeric (serum hAlb 2.5 ± 0.8 mg/ml) gt3 HEV-
infected livers (6.1 ± 0.25 log HEV RNA IU/gr) at different time 
points post infection. Human transcript specificity was confirmed 
by including RNA from 3 non-chimeric livers and led to the 
removal of 50 cross-reactive genes from further analyses. Based 
on set criteria (<100 relative RNA counts and below four times the 
standard deviation in all samples), 255 genes were defined as non-
expressed. Principal component analyses did not reveal clustering 
of samples (Fig. 2d). Of 18 genes related to interferon signaling 
and response, none showed consistent upregulation compared 
to non-infected chimeric mice (Fig. 2e). Down regulation of 
STAT1 and MX1 as observed by qRT-PCR, was confirmed in the 
Nanostring gene expression data (Fig. 2b+c, e). Taken together, 
these data show that ongoing HEV gt1 or gt3 replication for up 
to 14 weeks does not elicit an innate immune response in human 
hepatocytes in vivo. 
HEV but not HBV is sensitive to pegIFNɑ-2a treatment in human-
liver chimeric mice
Baseline ISG expression in hepatocytes has been shown to predict 
the	response	to	IFNɑ	treatment	in	chronic	HCV	infected	patients	
(43, 44, 220). As HEV did not induce an ISG response in vivo, we 
examined	the	HEV-sensitivity	to	pegIFNɑ	treatment.	As	a	negative	
antiviral control, we applied the same treatment to HBV gtA 
infected mice, which has been shown to only slightly reduce serum 
HBV DNA levels in a similar humanized mouse model (221). After 
1	to	2	pegIFNɑ	injections,	HEV	gt3	RNA	became	undetectable	in	
feces of all treated animals (Fig. 3a-c). Complete viral clearance in 
liver and bile was observed in all mice at euthanasia 24 hours after 
4	or	8	pegIFNɑ	injections	(Fig.	3d).	To	examine	whether	a	single	
dose	of	30	µg/kg	pegIFNɑ	would	suffice	to	clear	HEV	gt3	in	vivo,	
4 animals received one injection after 6 weeks of ongoing HEV 
gt3 replication and were observed for an additional 4 weeks. This 
led to a complete viral clearance in 2 out of 4 mice and relapse in 
feces in the remainder 2 (Fig. 3c+d). Four weeks after the initial 
single	pegIFNɑ	dose,	the	latter	2	animals	received	repetitive	10-
fold	 lower	pegIFNɑ	doses	 for	2	weeks.	Again	a	 steep	decline	 in	
fecal HEV RNA loads was noted, but HEV RNA reemerged in feces 
and was detectable in bile and liver at euthanasia one day after 
the	second	pegIFNɑ	treatment	course	(Fig.	3c+d).	The	high	in	vivo	
HEV	IFNɑ	sensitivity	was	corroborated	in	HEV	gt1	infected	animals.	
Again rapid suppression of HEV replication was noted in feces 
(Fig. 3e), liver and bile (data not shown) after a 2 week treatment 
course	with	 30	 µg/kg	 pegIFNɑ.	 In	 contrast,	 a	 similar	 treatment	
regimen of HBV gtA infected mice induced a maximum decline of 
0.7 ± 0.2 log HBV DNA copies/ml in serum with high intrahepatic 
viral loads at necropsy (6.9 ± 0.6 log HBV DNA copies/gr liver) (Fig. 
3f). Non-treated HEV gt1, HEV gt3 and HBV infected mice never 
showed spontaneous viral clearance (Fig. 1b-d and Suppl. Fig. 2a-
c),	nor	was	loss	of	human	chimerism	in	pegIFNɑ-treated	animals	
observed, based on persistent detection of human albumin levels 
in mouse serum (data not shown). These data indicate that HEV, 
but	not	HBV	is	highly	sensitive	to	pegIFNɑ	in	humanized	mice.
Upregulation of intrahepatic ISG and serum CXCL10 upon 
pegIFNɑ treatment
To	 examine	 whether	 pegIFNɑ	 induced	 HEV	 clearance	 was	
associated with an induction of human hepatocyte ISG responses, 
human specific transcript levels of several innate immune response 
genes were studied in chimeric livers of HEV gt3, HEV gt1 and HBV 
gtA	infected	and	pegIFNɑ	treated	animals.	PegIFNɑ	treatment	led	
to an 20-fold increase of CXCL10 transcription, conjointly with 
induction of TLR3, DDX58, STAT1, CXCL9, ISG15, RSAD2, OAS1, 
MX1, and IFIT1 genes in the livers of HEV infected humanized mice 
(Fig. 4a and Suppl. Fig. 3). In addition, treatment was associated 
with an increase in serum human CXCL10 levels of HEV gt1 and 
Figure 1. Higher viral loads in HEV gt1 compared to HEV gt3 infected mice despite similar degrees of human chimerism. Comparison of peak HEV 
RNA	levels	as	measured	by	qRT-PCR	in	serum	(a)	and	in	feces	(b).	At	sacrifice	viral	titers	of	HEV	gt3	and	gt1	infected	mice	were	compared	in	bile	(c,	n=7	
and	n=6,	respectively)	and	in	liver	(d).	Human	albumin	levels	were	determined	in	mouse	serum	to	quantify	degree	of	chimerism	at	euthanasia	(e).	*,	P	
<	0.05,	n=20	for	HEV	gt3	and	n=10	for	HEV	gt1	(a,	b,	d,	e).	Data	are	pooled	from	2,	6,	and	14	weeks	infection	experiments.	Red	dots	indicate	mice	who	
received a diluted HEV inoculum (a-d).
54  |
Chapter 6  |  Immunodeficient human-liver chimeric mouse model
Figure 2. Minimal intrahepatic interferon-stimulated gene induction in HEV infected human-liver chimeric mice, between weeks 2 to 14 post infection. 
Whole chimeric-liver RNA was isolated from HEV gt3 and gt1 infected mice and analyzed for the human specific gene expression of sensing molecules 
TLR3 and DDX58 (a), transcription factor STAT1 (b), and interferon stimulated genes CXCL9, CXCL10, ISG15, RSAD2, OAS1, MX1 and IFIT1 (c) using qRT-
PCR.	Groups	consist	of	n=	4,	6,	4,	3,	6	and	4	mice	from	left	to	right	(a-c).	Given	values	on	y-axes	are	fold	changes	over	HEV	RNA	negative	chimeric-livers	
transplanted with the same hepatocyte donor. X-axes shows weeks post infection, HEV genotype, and hepatocyte donor. Significance was assessed 
within groups of the same hepatocyte donor using Krukskal-Wallis one-way Anova with Dunnett’s Multiple comparison test. *, P < 0.05, Gray bars 
indicate HEV gt1, black bars HEV gt3 (a-c). In-depth  human gene expression analysis was performed on RNA from chimeric mouse livers before infection, 
and after 2, 6 and 14 weeks of HEV gt3 infection using nCounter® Human Immunology V2 panel. Principal component 1 (x-axis) and 2 (y-axis) comprise 
49% of the variance between samples using all non-cross reactive genes (d). Uninfected samples are indicated in green, infected samples are indicated 
in blue, red (HEV0069), purple (HEV0122) and yellow and by the number of weeks infected HEV2, HEV6, HEV6, HEV14, respectively (d). Heatmap shows 
fold change over average of 4 uninfected mice for interferon signaling and response genes (e). Gene legend is indicated on the right side and sample 
legend	below	the	heatmap	(e).	Dark	red	indicates	≥	5	fold	change,	and	dark	blue	≤	5	fold	change	(e).
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gt3 infected mice (59 ± 10 and 108 ± 14 pg/ml, respectively, Fig. 
4b). Interestingly, intrahepatic CXCL10 expression levels remained 
elevated (3.4-fold compared to HEV-infected non-treated mice) 4 
weeks	after	a	single	pegIFNɑ	dose	 in	the	two	mice	that	cleared	
HEV. Similar to previous reports, HBV persistence in vivo was not 
due to absence of an ISG response, as IFIT1, ISG15, MX1, STAT1, 
and CXCL10 all were strongly induced (Fig. 4a and data not shown) 
(221). Overall, HEV but not HBV was found to be sensitive to 
pegIFNɑ	induced	hepatocyte-specific	innate	responses	in		vivo.
Figure 3. HEV is more sensitive than HBV to pegIFNɑ treatment in human-liver chimeric mice. HEV RNA was measured by qRT-PCR in feces of human-
liver	chimeric	mice	infected	with	HEV	gt3	or	HEV	gt1	before	and	during	4	weeks	(a,	n=3),	2	weeks	(b,	n=4;	e,	n=3).	and	single	(c,	n=4)	pegIFNɑ	treatment.	
Horizontal	gray	bars	indicate	pegIFNɑ	treatment	duration	and	dosage	in	µg/kg	(a,	b).	Arrow	indicates	time	point	of	the	single	30	µg/kg	pegIFNɑ	injection	
(c). One day after last dosage mice were sacrificed and viral load was determined in liver and bile (d). Non-treated infected mice were added as control 
(d).	X-axes	indicates	number	of	pegIFNɑ	injections	(d).	HBV	DNA	was	measured	in	serum	of	HBV	gtA	infected	human-liver	chimeric	mice	before	and	
during	pegIFNɑ	treatment,	and	one	day	after	last	treatment	mice	were	euthanized	and	intrahepatic	HBV	DNA	was	measured	(f,	n=6).	#	indicates	3	µg/
kg	pegIFNɑ	dosages.	All	mice	were	transplanted	with	the	same	hepatocyte	donor	(HD2,	a-f).	Y-axes	indicate	log	HEV	RNA	IU/gram	(a-c,	d	left	panel,	e),	
log HEV RNA IU/ml (d right panel), and log HBV DNA copies/ml (f). X-axes indicate days post infection (a-c, e-f).
Discussion
Despite increasing reports on acute and chronic Hepatitis E Virus 
infections in Europe, antiviral treatment options are limited 
and immunological determinants of viral persistence remain 
largely unexplored (199). Here we aimed to study baseline and 
therapeutically induced innate immune responses in a recently 
established humanized mouse model for chronic HEV infection. 
We	 demonstrate	 that	 (1)	 HEV	 is	 highly	 sensitive	 to	 pegIFNɑ	
treatment in vivo; (2) HEV infection in human hepatocytes doesn’t 
elicit an innate immune response; (3) HEV gt1 presents higher 
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viral loads compared to HEV gt3.
HEV gt1 and gt3, but not HBV, showed to be highly sensitive to 
pegIFNɑ	 treatment	 in	 immune	 deficient	 human	 liver	 chimeric	
uPA+/+NOG mice. Viral clearance in feces, liver and bile was 
achieved after 4 and 2 weeks treatment and even after a single 
pegIFNɑ	injection	in	2/4	mice.	PegIFNɑ	associated	viral	clearance	
was accompanied by an increase of intrahepatic human ISGs and 
serum CXCL10 levels. In line with our data (Fig. 3f), the antiviral 
potency	 of	 pegIFNɑ	 against	 other	 hepatotropic	 viruses	 was	
less	 pronounced	 in	 similar	 humanized	mouse	models.	 PegIFNɑ	
reduced HBV viremia by 2.5 log IU/ml and HCV loads with 2.3 log 
IU/ml after 12 and 4 weeks of treatment respectively, without 
clearing	 the	 infection	 (221-223).	 Successful	 IFNɑ	 treatment	
in immunocompetent woodchucks chronically infected with 
woodchuck hepatitis virus (a model for chronic HBV infection), 
is	 associated	 with	 an	 intrahepatic	 IFN-γ	 and	 NK/T	 cell	 gene	
signature, but not an ISG signature (224). All together this suggests 
that	 pegIFNɑ	 has	 a	 strong	 direct	 anti-viral	 effect	 against	 HEV,	
whereas HBV and HCV require the immune system to achieve viral 
clearance or complete suppression. 
Ongoing HEV gt1 or gt3 replication did not elicit human-innate 
immune responses in humanized livers of 30 uPA+/+NOG mice, 
irrespective of the infection duration, the human hepatocyte 
donor or viral isolate used. We specifically addressed the genomic 
response of human hepatocytes to HEV without that of infiltrating 
immune cells in our profound immune deficient uPA+/+NOG 
mice. In addition, we carefully eliminated cross hybridizing probes 
by including non-chimeric mice. After prolonged HEV gt3 infection 
for more than 3 months, significantly lower expression levels of 
STAT1, RSAD2 and MX1 compared to uninfected controls were 
observed, suggesting possible viral interference with the host’s 
cell innate immune signaling. Hepatotropic pathogens have 
developed different methods to evade innate immune defenses 
(225). In our model, expression of TLR3 and DDX58 was detected 
in all HEV-infected chimeric livers indicating that these host 
sensing molecules were not counteracted at the transcription level 
(Fig. 2a). Several studies in HEK293T, A549 and Huh7 cells have 
suggested that HEV can directly interfere with phosphorylation of 
STAT1	and	the	induction	of	IFNɑ	(206,	207,	226).	However,	most	of	
these studies use non-physiological HEV-infection models or are 
influenced by defects in the innate signaling of target cells (208). 
Our findings indicate possible HEV mediated innate immune 
inhibitory effects in primary human hepatocytes. Further studies 
in differentiated human hepatocytes are required to determine 
how HEV is able to prevent immune sensing or disrupt innate 
signaling and how this influences viral fitness.  
In contrast to our findings, one recent study infected a similar, but 
less profound immunodeficient uPA-SCID mouse model  with the 
same HEV gt1 strain (Sar-55) and showed elevated ISG expression 
in 2 HEV-infected mice compared to one control animal (213). 
While the impact of the hepatocyte donor type on expression 
levels cannot be disregarded as shown here (Suppl. Fig. 1), 
remnant mouse natural killer cell and Kupffer cell activity in the 
SCID compared to the NOG background might have contributed to 
the observed differences (227, 228). The role of infiltrating innate 
immune cells in the liver during HEV-clearance was recently shown 
in the chimpanzee model (229). In HEV-infected chimpanzees the 
intrahepatic expression levels of BST2 (present in monocytes, 
macrophages and dendritic cells) and not those of the adaptive 
immune system, corresponded with the expression kinetics of 
several ISG’s, including CXCL10, ISG15 and OAS1 (229, 230).
An important finding of our study was that during both HEV gt1 
and gt3 infections, no innate immune responses were induced 
despite higher HEV gt1 viral loads in mouse feces, bile and liver. 
These observations point to an intrinsic phenotypical difference 
of the distinct HEV genotypes, but cannot explain the different 
immune pathogenesis seen in patients, who have a strikingly 
different clinical presentation. Not only is disease severity higher 
in HEV gt1 infections, but also chronicity rates for HEV gt1 are 
found to be low or even zero. Possibly, different amounts of viral 
antigens or epitopes, could induce different magnitudes of natural 
killer cell or HEV-specific T cell responses resulting in respectively 
more clinical disease or less chronic infections for the different 
genotypes (231, 232). 
The clinical experience with pegIFN based therapies for chronic 
HEV is minimal. Eight cases have been published of which 5 
showed a suppression of viremia at the first measured timepoint 
after	initiation	of	pegIFNɑ	treatment.	PegIFNɑ	treatment	in	HEV	
infected humanized mice modelled the viral decline seen in 
these 5 patients. It remains however unclear why some chronic 
HEV patients show slow viral declines upon IFN-treatment. We 
observed a viral relapse in feces, liver and bile of 2 humanized 
Figure 4. CXCL10 transcripts and protein are induced after pegIFNɑ treatment in HEV infected mice. RNA was isolated from non-treated and 2 weeks 
pegIFNɑ	treated	HEV	gt1,	gt3	and	HBV	infected	mouse	livers	and	was	analyzed	for	the	expression	of	human	CXCL10	(a).	X-axes	indicate	treatment	dosage	
and virus genotype (a). Given values on y-axes are RNA levels in fold changes over uninfected non-treated mice (a). Human CXCL10 levels were measured 
using	ELISA	in	mouse	serum	of	uninfected,	HEV-infected	and	HEV-infected	pegIFNɑ	treated	mice	(b).	Dotted	line	indicates	lower	limit	of	detection	(LLOD)	
(b). Gray bars indicate HEV gt1, black bars HEV gt3 and striped bar uninfected (a+b).
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mice	after	a	second	pegIFNɑ	treatment	course	(Fig	3c+d).	While	
animals	received	a	10-fold	lower	pegIFNɑ	dose,	the	relapse	might	
be partially ascribed to elevated intrahepatic ISG levels before 
retreatment. Increased CXCL10 levels were measured in the 
liver	 of	 2	mice	 4	weeks	 after	 a	 single	 pegIFNɑ	 injection,	which	
corresponds to the timepoint at which retreatment was given to 
the remainder mice of that group. Since in chronic HCV patients 
the	virologic	response	to	pegIFNɑ	is	associated	with	low	baseline	
ISG expression levels (44), it would be interesting to examine 
whether this holds true for chronic HEV patients as well. 
In conclusion, despite higher viral loads for HEV gt1 in human-liver 
chimeric mice, both HEV gt1 and gt3 do not induce an intrahepatic 
innate immune response. HEV, but not HBV, is highly sensitive to 
pegIFNɑ	treatment	in	humanized	mice.	
Supplemental figure 1. Hepatocytes donor is an important variable in the baseline gene expression profile. UPA+/+NOG mice were transplanted with 
hepatocytes from one of three available donors (HD1, HD2, or HD3). Whole liver RNA was isolated from HEV infected and uninfected chimeric-mice (HEV 
RNA+ or – below X axis), and was analyzed for human specific gene expression of sensing molecules TLR3 and DDX58 (a), transcription factor STAT1 (b), 
and interferon stimulated genes CXCL9, CXCL10, ISG15, RSAD2, OAS1, MX1 and IFIT1 (c) using qRT-PCR. Given values on y-axes are relative expression 
to GAPDH. X-axes shows HEV RNA presence and hepatocyte donor (a-c). Significance was assessed between all samples using Krukskal-Wallis one-way 
Anova with Dunnett’s Multiple comparison test. * P < 0.05
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Supplemental figure 2. No drop in HEV RNA or viral clearance in gt1 or gt3 HEV, and HBV infected mice without pegIFNɑ treatment. HEV RNA was 
measured	in	feces	of	HEV	gt3	(a,	n=7)	and	HEV	gt1	(b,	n=9)	inoculated	mice.	HBV	DNA	was	measured	in	serum	of	mice	challenged	with	HBV	gtA	(c,	n=5).	
X-axes indicate days post infection until euthanasia (a-c). Y-axes indicated log HEV RNA IU/gram feces (a-b) or log HBV DNA copies/ml (c).
Supplemental figure 3. Genes related to interferon signaling and response are strongly upregulated after pegIFNɑ treatment in human-liver chimeric 
mice. Whole	liver	RNA	was	isolated	from	non-infected	(n=4),	non-infected	treated	(n=2),	and	HEV	gt3	(n=7)	and	gt1	(n=4)	 infected	pegIFNɑ	treated	
chimeric mice, and was analyzed for human specific gene expression of sensing molecules TLR3 and DDX58 (a), transcription factor STAT1 (b), and 
interferon stimulated genes CXCL9, CXCL10, ISG15, RSAD2, OAS1, MX1 and IFIT1 (c) using qRT-PCR. Given values on y-axes are relative expression to 
GAPDH. X-axes shows virus used for infection, time after infection at which treatment was started, and the duration of treatment in weeks (a-c). 
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Supplemental figure 4. Overview of experimental groups of untreated and pegIFNɑ-treated infected mice. HEV gt3 infection experiment is illustrated 
and described in figure 1a-d, figure 2a-e and supplemental figures 1+2 (a). HEV gt3 treatment experiments are illustrated and described in figures 3a-d, 
figure 4a+b, and supplemental figure 3 (b-d). HEV gt1 infection experiment is illustrated and described in figure 1a-d, figure 2a, and supplemental figure 
2 (e). HEV gt1 treatment experiment is illustrated and described in figure 3e, figure 4a+b, and supplemental figure 3 (f). HBV gtA infection experiment is 
illustrated and described in figure 4a, and supplemental figure 2 (g). HBV gtA treatment experiment is illustrated and described in figure 3f, and figure 
4a (h). ‘Tx’ indicates human hepatocytes transplantation, ‘f’ indicates feces collection (a-f), ‘s’ indicates serum collection (a-b, g-h). † indicates time of 
euthanization at which serum, feces, bile and liver were collected for HEV quantification, qPCR analysis, Nanostring analysis or serum hAlbumin/cytokine 
quantification	(a-h).	Arrow	below	X-axes	indicates	single	pegIFNɑ	treatment	dosage	(d).	Numbers	above	X-axes	refer	to	weeks	after	human	hepatocyte	
transplantation	(transplantation	time=0).	Numbers	below	X-axes	refer	to	weeks	after	HEV	or	HBV	inoculation	(inoculation	time	=0).
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Discussion
Liver-residing leukocytes are essential in determining the outcome 
of infection with hepatitis viruses. In hepatitis patients, liver 
leukocytes are mainly studied during chronic infection using core 
needle biopsies or the less invasive fine needle aspiration biopsy 
(233-235). Despite successful studies of liver innate immune 
cells during chronic infection, these studies are hampered by 
the lack of baseline samples and unknown variable time point of 
infection. Furthermore, it is very difficult to obtain these samples 
during initial acute phase of infection in which these cells play a 
very important role. In addition, number of cells isolated is low 
allowing phenotypical studies, but functional studies are more 
restricted. Therefore, animal models are essential to study of 
innate immune responses in viral hepatitis. 
The restricted host range of the hepatitis viruses has hampered 
the development of suitable animal models for years. The 
development of human-liver chimeric mouse models was a 
big leap forward in the study of human hepatitis C virus (HCV), 
hepatitis B virus (HBV), and hepatitis D virus (HDV) infections. 
Models to study chronic hepatitis E virus (HEV) were not available, 
therefore in this thesis we established the use of humanized mice 
as attractive model to study this emerging virus. In the same year, 
different labs have shown the use of comparable animal models, 
which indicates the urgent need for models to study this virus. 
Using this in vivo model for the study of HEV, we have shown that 
direct interaction of the virus with the primary human hepatocyte 
does not induce an intracellular innate immune response. This 
indicates that the virus is either not sensed by the host cell or 
that the virus has evasive measures in place to prevent immune 
activation. Treatment of chronically HEV-infected mice with 
pegylated	 interferon-alpha	 (pegIFNα),	 a	 drug	 that	 activates	 the	
intracellular immune response, showed to be very potent and was 
able to clear the virus after 1-4 dosages. These results suggest 
that	 HEV	 is	 very	 sensitive	 to	 the	 pegIFNα-induced	 intracellular	
immunity.	The	use	of	pegIFNα	to	treat	these	mice	may	pave	the	
way	for	further	study	of	pegIFNα	treatment	in	specific	groups	of	
chronic HEV patients.
The immune-deficient background of these humanized mice 
precludes studies focusing on the immune pathogenesis. 
Therefore, in this thesis we used an immunocompetent surrogate 
model for the study of innate cellular immunity in viral hepatitis 
based on lymphocytic choriomeningitis virus (LCMV) infection in 
C57BL/6 mice. The role of Kupffer cell (KCs) and monocytes during 
early and chronic liver inflammation is not well understood. 
Difficulty in studying these cells arises with their high plasticity 
and their strong phenotypical resemblance to each other. Using 
the LCMV- infected mice, we were able to perform transcriptome 
analyses on cell-sorted KCs and liver monocytes before, during 
and after chronic LCMV-induced hepatitis. Despite the strong 
resemblance between both cell types, our data nicely illustrate 
that both KC and monocytes remain distinct cell types at all stages 
of infection. Our study strongly points to distinct roles for KC and 
monocytes during viral hepatitis. 
Cellular immunity
KCs are cells with high plasticity and can exert diverse functions 
depending on their environment. The main function of KCs is to 
screen the blood flowing through the liver as part of the immune 
surveillance. In a steady state condition, liver immune cells are 
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mainly exposed to microbial products derived from the intestine. 
Despite possible binding of microbial antigens to surface TLRs in 
the liver these cells do not initiate a full-blown immune response. 
Regulatory cytokines such as interleukin (IL)10 and transforming 
growth factor (TGF)-β, have shown to be essential in maintaining 
the balance between inflammation and tolerance. During viral 
infection of the liver, intrahepatic immune cells should get 
activated to prevent viral spread and initiate adaptive immune 
responses to eventually clear the infection. Limited information 
is available on the orchestration of the intrahepatic immunity, 
the phenotype, and function of liver immune cells during viral 
infection. We studied the KCs during the early phases of LCMV 
infection in chapter 2 and during the chronic phase of infection 
in chapter 3. 
In steady-state condition KCs act as specialized phagocytes with 
only marginal cytokine production ex vivo (125), and are among 
the first to stain positive for the LCMV nucleoprotein thereby 
limiting viral spread (77, 83, 102). Therefore, KCs likely play a 
role in shaping the immune response, and thereby affect the 
outcome of a viral infection in the liver. Indeed, we showed that 
within 24 hours after infection KCs produce various inflammatory 
cytokines (TNF, IL6, MCP-1, CXCL10, RANTES), interferon-beta, and 
regulatory cytokine IL10. Interestingly, KC showed no or minimal 
inflammatory cytokine production 24 hours after exposure to LPS, 
indicating disruption of the steady state ‘tolerance’ balance upon 
viral infection but not after high dose bacterial products.
Regulatory cytokines, such as IL10, are able to dampen 
inflammatory responses. The production of IL10 by KCs during 
viral infection might indicate that KCs remain instigators of 
tolerance in the liver. Furthermore, KCs largely maintained their 
filtering function, as indicated by the uptake of dextran ex vivo 
after infection. Next to maintaining their phagocytic functions, 
KCs also showed stable or upregulated expression of complement 
genes and surface receptors (FcyR1, F4/80, and Marco). Overall, 
these data show that within 24 hours of infection KCs are able to 
initiate an inflammatory response but in essence these cells try to 
maintain their steady state functions. Possibly, KCs are ‘allowed’ 
to largely maintain their steady state function due to the vast 
recruitment of inflammatory monocytes to the liver upon viral 
infection.
Monocytes are one of the first cells to respond and infiltrate 
inflamed tissue. Within the first day after LCMV infection we 
already observed a vast influx of these monocytes into the liver. In 
the inflamed tissue, monocytes can either be regulatory or exert 
inflammatory responses. Monocytes showed a strong plasticity 
dependent on the nature of the inflammatory signal, either viral 
or sterile. In contrast to KC, liver monocytes completely lost their 
ability to take up dextran during LCMV infection, but increased 
dextran uptake after LPS challenge. Furthermore, monocytes 
sorted from LCMV-infected liver showed strong transcript 
induciton of inflammatory cytokines (Tnf, Il6, Mcp1, Cxcl10 
and Rantes), but not Il10 as KCs did. Our data support the pro-
inflammatory role of recruited monocytes in the setting of early 
virus-induced liver disease.
The distinctive roles of intrahepatic monocytes and KC are also 
present during chronic virus-induced hepatitis. During chronic 
infection, monocytes were still activated and transcribed Tnf, 
but the complete gene expression profile did not reveal clear 
functional specializations for these cells. We found elevated 
serum IL10 levels during chronic LCMV infection and an exclusive 
transcription of Il10 in sorted KC and not monocytes suggesting 
a cell-specific regulation of immune responses. Similarly, in HBV 
patients the anti-inflammatory IL10 in serum has also been 
shown to be elevated and may play a role in the decreased 
cytokine production by monocytes (140, 155, 156). This suggests 
that their function might be tightly regulated between a pro- or 
non-inflammatory state.  Further insight will require a selective 
depletion of either KC or monocytes during or before LCMV, 
without disturbing the entire mononuclear phagocyte system. 
Until recently, it was impossible to selectively deplete only one 
population of tissue-resident macrophages, without disturbing 
the entire mononuclear phagocyte system. Current depletion 
methods target all immune cells (e.g. irradiation), all phagocytic 
cells (e.g. clodronate liposomes), or require specific markers 
expressed on cell surface (e.g. CD11b-DTR mice) (236-238). 
The latter has proven to be challenging due to large overlap in 
surface proteins between cells of the myeloid lineage (239). 
The identification of Clec4f as KC-specific gene enabled the 
development of a KC-Knock out mouse, which poses an interesting 
mouse model to study the innate cellular immune response in the 
absence of KC during early and chronic LCMV infection (157).
Intracellular immunity
Innate and adaptive cellular immunity are required to clear viral 
pathogens from an organism. However, the first line of defense is 
set in the target host cell of the virus. Each cell is equipped with 
sensors, which are able to recognize foreign molecules, the so 
-called pattern recognition receptors (PRR). Upon recognition of 
viral molecules, these receptors can initiate intracellular immunity 
to counteract the virus. Previous research has shown that these 
defense mechanisms are not well activated in hepatocytes upon 
infection with HBV, which is therefore regarded as a ‘stealth’ 
virus (240). In contrast, HCV infection in hepatocytes does elicit 
a strong defense response (241, 242). However, despite the host 
cell’s innate immune response, most individuals do not clear the 
infection and become chronically infected. The current knowledge 
on HEV infection in host cells is limited to in vitro cell lines. In 
chapter 6, we investigated the interaction of HEV with primary 
human hepatocytes in infected human-liver chimeric mice. We did 
not detect any upregulation of genes related to the intracellular 
immunity during chronic HEV genotype (gt) 3 and gt1 infection, 
despite the presence of PRRs. Whether HEV is not sensed by the 
host cell or if viral counteractive mechanisms prevent immune 
activation is not known. In vitro studies have suggested that HEV 
is able to counteract the downstream signaling of the PRRs. To 
confirm the in vitro findings, the humanized mouse model may 
contribute to unravel HEV’s counteractive mechanisms in primary 
human hepatocytes. Understanding the interaction of HEV with 
the host cells is crucial in understanding current pathology and 
the development of possible intervention strategies.
Cellular Immunity against HEV
Despite the fact that HEV does not induce intracellular innate 
immune responses, most HEV infected individuals clear the virus. 
The cellular immunity against HEV has been suggested to play a 
major role in HEV clearance. It has been shown that strong and 
multi HEV-specific CD4+ and CD8+ T cell responses are present in 
seropositive patients, but not in chronic HEV solid organ transplant 
(SOT) patients (231). In addition, in HEV gt1 patients with acute 
liver failure a massive influx of cytotoxic CD8+ T cells has been 
observed (243). Exposure to HEV also induces the development 
of a humoral response, which may contribute to the clearance of 
the infection. Cynomolgus monkeys showed no or less signs of 
HEV gt1 (Sar-55) infection after passive or active immunization, 
indicating a virus-neutralizing role for anti-HEV antibodies (244). 
The human-liver chimeric mouse model may be an interesting 
62  |
Chapter 7  |  General discussion and future perspectives
model to test whether passive immunization or pre-incubation 
of viral stock with anti-HEV gt3 antibodies can block infection in 
these mice. In addition, T cell transfers into humanized mice can 
help us to further elucidate the role of epitope-specific CD4+ and 
CD8+ anti-HEV T cells.
As discussed above, innate immune cell responses are a 
determining factor for good adaptive immune responses. The 
roles of innate immune cells in HEV infections are so far elusive. 
It would be interesting to determine whether KCs take up the 
virus, are able to orchestrate the initial inflammatory response, 
and recruit inflammatory monocytes to the liver during acute 
HEV infection. Moreover, the impact of immunosuppressing 
drugs on the function of these cells is subject for future study. 
In addition, intra-genotype comparison of innate immune cell 
function during HEV infection may unravel important differences 
in immunopathology. Preliminary studies on innate immune cells 
during HEV infection could be studied using liver biopsies. Using 
flow cytometric analysis, immune histochemical stainings or gene 
expression profiling, the role of these cells can be elucidated. 
The here applied mouse models are either not susceptible to 
HEV (C57BL/6) or lack immune cells (UPANOG). However, recent 
development allowed reconstitution of the mouse bone-marrow 
with human immune cells, followed by the engraftment of human 
hepatocytes to generate a human-liver chimeric mouse with a 
human immune system (HIS-HUHEP mice) (245). This model may 
enable the study of HEV gt1 and gt3 immune pathobiology.
 
HEV isolate infectivity differences
HEV gt3 infections are emerging in west European countries, 
including France, the United Kingdom and the Netherlands (26-
28). While recent reports have shown HEV gt3 viremia among 
blood donors (246), Dutch national blood safety guidelines do 
not require nucleic acid testing of the donor pool (180). This is 
of concern for immune-compromised and SOT patients, who are 
prone to develop chronic infections, which may quickly progress 
to severe liver fibrosis. Interestingly, only a limited number 
of cases of transfusion-transmitted HEV have been reported 
despite administration of contaminated blood products (28, 178, 
179, 199). In addition, a recent retrospective survey of United 
Kingdom’s plasma pool, surprisingly showed that only half of 
HEV-viremic British blood donors infected their recipients (28). 
Determinants of HEV transmission rate are not well studied yet, 
but seemed to be dependent on the HEV RNA load and anti-HEV 
antibodies status in donor plasma.
We observed intrinsic HEV infectivity differences that were most 
apparent when plasma-, feces- and liver-HEV isolates from the 
same patient were examined: plasma-derived HEV demonstrated 
slower or no replication in vitro and in vivo, respectively (Chapter 
3). The determining factor for these infectivity differences is not 
completely understood. In chapter 4 we showed limited genomic 
differences between HEV derived from plasma and feces of two 
chronic HEV patients, minimizing genomic alterations as the cause 
for the observed differences. Other studies described that HEV 
virions from plasma and feces differ in virion density, ascribed 
to the presence or absence of a lipid membrane content. This 
different buoyant density may influence in vivo  infectivity, as has 
previously been shown for HCV (167). The detergent activity of bile 
acids could strip HEV virions of their lipid content upon passage 
towards the intestinal system, which may explain the observed 
difference between plasma and feces viruses (173). In addition, 
circulating inhibiting factors in blood, such as virus-specific 
antibodies, can also act as negative influencers of infectivity of 
virus preparations. However, for HEV it has not been proven yet 
that presence of anti-HEV antibodies reduces infectivity in vivo . In 
vitro studies have shown that HEV serum samples can still initiate 
efficient replication despite the presence of HEV antibodies (247). 
Ultimate proof of intrinsic infectivity differences of membranous 
or antibody-coated HEV particles will require delipidation and 
antibody depletion of plasma derived inocula. Nevertheless, 
we used only pre-seroconversion plasma samples in our in vivo 
infectivity assays, excluding any inhibitory effects of anti-HEV 
antibodies. Overall, the observation that human plasma-derived 
virus is less infectious in vivo  may be relevant for the infectivity 
and epidemiology of HEV in humans. Future studies should aim at 
unravelling the determinants of infectivity for HEV.
The differences in clinical presentation between HEV gt1 and 3 
are so far not understood. HEV gt1 infections in pregnant women 
occur in countries in south-east Asia, whereas HEV gt3 infections 
result in clinical disease mainly for immunocompromised patients, 
but not for pregnant women, in Europe. Possible intrinsic viral 
differences may play a role, such as the observed increased 
replication described in chapter 6. All mice inoculated with either 
high or low HEV gt1 or gt3 inocula, all animals became chronically 
infected. Irrespective of lower absolute inocula for HEV gt1 
compared to gt3, higher viral loads were detected in feces, bile 
and liver of HEV gt1-inoculated animals. These results corroborate 
a higher intrinsic virulence of HEV gt1 compared to gt3. However, 
the molecular mechanisms associated with enhanced HEV gt1 
replication remain to be determined. 
Treatment of chronic HEV
Current antiviral treatment options for chronic HEV-infected 
immunocompromised patients are limited, and consist of two 
strategies. First, a reduction of immunosuppressive drugs is opted, 
and	second,	anti-viral	treatment	with	either	pegIFNα	or	ribavirin	
can be used. The latter are based on safety and efficacy treatment 
studies for chronic HCV infections, as no such study has been 
performed in chronic HEV patients. No universal definition for 
HEV treatment outcome exists, therefore the current sustained 
virological response (SVR) is considered as HEV RNA-negative PCR 
result in the period of follow-up after end of treatment (47).
Reducing the dose of immunosuppressive drugs in SOT patients 
has shown to result in HEV clearance in up to one third of the 
patients	 (3,	 248).	 PegIFNα	 has	 been	 administered	 to	 eight	
patients, in doses comparable to HCV treatment regimens, and 
resulted in SVR in 75% of the patients treated (47, 48). Despite 
the treatment success, reduction of immunosuppressive drugs 
and	the	use	of	pegIFNα	in	kidney	and	heart	transplant	recipients	
are not preferred, due to concerns for acute graft rejection. 
Currently, the preferred treatment is the use of ribavirin (RBV) for 
these	patients.	Similar	to	pegIFNα	treatment,	SVR	was	achieved	
in 74% of the patients, despite any knowledge on optimal dose 
and treatment duration (47). RBV is quite well tolerated in most 
patients, however anaemia has been described as the main side 
effect. Patients suffering from RBV-induced anaemia require a 
dose reduction, administration of erythropoietin, or eventually 
need a blood transfusion (47). The precise mechanisms of RBV 
treatment are not completely understood and should be subject 
to further study, especially in the context of HEV. In addition, the 
emergence of HEV strains non-responding to RBV treatment has 
been described. The RBV-resistant strains have been linked to 
mutations in their polymerase gene (G1634R) (191, 249, 250). 
Treatment possibilities for chronic HEV patients developing a RBV-
resistant HEV strain are limited to the non-preferred reduction of 
immunosuppressive	drugs	or		treatment	with	pegIFNα.	In	chapter	
6	we	investigated	the	effect	of	pegIFNα	on	HEV	in	humanized	mice.	
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We	showed	that	HEV,	but	not	HBV,	was	highly	sensitive	to	pegIFNα	
treatment, with viral clearance in feces, liver and bile after 4 and 
2	weeks	treatment	and	even	after	a	single	pegIFNα	dose	 in	2/4	
mice.	PegIFNα-associated	viral	clearance	was	accompanied	by	an	
increase of intrahepatic human interferon-stimulated genes (ISGs) 
and serum CXCL10 levels. In line with our data, in similar chimeric 
mouse	models,	pegIFNα	reduced	HBV	viremia	and	HCV	loads	after	
12 and 4 weeks of treatment, respectively, without clearing the 
infection	(62,	221,	223).	All	together,	this	suggests	that	pegIFNα	
has a strong direct anti-viral effect against HEV, whereas HBV and 
HCV require the immune system to achieve viral clearance or 
complete	suppression.	The	comparative	effectiveness	of	pegIFNα	
treatment for HEV, HBV and HCV infection in humanized mice, 
should	 incite	 further	 studies	 on	 the	 optimal	 antiviral	 pegIFNα	
dose and treatment duration without increased risk for rejection 
in SOT patients. 
In	 chronic	 HCV	 patients,	 the	 virologic	 response	 to	 pegIFNα	 is	
associated with low baseline ISG expression levels. Whether this 
can also be used as prognostic marker for treatment success 
of	 pegIFNα	 for	 HEV	 remains	 to	 be	 determined.	 However,	 in	
chapter 6 we observed a viral relapse in feces, liver and bile of 
two	humanized	mice	after	a	 second	pegIFNα	treatment	course.	
While	animals	received	a	10-fold	lower	pegIFNα	dose,	the	relapse	
might be partially ascribed to elevated intrahepatic ISG levels 
before retreatment. Increased CXCL10 levels were measured 
in	 the	 liver	 of	 2	mice	 4	weeks	 after	 a	 single	 pegIFNα	 injection,	
which corresponds to the time point at which retreatment was 
started for the remainder mice of that group. Interestingly, the 
cases	 described	 of	 chronic	 HEV	 patients	 treated	with	 pegIFNα,	
showed a rapid viral response within 1 month in 5/8 patients 
(47). This indicates that chronic HEV patients may be categorized 
in rapid responders and non-responders. The determinants that 
distinguish	 rapid	 responders	 and	 non-responders	 to	 pegIFNα	
should carefully be examined.
The	 use	 of	 pegIFNα	 is	 not	 preferred	 in	 SOT	 patients	 due	 to	
concerns for acute graft rejection. Alternatively, other intracellular 
innate immune-activating compounds should be explored. Type 
III interferons (Interferon lambda (IFNλ)) have shown to induce 
antiviral	 genes	 similar	 to	 IFNα,	 but	 signals	 through	 a	 different	
receptor	 (251).	 The	 IFNλ	 receptor	 is	 less	 widely	 expressed	
and	 distributed	 compared	 to	 the	 IFNα	 receptor,	 implying	 that	
IFNλ	 may	 induce	 fewer	 side-effects	 such	 as	 off-target	 immune	
activation. Another treatment option could be the use of 
immune-stimulating compounds targeting the Toll-Like Receptors 
(TLR). The use of TLR agonist has been investigated to treat HBV 
and HIV infections in vitro and in vivo (252-254). In our mice, 
HEV	was	much	more	 susceptible	 to	 pegIFNα-stimulated	 innate	
immune activation compared to HBV. Therefore, HEV may also be 
vulnerable to TLR agonist-induced immune responses. However, 
as discussed above, HEV might have counteractive mechanisms 
to prevent immune activation, which may block down-stream TLR 
signaling and thus prevent upregulation of anti-viral genes. These 
treatment options pose interesting alternatives to treat chronic 
HEV infections in SOT patients. However, future studies are 
required to determine the effectiveness, the possible side-effects, 
and the off-target immune activation.
Conclusions
The work described in this thesis contributes to our understanding 
of the cellular and intracellular innate immune responses in the 
liver. We have established the use of human-liver chimeric mice 
for the study of chronic HEV infection and used LCMV infection 
in C57BL/6 as immunocompetent model for viral hepatitis. Our 
LCMV data indicate that KC and liver monocytes should always 
be considered as separate cell populations that play distinct roles 
during viral infections. Humanized mice could be productively 
infected with HEV isolated from feces, but not from plasma. HEV 
gt3 genomically adapts to in vitro culture, but the in vivo selection 
pressure in immune-deficient hosts is minimal. HEV infection 
of human hepatocytes did not activate the intracellular innate 
immune	responses,	but	activation	of	these	responses	via	pegIFNα	
treatment resulted in quick clearance of the virus. 
Future perspectives
The first documented outbreak of HEV was in 1955 in New Delhi, 
India. Since then, our knowledge on this virus has advanced, but 
is still limited. With the emergence of HEV gt3 in Europe more 
research has been performed on this virus including our work 
described in this thesis. However, with all the new knowledge 
generated, more questions arise and Europe’s new Hepatitis 
problem is not solved yet. Future research on HEV should focus 
around several questions: 1) How can we prevent HEV infection? 
What are all the infectious sources of human HEV and how can 
we eliminate HEV from these sources? 2) How can we efficiently 
and safely treat chronic HEV gt3 SOT patients and acute pregnant 
HEV gt1 patients? 3) What viral epitopes are recognized by T and B 
cells after HEV infection, and are the responses evoked protective 
against other genotypes? 4) What are the intrinsic differences 
between HEV genotypes? Why do gt1 HEV infections result in 
acute liver failure (ALF) in pregnant women but gt3 HEV infections 
do not? 5) How does the complete immune system orchestrate 
a successful immune response against HEV and what are the 
determinants for chronicity in gt3 or ALF in gt1 infections? Next 
to studies in patients, our mouse models can contribute in future 
attempts to find answers to these questions. The LCMV infection 
model can contribute to our general understanding in immune 
pathobiology of chronic (liver) infections unravelling potential 
essential factors for the development of chronicity. The human-
liver chimeric mouse is useful in infectivity studies, including 
the comparison of different HEV isolates (HEV gt4, gt2, or other 
animal HEV strains), testing the neutralization effect of anti-
HEV polyclonal and monoclonal antibodies, and test the effect 
of delipidation on infectivity. Moreover, this model shows great 
potential for treatment studies including intracellular immune-
activating	 drugs	 (IFNλ,	 TLR3	 agonists),	 and	may	 contribute	 as	 a	
model for testing new direct-acting antivirals. Furthermore, the 
anti-viral effect of adoptively transferred immune cells (e.g. HEV-
specific T cells) can be studied. Lastly, the human-liver chimeric 
mouse will contribute to the ability to study the direct interaction 
of the virus with differentiated primary human hepatocytes and 
to in vivo  efficacy studies of new direct acting antivirals.
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Liver-residing leukocytes are essential in determining the 
outcome of infection with hepatitis viruses. Patient studies of 
liver innate immune cells during chronic viral hepatitis have 
been performed but are hampered by, amongst others, a lack 
of baseline data and unknown time of infection. Therefore, 
animal models are essential for the study of the innate immune 
response in viral hepatitis. In the studies presented in this thesis, 
we aimed to better understand the cellular innate immune 
responses in the liver during lymphocytic choriomeningitis virus 
(LCMV) clone 13 induced chronic hepatitis, and to establish the 
human-liver chimeric mice as model for chronic Hepatitis E virus 
(HEV) infections in order to study the intracellular innate immune 
mechanisms upon HEV infection.
In chapter 2 and 3, we aimed to unravel how the cellular innate 
immune system deals with chronic viral infection in the liver using 
the LCMV infection mouse model. In chapter 2, we described that 
early after LCMV infection a functional dichotomy is observed for 
inflammatory monocytes and F4/80high-Kupffer cells with respect 
to endocytosis, but their activation and cytokine gene expression 
profiles exhibit a strong resemblance. In addition, inflammatory 
monocytes exhibit a huge capacity for recruitment to the liver and 
plasticity dependent on the nature of the inflammatory signal, 
either viral or sterile. This suggests that inflammatory monocytes 
play a crucial role in shaping the inflammatory environment 
in the liver early after infection. In chapter 3, we showed that 
LCMV induces chronic viral hepatitis with limited intrahepatic 
cytokine and interferon responses during the chronic infection. 
Furthermore, we identified KC and IM as distinct cell populations 
before, during, and after chronic infection, with important 
differences in activation status, antigen presentation, and gene 
expression profile correlating with the presence of viral antigens. 
Overall, these data suggest that intrahepatic monocytes and KC 
play distinctive roles during chronic virus-induced hepatitis, which 
is crucial knowledge in order to develop new antiviral strategies 
aimed at eradicating chronic viral infection.
In chapters 4, 5, and 6, we investigated Europe’s new hepatitis 
threat. Increasing numbers of endemic infections with genotype 
(gt) 3 HEV are observed in European countries. Unfortunately, no 
adequate in vivo model system exists to mimic this disease course, 
which hampers studies on HEV infectivity, transmission, and 
antiviral drug development. Therefore, in chapter 4, we explored 
and showed that human-liver chimeric mice can model chronic 
HEV infections. Humanized mice could productively be infected 
with clinical fecal, but not plasma, samples from several chronic 
HEV patients. In chapter 5, we described that HEV gt3 genomically 
adapted to in vitro culture, but that in vivo selection pressure in 
immune-deficient hosts was minimal. In chapter 6, we compared 
infection of HEV gt1 and HEV gt3 in human liver chimeric mice, 
and examined the intracellular innate immune responses in 
human hepatocytes upon infection. Despite higher viral loads for 
HEV gt1 in human-liver chimeric mice, neither HEV gt1 nor gt3 
induced an intrahepatic innate immune response. Interestingly, 
treatment of infected chimeric mice with intracellular innate 
immune activating drugs pegIFNɑ, showed rapid clearance of 
HEV. Overall, these data show that humanized mice  could be 
productively infected with HEV isolated from feces, and that HEV 
does not induce intracellular innate immune responses in human 
hepatocytes, but is very sensitive to these immune mechanisms 
induced by pegIFNɑ.
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Afweercellen in de lever zijn essentieel om een hepatitis 
virus infectie onder controle te houden. Door beperkingen in 
patiëntenstudies kunnen de aangeboren niet-specifieke directe 
afweercellen in lever niet altijd even goed bestudeerd worden. 
Daarom zijn diermodellen essentieel in het bestuderen van 
de aangeboren directe immuunrespons in de lever tijdens 
een virale infectie. In de studies beschreven in dit proefschrift 
hebben wij de aangeboren directe afweercellen bestudeerd in 
de lever tijdens virale hepatitis door gebruik te maken van het 
Lymphocytic Choriomeningitis Virus (LCMV) infectie muismodel. 
Daarnaast hebben wij intracellulaire directe immuunmechanisme 
onderzocht in muizen met een chimeren humane lever 
geïnfecteerd met hepatitis E virussen (HEV). In hoofdstuk 2 en 3 van 
dit proefschrift hebben wij het LCMV infectiemodel gebruikt om 
in de lever de aangeboren niet-specifieke directe immuunrespons 
te onderzoeken tijdens infectie. In hoofdstuk 2 beschrijven we 
dat dat tijdens de initiële infectie er een functionele dichotomie 
bestaat tussen twee verschillende aangeboren afweercellen, de 
monocyten en Kupffer cellen. Desondanks vertonen beide cellen 
wel een vergelijkbaar activatie en cytokine genexpressieprofiel. 
Daarnaast, beschrijven wij dat de inflammatoire monocyten 
snel naar de lever gerekruteerd worden tijdens de initiële 
infectie, en dat deze cellen zich goed kunnen aanpassen aan 
verschillende ontstekingssignalen. Deze data suggereren een 
belangrijke rol voor de inflammatoire monocyten in het vormen 
van de ontstekingsreactie in de lever kort na infectie. In hoofdstuk 
3 laten we zien dat LCMV infectie zorgt voor een duidelijke 
chronische virale leverontsteking, maar met beperkte cytokine en 
interferon activatie tijdens de chronische fase. Tevens laten wij 
zien dat Kupffer cellen en inflammatoire monocyten verschillende 
cellen zijn voor, tijdens, en na de chronische lever infectie. 
Beide cellen laten belangrijke verschillen zien in activatiestatus, 
antigeenpresentatie, en in het genexpressieprofiel dat correleert 
aan de aanwezigheid van het virus. Algeheel laten deze data zien 
dat Kupffer cellen en monocyten een verschillende rol spelen 
tijdens chronische virale hepatitis. Deze kennis is van belang om 
mogelijke nieuwe behandel strategieën te ontwikkelen die zich 
richten op het genezen van chronische virusinfecties.
In hoofdstukken 4, 5, en 6, hebben we onderzoek gedaan naar 
de nieuwe hepatitis dreiging van Europa. Laatste jaren zijn het 
aantal endemische infecties met genotype 3 HEV zijn gestegen 
in Europa. Helaas worden studies naar HEV besmettelijkheid, 
transmissie, en behandel methode beperkt door de afwezigheid 
van goede diermodellen die het ziekteverloop nabootsen. In 
hoofdstuk 4 beschrijven we ons onderzoek naar de mogelijkheid 
om een muis met een chimeren humane lever te gebruiken als 
model voor chronische HEV infecties. Deze gehumaniseerde 
muizen bleken vatbaar te zijn voor het virus uit feces, maar 
niet bloed, van chronische HEV patiënten. In hoofdstuk 5 laten 
wij zien dat het genotype 3 HEV zich genetisch aanpast aan 
celkweek condities, maar dat deze genetische aanpassingen 
beperkt blijven in de immuundeficiëntie gastheer. In hoofdstuk 
6 vergelijken wij genotype 3 HEV en genotype 1 HEV infecties 
in de gehumaniseerde muis, tevens onderzoeken wij de directe 
afweermechanisme van de cel tijdens infectie. Ondanks het hoger 
aantal genotype 1 virussen in de gehumaniseerde muis, activeren 
beide virussen niet het directe afweermechanisme van de levercel 
tijdens chronische infectie. Echter genezen muizen snel van het 
virus wanneer we deze behandelden met een geneesmiddel 
(pegIFNɑ) dat deze immuunmechanisme aanzet. Algeheel laten 
deze studies zien dat het gehumaniseerde muismodel gebruikt 
kan worden voor onderzoek naar chronische HEV infecties met 
minimale genetische aanpassing van het virus. Daarnaast laten 
we zien dat pegIFNɑ behandeling het virus succesvol klaard in dit 
muismodel. Dit bied nieuwe inzichten voor de behandeling van 
chronische HEV patiënten.
Samenvatting
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HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HBX Hepatitis B X protein
HCV Hepatitis C virus
HD Hepatocyte donor
HDV Hepatitis D virus
HEV Hepatitis E virus
HIV Human Immunodeficiency Virus
i.p  Intraperitoneal.
i.v  Intravenous
IFN Interferon
IL Interleukin
IM  Inflammatory monocytes
iNOS Inducible nitric oxide synthase 
IRF Interferon regulatory factor
ISG Interferon stimulated gene
IU  International units
KC Kupffer cell
LCMV Lymphocytic choriomeningitis virus
LPS Lipopolysaccharides 
MARCO  Macrophage receptor with collagenous structure
MDA5 Melanoma Differentiation-Associated protein 5
MDSC  Myeloid derived suppressor cells 
MHC Major Histocompatibility complex
NCR None coding region
NK Natural killer
NOG HSVtk-NOD/Shi-scid IL2Rgnull 
OAS Oligoadenylate synthetase
ORF Open Reading Frame
P  Passage
p.i. Post infection
PAMP Pathogen-associated molecular pattern
PBS  Phosphate buffered saline
PCR Polymerase chain reaction 
pegIFNα	 Pegylated	interferon-alpha
pen/strep Penicillin/streptomycin 
PFU   Plaque forming units
PMA  Phorbol 12-myristate 13-acetate
PRR Pathogen recognition receptor
RBV Ribavirin
RIG-I Retinoic acid-inducible gene I
RNA  Ribonucleic acid
ROS  Reactive oxygen species
SEM  Standard error of the mean
SOT Solid Organ Transplant
SVR Sustained virologic response
TGF Transforming growth factor
TLR Toll like receptor
TNF Tumor necrosis factor
uPA urokinase-type plasminogen activator
VLP Virus like particle
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